Patent Grant
11806528
The present invention relates to methods and apparatus for patient treatment by means of active elements delivering electromagnetic energy and/or secondary energy in such a way that the treatment area is treated homogeneously without the need for manipulation of the active elements during the therapy.
Skin ages with time mostly due to UV exposure—a process known as photoaging. Everyday exposure to UV light gradually leads to decreased skin thickness and a lower amount of the basic building proteins in the skin—collagen and elastin. The amounts of a third major skin component are also diminished, those of hyaluronic acid. These changes appear more quickly on the visible parts of the body, most notably the face. There are several technologies used for facial non-invasive skin rejuvenation such as lasers, high-intensity focused ultrasound and radiofrequency. It is expected that the ultrasound and RF fields also lead to an increase in levels of hyaluronic acid in the dermis.
Delivering various forms of electromagnetic energy into a patient for medical and cosmetic purposes has been widely used in the past. These common procedures for improvement of a visual appearance include, but are by no means limited to, skin rejuvenation, wrinkle removal, rhytides, skin tightening and lifting, cellulite and fat reduction, treatment of pigmented lesions, tattoo removal, soft tissue coagulation and ablation, vascular lesion reduction, face lifting, muscle contractions and muscle strengthening, temporary relief of pain, muscle spasms, increase in local circulation etc.
Besides many indisputable advantages of thermal therapies, these procedures also bring certain limitations and associated risks. Among others is the limited ability of reproducible results as these are highly dependent on applied treatment techniques and the operator's capabilities. Moreover, if the therapy is performed inappropriately, there is an increased risk of burns and adverse events.
It is very difficult to ensure a homogeneous energy distribution if the energy delivery is controlled via manual movement of the operator's hand which is the most common procedure. Certain spots can be easily over- or under-treated. For this reason, devices containing scanning or other mechanisms capable of unattended skin delivery have emerged. These devices usually deliver energy without direct contact with the treated area, and only on a limited, well-defined area without apparent unevenness. Maintaining the same distance between the treated tissue and the energy generator or maintaining the necessary tissue contact may be challenging when treating uneven or rugged areas. Therefore, usage of commonly available devices on such specific areas that moreover differ from patient to patient (e.g. the face) might be virtually impossible.
Facial unattended application is, besides the complications introduced by attachment to rugged areas and necessity of adaptation to the shapes of different patients, specific by its increased need for protection against burns and other side effects. Although the face heals more easily than other body areas, it is also more exposed, leading to much higher requirements for treatment downtime. Another important aspect of a facial procedure is that the face hosts the most important human senses, whose function must not be compromised during treatment. Above all, eye safety must be ensured throughout the entire treatment.
The current aesthetic market offers either traditional manually controlled radiofrequency or light devices enabling facial tissue heating to a target temperature in the range of 40° C.-100° C. or unattended LED facial masks whose operation is based on light effects (phototherapy) rather than thermal effects. These masks are predominantly intended for home use and do not pose a risk to patients of burns, overheating or overtreating. The variability in facial shapes of individual patients does not represent any issue for these masks as the delivered energy and attained temperatures are so low that the risk of thermal tissue damage is minimized and there is no need for homogeneous treatment. Also, due to low temperatures, it is not important for such devices to maintain the predetermined distance between the individual diodes and the patient's skin, and the shape of the masks is only a very approximate representation of the human face. But their use is greatly limited by the low energy and minimal to no thermal effect and they are therefore considered as a preventive tool for daily use rather than a method of in-office skin rejuvenation with immediate effect.
Nowadays, the aesthetic market feels the needs of the combination of the heating treatment made by electromagnetic energy delivered to the epidermis, dermis, hypodermis or adipose tissue with the secondary energy providing muscle contraction or muscle stimulation in the field of improvement of visual appearance of the patient. However, none of the actual devices is adapted to treat the uneven rugged areas like the face. In addition, the commercially available devices are usually handheld devices that need to be operated by the medical professional during the whole treatment.
Thus it is necessary to improve medical devices providing more than one treatment energy (e.g. electromagnetic energy and electric current), such that both energies may be delivered via different active elements or the same active element (e.g. electrode). Furthermore, the applicator or pad of the device needs to be attached to the patient which allows unattended treatment of the patient and the applicator or pad needs to be made of flexible material allowing sufficient contact with the uneven treatment area of the body part of the patient.
In order to enable well defined unattended treatment of the uneven, rugged areas of a patient (e.g. facial area) while preserving safety, methods and devices of minimally invasive to non-invasive electromagnetic energy delivery via a single or a plurality of active elements have been proposed.
The patient may include skin and a body part, wherein a body part may refer to a body area.
The desired effect of the improvement of visual appearance of the patient may include tissue (e.g. skin) heating in the range of 37.5° C. to 55° C., tissue coagulation at temperatures of 50° C. to 70° C., or tissue ablation at temperatures of 55° C. to 130° C. depending on the patient. Various patients and skin conditions may require different treatment approaches—higher temperatures allow better results with fewer sessions but require longer healing times while lower temperatures enable treatment with no downtime but limited results within more sessions. Another effect of the heating may lead to decreasing the number of the fat cells.
Another desired effect may be muscle contraction causing muscle stimulation (e.g. strengthening or toning) for improving the visual appearance of the patient.
An arrangement for contact or contactless therapy has been proposed.
For contact therapy, the proposed device and methods comprise at least one electromagnetic energy generator inside a main unit that generates an electromagnetic energy which is delivered to the treatment area via at least one active element attached to the skin. At least one active element may be embedded in a pad made of flexible material that adapts to the shape of the rugged surface. An underside of the pad may include an adhesive layer allowing the active elements to adhere to the treatment area and to maintain necessary tissue contact. Furthermore, the device may employ a safety system capable of adjusting one or more therapy parameters based on the measured values from at least one sensor, e.g. thermal sensors or impedance measurement sensors capable of measuring quality of contact with the treated tissue.
For contactless therapy, the proposed device and methods comprise at least one electromagnetic energy generator inside a main unit that generates an electromagnetic energy which is delivered to the treatment area via at least one active element located at a defined distance from the tissue to be treated. A distance of at least one active element from the treatment area may be monitored before, throughout the entire treatment or post-treatment. Furthermore, the device may employ a safety system capable of adjusting one or more therapy parameters based on the measured values from at least one sensor, for example one or more distance sensors. Energy may be delivered by a single or a plurality of static active elements or by moving a single or a plurality of active elements throughout the entire treatment area, for example via a built-in automatic moving system, e.g. an integrated scanner. Treatment areas may be set by means of laser sight—the operator may mark the area to be treated prior to the treatment.
The active element may deliver energy through its entire surface or by means of a so-called fractional arrangement when the active part includes a matrix formed by points of defined size. These points may be separated by inactive (and therefore untreated) areas that allow faster tissue healing. The points surface may make up from 1% to 99% of the active element area.
The electromagnetic energy may be primarily generated by a laser, laser diode module, LED, flash lamp or incandescent light bulb or by radiofrequency generator for causing the heating of the patient. Additionally, an acoustic energy or electric or electromagnetic energy, which does not heat the patient, may be delivered simultaneously, alternately or in overlap with the primary electromagnetic energy.
Additionally, the heating of the patient may be provided by a heated fluid, magnetic field, ultrasound, or by a heating element (e.g. resistance wire or thermoelectric cooler (TEC)).
The active element may deliver more than one energy simultaneously (at the same time), successively or in overlap. For example, the active element may deliver a radiofrequency energy and subsequently an electric energy (electric current). In another example, the active element may deliver the radiofrequency energy and the electric energy at the same time.
Furthermore the device may be configured to deliver the electromagnetic field by at least one active element and simultaneously (at the same time) deliver e.g. electric energy by a different elements.
The proposed methods and devices may provide heating of tissue, contractions of muscles or the combination of heating and muscle contractions.
In one aspect, the proposed device may provide three different types of energies. For example, radiofrequency energy, electric current, and magnetic field; radiofrequency energy, electric current, and pressure pulses; radiofrequency energy, magnetic field, and pressure pulses; or any other possible combinations of energies provided by the proposed device.
Thus the proposed methods and devices may lead to improvement of a visual appearance including, but by no means limited to a proper skin rejuvenation, wrinkle removal, skin tightening and lifting, cellulite and fat reduction, treatment of pigmented lesions, rhytides, tattoo removal, soft tissue coagulation and ablation, vascular lesions reduction, temporary relief of pain, muscle spasms, increase in local circulation, etc. of uneven rugged areas without causing further harm to important parts of the patient's body, e.g. nerves or internal organs. The proposed method and devices may lead to an adipose tissue reduction, e.g. by fat cells lipolysis or apoptosis.
Furthermore, the proposed methods and devices may lead to improvement of a visual appearance, e.g. tissue rejuvenation via muscle strengthening or muscle toning through muscle contractions caused by electric current or electromagnetic energy and via elastogenesis and/or neocolagenesis and/or relief of pain and/or muscle spasms and/or increase in local circulation through heating by radiofrequency energy.
Alternatively, the proposed devices and methods may be used for post-surgical treatment, e.g. after liposuction, e.g. for treatment and/or healing of the wounds caused by surgery.
The presented methods and devices may be used for stimulation and/or treatment of a tissue, including but not limited to skin, epidermis, dermis, hypodermis or muscles. The proposed apparatus is designed for minimally to non-invasive treatment of one or more areas of the tissue to enable well defined unattended treatment of the uneven, rugged areas (e.g. facial area) by electromagnetic energy delivery via a single or a plurality of active elements without causing further harm to important parts of the patient's body, e.g. nerves or internal organs.
Additionally the presented methods and devices may be used to stimulate body parts or body areas like head, neck, bra fat, love handles, torso, back, abdomen, buttocks, thighs, calves, legs, arms, forearms, hands, fingers or body cavities (e.g. vagina, anus, mouth, inner ear etc.).
The proposed methods and devices may include a several protocols improving of visual appearance, which may be preprogramed in the control unit (e.g. CPU—central processing unit, which may include a flex circuit or a printed circuit board and may include a microprocessor or memory for controlling the device).
The desired effect may include tissue (e.g. a surface of the skin) heating (thermal therapy) in the range of 37.5° C. to 55° C. or in the range of 38° C. to 53° C. or in the range of 39° C. to 52° C. or in the range of 40° C. to 50° C. or in the range of 41° C. to 45° C., tissue coagulation at temperatures in the range of 50° C. to 70° C. or in the range of 51° C. to 65° C. or in the range of 52° C. to 62° C. or in the range of 53° C. to 60° C. or tissue ablation at temperatures in the range of 55° C. to 130° C. or in the range of 58° C. to 120° C. or in the range of 60° C. to 110° C. or in the range of 60° C. to 100° C. The device may be operated in contact or in contactless methods. For contact therapy a target temperature of the skin may be typically within the range of 37.5° C. to 95° C. or in the range of 38° C. to 90° C. or in the range of 39° C. to 85° C. or in the range of 40° C. to 80° C. while for contactless therapy a target temperature of the skin may be in the range of 37.5° C. to 130° C. or in the range of 38° C. to 120° C. or in the range of 39° C. to 110° C. or in the range of 40° C. to 100° C. The temperature within the range of 37.5° C. to 130° C. or in the range of 38° C. to 120° C. or in the range of 39° C. to 110° C. or in the range of 40° C. to 100° C. may lead to stimulation of fibroblasts and formation of connective tissue—e.g. collagen, elastin, hyaluronic acid etc. Depending on the target temperature, controlled tissue damage is triggered, physiological repair processes are initiated, and new tissue is formed. Temperatures within the range of 37.5° C. to 130° C. or in the range of 38° C. to 120° C. or in the range of 39° C. to 110° C. or in the range of 40° C. to 100° C. may further lead to changes in the adipose tissue. During the process of apoptosis caused by high temperatures, fat cells come apart into apoptotic bodies and are further removed via the process of phagocytosis. During a process called necrosis, fat cells are ruptured due to high temperatures, and their content is released into an extracellular matrix. Both processes may lead to a reduction of fat layers enabling reshaping of the face. Removing fat from the face may be beneficial for example in areas like submentum or cheeks.
Another desired effect may include tissue rejuvenation, e.g. muscle strengthening through the muscle contraction caused by electric or electromagnetic energy, which doesn't heat the patient, or the muscle relaxation caused by a pressure massage. The combined effect of muscle contractions via electric energy and tissue (e.g. skin) heating by electromagnetic field in accordance to the description may lead to significant improvement of visual appearance.
Main unit 2 may include one or more generators: a primary electromagnetic generator 6, which may preferably deliver radiofrequency energy in the range of 10 kHz to 300 GHz or 300 kHz to 10 GHz or 400 kHz to 6 GHz, or in the range of 100 kHz to 550 MHz or 250 kHz to 500 MHz or 350 kHz to 100 MHz or 400 kHz to 80 MHz, a secondary generator 9 which may additionally deliver electromagnetic energy, which does not heat the patient, or deliver electric current in the range of 1 Hz to 10 MHz or 5 Hz to 5 MHz or in the range of 10 Hz to 1 MHz or in the range of 20 Hz to 1 kHz or in the range of 40 Hz to 500 Hz or in the range of 50 Hz to 300 Hz and/or an ultrasound emitter 10 which may furthermore deliver an acoustic energy with a frequency in the range of 20 kHz to 25 GHz or 20 kHz to 1 GHz or 50 kHz to 250 MHz or 100 kHz to 100 MHz. In addition, the frequency of the ultrasound energy may be in the range of 20 kHz to 80 MHz or 50 kHz to 50 MHz or 150 kHz to 20 MHz.
The output power of the radiofrequency energy may be less than or equal to 450 W, 300 W, 250 W or 220 W. Additionally, the radiofrequency energy on the output of the primary electromagnetic generator 6 (e.g. radiofrequency generator) may be in the range of 0.1 W to 400 W, or in the range of 0.5 W to 300 W or in the range of 1 W to 200 W or in the range of 10 W to 150 W. The radiofrequency energy may be applied in or close to the ISM bands of 6.78 MHz, 13.56 MHz, 27.12 MHz, 40.68 MHz, 433.92 MHz, 915 MHz, 2.45 GHz and 5.8 GHz.
The primary generator 6 may also provide more than one radiofrequency energy with different parameters. As one non-limiting example, the primary generator may generate one radiofrequency energy with frequency in a range of 100 kHz to 550 MHz, 250 kHz to 500 MHz, 350 kHz to 100 MHz, or 400 kHz to 80 MHz and a second radiofrequency energy with a frequency in a range of 400 kHz to 300 GHz, 500 kHz to 30 GHz, 600 kHz to 10 GHz, or 650 kHz to 6 GHz.
Additionally, the heating of the patient may be provided by a heated fluid. In one aspect, the fluid may be heated in the heat generator inside the main unit 2 and may be coupled to the pad 4 by a fluid conduit, which may be in a form of a closed loop. When the heated fluid is delivered, e.g. via a pump, fan or other fluid delivery system, towards the patient via the active element in the pad 4, it dissipates its heat, and then the fluid is brought back to the heat generator where it is heated again. The fluid may be in form of a liquid (e.g. water, or oil) or a gas (e.g. air, nitrogen, carbon dioxide, carbon oxide, or other suitable gases know in the prior art). The fluid may be heated to the temperature in a range of 37.5° C. to 100° C., in a range of 38° C. to 64° C., or in a range of 40° C. to 57° C. In one aspect, the heated fluid may be supplementary heating energy for the electromagnetic heating energy or vice versa.
In one aspect, the heating may be provided by a heating element, for example a resistance wire or a thermoelectric cooler (TEC) which may be connected to primary electromagnetic generator 6 or secondary generator 9. In this aspect, the active element may be the heating element. The heating element may have the temperature on its surface in a range of 37.5° C. to 68° C., in a range of 38° C. to 62° C., or in a range of 39° C. to 50° C.
Main unit 2 may further comprise a human machine interface 8 represented by a display, buttons, a keyboard, a touchpad, a touch panel or other control members enabling an operator to check and adjust therapy and other device parameters. For example, it may be possible to set the power, treatment time or other treatment parameters of each generator (primary electromagnetic generator 6, secondary generator 9 and ultrasound emitter 10) independently. The human machine interface 8 may be connected to control unit 11 (e.g. CPU). The power supply 5 located in the main unit 2 may include a transformer, disposable battery, rechargeable battery, power plug or standard power cord. The output power of the power supply 5 may be in the range of 10 W to 600 W, or in the range of 50 W to 500 W, or in the range of 80 W to 450 W.
In addition the human machine interface 8 may also display information about the applied therapy type, remaining therapy time and main therapy parameters.
Interconnecting block 3 may serve as a communication channel between the main unit 2 and the pad 4. It may be represented by a simple device containing basic indicators 17 and mechanisms for therapy control. Indicators 17 may be realized through the display, LEDs, acoustic signals, vibrations or other forms capable of providing adequate notice to an operator and/or the patient. Indicators 17 may indicate actual patient temperature, contact information or other sensor measurements as well as a status of a switching process between the active elements, quality of contact with the treated tissue, actual treatment parameters, ongoing treatment, etc. Indicators 17 may be configured to warn the operator in case of suspicious therapy behavior, e.g. temperature out of range, improper contact with the treated tissue, parameters automatically adjusted etc. Interconnecting block 3 may be used as an additional safety feature for heat-sensitive patients. It may contain emergency stop button 16 so that the patient can stop the therapy immediately anytime during the treatment. Switching circuitry 14 may be responsible for switching between active elements or for regulation of energy delivery from primary electromagnetic generator 6, secondary generator 9 or ultrasound emitter 10. The rate of switching between active elements 13 may be dependent on the amount of delivered energy, pulse length etc, and/or on the speed of switching circuitry 14 and control unit 11 (e.g. CPU). The switching circuitry 14 may include relay switch, transistor (bipolar, PNP, NPN, FET, JFET, MOSFET) thyristor, diode, optical switch, opto-electrical switch or opto-mechanical switch or any other suitable switch know in the prior art. The switching circuitry in connection with the control unit 11 (e.g. CPU) may control the switching between the primary electromagnetic energy generated by the primary electromagnetic generator 6 and the secondary energy generated by the secondary generator 9 on the at least one active element 13.
Additionally, the interconnecting block 3 may contain the primary electromagnetic generator 6, the secondary generator 9 or ultrasound emitter 10 or only one of them or any combination thereof.
In one not limiting aspect, the main unit 2 may comprise the primary electromagnetic generator 6, the interconnecting block 3 may comprise the secondary generator 9, and ultrasound emitter 10 may not be present at all.
The control unit 11 (e.g. CPU) controls the primary electromagnetic generator 6 such that the primary electromagnetic energy may be delivered in a continuous mode (CM) or a pulse mode to the at least one active element, having a fluence in the range of 10 mJ/cm2 to 50 kJ/cm2 or in the range of 100 mJ/cm2 to 10 kJ/cm2 or in the range of 0.5 J/cm2 to 1 kJ/cm2. The electromagnetic energy may be primarily generated by a laser, laser diode module, LED, flash lamp or incandescent light bulb or by radiofrequency generator for causing the heating of the patient. The CM mode may be operated for a time interval in the range of 0.05 s to 60 min or in the range of 0.1 s to 45 min or in the range of 0.2 s to 30 min. The pulse duration of the energy delivery operated in the pulse regime may be in the range of 0.1 ms to 10 s or in the range of 0.2 ms to 7 s or in the range of 0.5 ms to 5 s. The primary electromagnetic generator 6 in the pulse regime may be operated by a control unit 11 (e.g. CPU) in a single shot mode or in a repetition mode. The frequency of the repetition mode may be in the range of 0.05 to 10 000 Hz or in the range of 0.1 to 5000 Hz or in the range of 0.3 to 2000 Hz or in the range of 0.5 to 1000 Hz. Alternatively, the frequency of the repetition mode may be in the range of 0.1 kHz to 200 MHz or in the range of 0.5 kHz to 150 MHz or in the range of 0.8 kHz to 100 MHz or in the range of 1 kHz to 80 MHz. The single shot mode may mean generation of just one electromagnetic pulse of specific parameters (e.g. intensity, duration, etc.) for delivery to a single treatment area. The repetition mode may mean generation of an electromagnetic pulses, which may have the specific parameters (e.g. intensity, duration, etc.), with a repetition rate of the above-mentioned frequency for delivery to a single treatment area. The control unit (e.g. CPU) 11 may provide treatment control such as stabilization of the treatment parameters including treatment time, power, duty cycle, time period regulating switching between multiple active elements, temperature of the device 1 and temperature of the primary electromagnetic generator 6 and secondary generator 9 or ultrasound emitter 10. The control unit 11 (e.g. CPU) may drive and provide information from the switching circuitry 14. The control unit 11 (e.g. CPU) may also receive and provide information from sensors located on or in the pad 4 or anywhere in the device 1. The control unit (e.g. CPU) 11 may include a flex circuit or a printed circuit board and may include a microprocessor or memory for controlling the device.
The electromagnetic waves 1101 (e.g. radiofrequency waves) may be modulated in amplitude or frequency within one electromagnetic pulse (1102 or 1103) or may be modulated differently in different electromagnetic pulses. For example, a first electromagnetic pulse may have a rectangular envelope and a second electromagnetic pulse following the first electromagnetic pulse may have a sinusoidal envelope. The pause time 1104 between two consecutive pulses 1102 may be in the range of 1 μs to 1 s, in the range of 500 μs to 500 ms, in the range of 1 ms to 450 ms, or in the range of 100 ms to 450 ms. The pause time 1104 is a time when there are no electromagnetic waves provided by the device.
The control unit (e.g. CPU) 11 may control the secondary generator 9 such that secondary energy (e.g electric current or magnetic field) may be delivered in a continuous mode (CM) or a pulse mode to the at least one active element, having a fluence in the range of 10 mJ/cm2 to 50 kJ/cm2 or in the range of 100 mJ/cm2 to 10 kJ/cm2 or in the range of 0.5 J/cm2 to 1 kJ/cm2 on the surface of the at least one active element. Applying the secondary energy to the treatment area of the patient may cause a muscle contractions of the patient. The CM mode may be operated for a time interval in the range of 0.05 s to 60 min or in the range of 0.1 s to 45 min or in the range of 0.2 s to 30 min. The pulse duration of the delivery of the secondary energy operated in the pulse regime may be in the range of 0.1 μs to 10 s or in the range of 0.2 μs to 1 s or in the range of 0.5 μs to 500 ms, or in the range of 0.5 to 10 s or in the range of 1 to 8 s or in the range of 1.5 to 5 s or in the range of 2 to 3 s. The secondary generator 9 in the pulse regime may be operated by a control unit 11 (e.g. CPU) in a single shot mode or in a repetition mode. The frequency of the repetition mode may be in the range of 0.1 to 12 000 Hz or in the range of 0.1 to 8000 Hz or in the range of 0.1 to 5000 Hz or in the range of 0.5 to 1000 Hz.
The secondary energy (e.g. electric current pulses or magnetic field pulses) generated by the secondary generator 9 may be modulated in frequency or amplitude in the same way as the electromagnetic energy (e.g. radiofrequency waves) generated by the primary generator 6, creating different shapes of the secondary energy envelopes (e.g. electric current envelopes) as seen in
The secondary energy (e.g. electric current or magnetic field) may be also modulated in frequency within the secondary energy envelope 1112, which may cause an increasing or decreasing treatment response in the patient's body. For example, the electric current or the magnetic field may be modulated such that the frequency of secondary energy pulses 1111 is increasing, which may cause an intensity of muscle contractions to increase. Then the frequency of the secondary energy pulses 1111 may be constant causing the same intensity of muscle contractions and then the frequency of the secondary energy pulses 1111 may be decreasing causing decreasing intensity of the muscle contractions. The same principle may be used for the primary electromagnetic energy, thus creating, for example, series of increasing, constant and decreasing amplitudes of the electromagnetic energy, or series of increasing, constant and decreasing frequencies of the electromagnetic waves, which both may cause an increasing, constant and decreasing heating of the tissue of the patient.
Alternatively, it may be also possible to use only one generator to generate one type of energy/signal and one or more converters that convert the energy/signal to other one or more types of energy/signal. For example, the primary generator may generate a radiofrequency signal that is converted to electric current by the convertor (e.g. by a converting electric circuit).
The proposed device may be multichannel device allowing the control unit (e.g. CPU) 11 to control the treatment of more than one treated area at once.
Alternatively, the interconnecting block 3 may not be a part of the device 1, and the control unit (e.g. CPU) 11, switching circuitry 14, indicators 17 and emergency stop button 16 may be a part of the main unit 2 or pad 4. In addition, some of the control unit (e.g. CPU) 11, switching circuitry 14, indicators 17 and emergency stop button 16 may be a part of the main unit 2 and some of them part of pad 4, e.g. control unit (e.g. CPU) 11, switching circuitry 14 and emergency stop button 16 may be part of the main unit 2 and indicators 17 may be a part of the pad 4.
Pad 4 represents the part of the device which may be in contact with the patient's skin during the therapy. The pads 4 may be made of flexible substrate material—for example polymer-based material, polyimide (PI) films, polytetrafluoroethylene (PTFE, e.g., Teflon®), epoxy, polyethylene terephthalate (PET), polyamide or polyethylene (PE) foam with an additional adhesive layer on an underside, e.g. a hypoallergenic adhesive gel (hydrogel) or adhesive tape that may be bacteriostatic, non-irritating, or water-soluble. The substrate may also be a silicone-based substrate. The substrate may also be made of a fabric, e.g. non-woven fabric. The adhesive layer may have the impedance for a current at a frequency of 500 kHz in the range of 1 to 150Ω or in the range of 5 to 130Ω or in the range of 10 to 100Ω, and the impedance for a current at a frequency of 100 Hz or less is three times or more the impedance for a current at a frequency of 500 kHz. The adhesive hydrogel may be made of a polymer matrix or mixture containing water, a polyhydric alcohol, a polyvinylpyrrolidone, a polyisocyanate component, a polyol component or has a methylenediphenyl structure in the main chain. Additionally, a conductive adhesive may be augmented with metallic fillers, such as silver, gold, copper, aluminum, platinum or titanium or graphite that make up 1 to 90% or 2 to 80% or 5 to 70% of adhesive. The adhesive layer may be covered by “ST-gel®” or “Tensive®” conductive adhesive gel which is applied to the body to reduce its impedance, thereby facilitating the delivery of an electric shock.
The adhesive layer, e.g. hydrogel may cover exactly the whole surface of the pad facing the body area of the patient. The thickness of the hydrogel layer may be in the range of 0.1 to 3 mm or in the range of 0.3 to 2 mm or in the range of 0.4 to 1.8 mm or in the range of 0.5 to 1.5 mm.
The adhesive layer under the pad 4 may mean that the adhesive layer is between the surface of the pad facing the patient and the body of the patient. The adhesive layer may have impedance 1.1 times, 2 times, 4 times or up to 10 times higher than the impedance of the skin of the patient under the pad 4. A definition of the skin impedance may be that it is a portion of the total impedance, measured between two equipotential surfaces in contact with the epidermis, that is inversely proportional to the electrode area, when the internal current flux path is held constant. Data applicable to this definition would be conveniently recorded as admittance per unit area to facilitate application to other geometries. The impedance of the adhesive layer may be set by the same experimental setup as used for measuring the skin impedance. The impedance of the adhesive layer may be higher than the impedance of the skin by a factor in the range of 1.1 to 20 times or 1.2 to 15 times or 1.3 to 10 times.
The impedance of the adhesive layer may have different values for the different types of energy delivered to the patient, e.g. the impedance may be different for radiofrequency and for electric current delivery. The impedance of the hydrogel may be in the range of 100 to 2000 Ohms or in the range of 150 to 1800 Ohms or 200 to 1500 Ohms or 300 to 1200 Ohms in case of delivery of the electric current (e.g. during electrotherapy). In one aspect, the impedance of an adhesive layer (e.g. hydrogel) for AC current at 1 kHz may be in the range of 100 to 5000 Ohms, or of 200 to 4500 Ohms, or of 500 to 4000 Ohms, or of 1000 to 3000 Ohms, or of 1200 to 2800 Ohms, or of 1500 to 2500 Ohms. In another aspect, the impedance of the adhesive layer (e.g. hydrogel) for AC current at 10 Hz may be in the range of 2000 to 4000 Ohms, or of 2300 to 3700 Ohms, or of 2500 to 3500 Ohms.
The electric conductivity of the adhesive layer at radiofrequency of 3.2 MHz may be in the range of 20 to 200 mS/m or in the range of 50 to 140 mS/m or in the range of 60 to 120 mS/m or in the range of 70 to 100 mS/m.
Alternatively, the adhesive layer may be a composition of more elements, wherein some elements may have suitable physical properties (referred to herein as adhesive elements), e.g. proper adhesive and/or conductivity and/or impedance and/or cooling properties and so on; and some elements may have nourishing properties (referred to herein as nourishing elements), e.g. may contain nutrients, and/or vitamins, and/or minerals, and/or organic and/or inorganic substances with nourishing effect, which may be delivered to the skin of the patient during the treatment. The volumetric ratio of adhesive elements to nourishing elements may be in the range of 1:1 to 20:1, or of 2:1 to 10:1, or of 3:1 to 5:1, or of 5:1 to 50:1, or of 10:1 to 40:1, or of 15:1. In one aspect, the adhesive layer composition may contain a hydrogel as an adhesive element and a hyaluronic acid as a nourishing element. In another aspect, the adhesive layer composition may contain a hydrogel as an adhesive element and one or more vitamins as nourishing elements. In another aspect, the adhesive layer composition may contain a hydrogel as an adhesive element and one or more minerals as nourishing elements.
In one aspect, the nourishing element may be released continuously by itself during the treatment. In another aspect, the nourishing element may be released due to delivery of a treatment energy (e.g. heat, radiofrequency, light, electric current, magnetic field or ultrasound), which may pass through the nourishing element and thus cause its release to the skin of the patient.
The pad comprising the adhesive layer may be configured for a single use (disposable).
Alternatively, the pad may not contain the adhesive layer and may comprise at least the substrate and the active element (e.g. electrode).
In one aspect, at the beginning of the treatment the adhesive layer (e.g. hydrogel) may be externally applied on the surface of the patient prior to the application of the pad. The pad is then coupled to the adhesive layer. In another aspect, a covering layer (e.g. thin foil) may be inserted between the adhesive layer and the pad. The foil may be adhesive on one side or on both sides and provide a coupling of the pad with the body of the patient. In this case, it may be possible to use the same pad more than once as the covering layer guarantee the hygienic safety of the pad.
In another aspect, layers of some other substance may be applied on the surface of the patient prior to the application of the pad and the pad is coupled to this layer. This may be active substance layer, cooling layer (e.g. cooling gel), partially adhesive layer, or any other non-adhesive layer. In one aspect, the active substance layer may comprise e.g. hyaluronic acid, one or more vitamins, one or more minerals or any of their combination. The active substance from the active substance layer may be in form of a solution (e.g. gel or cream) applied on the patient or may be coupled to the covering layer (e.g. thin foil), which is then attached to the skin of the patient. The active substance may be continuously released into the skin due to at least one energy provided by the pad (e.g. radiofrequency energy, or heat, or electric current or magnetic field, etc.) throughout the treatment. In another aspect, the active substance may be released into the skin at the beginning, at some time during, or at the end of the treatment in order to visually improve the skin.
The pad 4 may also have a sticker on a top side of the pad. The top side is the opposite side from the underside (the side where the adhesive layer may be deposited) or in other words the top side is the side of the pad that is facing away from the patient during the treatment. The sticker may have a bottom side and a top side, wherein the bottom side of the sticker may comprise a sticking layer and the top side of the sticker may comprise non-sticking layer (eg. polyimide (PI) films, PTFE (e.g. Teflon®), epoxy, polyethylene terephthalate (PET), polyamide or PE foam, PE film or PVC foam). Thus the sticker may be made of two layers (top non-sticking and bottom sticking layer). The sticker covers the top side of the pad and may also cover some sensors situated on the top side of the pad (e.g. thermal sensors).
The sticker may have the same shape as the pad 4 or may have additional overlap over the pad, e.g., extend beyond the shape of the pad 4. The sticker may be bonded to the pad such that the sticking layer of the bottom side of the sticker is facing toward the top side of the pad 4. The top side of the sticker facing away from the pad 4 may be made of a non-adhesive layer. The linear dimension of the sticker with additional overlap may exceed the corresponding dimension of the pad in the range of 0.1 to 10 cm, or in the range of 0.1 to 7 cm, or in the range of 0.2 to 5 cm, or in the range of 0.2 to 3 cm, or in the range of 0.3 to 1 cm. The area of the sticker (with the overlap) may be 0.5% to 50%, 1% to 40%, 1.5% to 33%, 2% to 25% 3% to 20%, or 5% to 15% larger than the area of the pad. This overlap may also comprise an adhesive layer and may be used to form additional and more proper contact of the pad with the patient. The thickness of the sticker may be in the range of 0.05 to 3 mm or in the range of 0.1 to 2 mm or in the range of 0.5 to 1.5 mm. The top side of the sticker may have a printed inscription for easy recognition of the pad, e.g. the brand of the manufacturer or the proposed treated body area.
In one aspect, the adhesive layer, e.g. hydrogel, on the underside of the pad facing the body area of the patient may cover the whole surface of the pad and even overlap the surface of the pad and cover at least partially the overlap of the sticking layer. In another aspect, the underside of the adhesive layer and/or the overlap of the sticker (both parts facing towards the patient) may be covered by a liner, which may be removed just before the treatment. The liner protects the adhesive layer and/or the overlap of the sticker, thus when the liner is removed the proper adhesion to the body area of the patient is ensured.
Alternatively, the pad 4 may comprise at least one suction opening, e.g. small cavities or slits adjacent to active elements or the active element may be embedded inside a cavity. The suction opening may be connected via connecting tube to a pump which may be part of the main unit 2. When the suction opening is brought into contact with the skin, the air sucked from the suction opening flows toward the connecting tube and the pump and the skin may be slightly sucked into the suction opening. Thus by applying a vacuum the adhesion of pad 4 may be provided. Furthermore, the pad 4 may comprise the adhesive layer and the suction openings for combined stronger adhesion.
In addition to the vacuum (negative pressure), the pump may also provide a positive pressure by pumping the fluid to the suction opening. The positive pressure is pressure higher than atmospheric pressure and the negative pressure or vacuum is lower than atmospheric pressure. Atmospheric pressure is a pressure of the air in the room during the therapy.
The pressure (positive or negative) may be applied to the treatment area in pulses providing a massage treatment. The massage treatment may be provided by one or more suction openings changing pressure value to the patient's soft tissue in the meaning that the suction opening apply different pressure to patient tissue. Furthermore, the suction openings may create a pressure gradient in the soft tissue without touching the skin. Such pressure gradients may be targeted on the soft tissue layer, under the skin surface and/or to different soft tissue structure.
Massage accelerates and improves treatment therapy by electromagnetic energy, electric energy or electromagnetic energy which does not heat the patient, improves blood and/or lymph circulation, angioedema, erythema effect, accelerates removing of the fat, accelerate metabolism, accelerates elastogenesis and/or neocolagenesis.
Each suction opening may provide pressure by a suction mechanism, airflow or gas flow, liquid flow, pressure provided by an object included in the suction opening (e.g. massaging object, pressure cells etc.) and/or in other ways.
Pressure value applied on the patient's tissue means that a suction opening providing massaging effect applies positive, negative and/or sequentially changing positive and negative pressure on the treated and/or adjoining patient's tissue structures and/or creates a pressure gradient under the patient's tissue surface
Massage applied in order to improve body liquid flow (e.g. lymph drainage) and/or relax tissue in the surface soft tissue layers may be applied with pressure lower than during the massage of deeper soft tissue layers. Such positive or negative pressure compared to the atmospheric pressure may be in a range of 10 Pa to 30 000 Pa, or in a range of 100 Pa to 20 000 Pa or in a range of 0.5 kPa to 19 kPa or in a range of 1 kPa to 15 kPa.
Massage applied in order to improve body liquid flow and/or relaxation of the tissue in the deeper soft tissue layers may be applied with higher pressure. Such positive or negative pressure may be in a range from 12 kPa to 400 kPa or from 15 kPa to 300 kPa or from 20 kPa to 200 kPa. An uncomfortable feeling of too high applied pressure may be used to set a pressure threshold according to individual patient feedback.
Negative pressure may stimulate body liquid flow and/or relaxation of the deep soft tissue layers (0.5 cm to non-limited depth in the soft tissue) and/or layers of the soft tissue near the patient surface (0.1 mm to 0.5 cm). In order to increase effectiveness of the massage negative pressure treatment may be used followed by positive pressure treatment.
A number of suction openings changing pressure values on the patient's soft tissue in one pad 4 may be between 1 to 100 or between 1 to 80 or between 1 to 40 or between 1 to 10.
Sizes and/or shapes of suction openings may be different according to treated area. One suction opening may cover an area on the patient surface between 0.1 mm2 to 1 cm2 or between 0.1 mm2 to 50 mm2 or between 0.1 mm2 to 40 mm2 or between 0.1 mm2 to 20 mm2. Another suction opening may cover an area on the patient surface between 1 cm2 to 1 m2 or between 1 cm2 to 100 cm2 or between 1 cm2 to 50 cm2 or between 1 cm2 to 40 cm2.
Several suction openings may work simultaneously or switching between them may be in intervals between 1 ms to 10 s or in intervals between 10 ms to 5 s or in intervals between 0.5 s to 2 s.
Suction openings in order to provide massaging effect may be guided according to one or more predetermined massage profile included in the one or more treatment protocols. The massage profile may be selected by the operator and/or by a control unit (e.g. CPU) with regard to the patient's condition. For example a patient with lymphedema may require a different level of compression profile and applied pressure than a patient with a healed leg ulcer.
Pressure applied by one or more suction openings may be gradually applied preferably in the positive direction of the lymph flow and/or the blood flow in the veins. According to specific treatment protocols the pressure may be gradually applied in a direction opposite or different from ordinary lymph flow. Values of applied pressure during the treatment may be varied according to the treatment protocol.
A pressure gradient may arise between individual suction openings. Examples of gradients described are not limited for this method and/or device. The setting of the pressure gradient between at least two previous and successive suction openings may be: 0%, i.e. The applied pressure by suction openings is the same (e.g. pressure in all suction openings of the pad is the same);
1%, i.e. The applied pressure between a previous and a successive suction opening decreases and/or increases with a gradient of 1% (e.g. the pressure in the first suction opening is 5 kPa and the pressure in the successive suction opening is 4.95 kPa);
2%, i.e. The pressure decreases or increases with a gradient of 2%. The pressure gradient between two suction openings may be in a range 0% to 100% where 100% means that one suction openings is not active and/or does not apply any pressure on the patient's soft tissue.
A treatment protocol that controls the application of the pressure gradient between a previous and a successive suction opening may be in a range between 0.1% to 95%, or in a range between 0.1% to 70%, or in a range between 1% to 50%.
The suction opening may also comprise an impacting massage object powered by a piston, massage object operated by filling or sucking out liquid or air from the gap volume by an inlet/outlet valve or massage object powered by an element that creates an electric field, magnetic field or electromagnetic field. Additionally, the massage may be provided by impacting of multiple massage objects. The multiple massage objects may have the same or different size, shape, weight or may be created from the same or different materials. The massage objects may be accelerated by air or liquid flowing (through the valve) or by an electric, magnetic or electromagnetic field. Trajectory of the massage objects may be random, circular, linear and/or massage objects may rotate around one or more axes, and/or may do other types of moves in the gap volume.
The massage unit may also comprise a membrane on the side facing the patient which may be accelerated by an electric, magnetic, electromagnetic field or by changing pressure value in the gap volume between wall of the chamber and the membrane. This membrane may act as the massage object.
During the treatment, it may be convenient to use a combination of pads with adhesive layer and pads with suction openings. In that case at least one pad used during the treatment may comprise adhesive layer and at least additional one pad used during the treatment may comprise suction opening. For example, pad with adhesive layer may be suited for treatment of more uneven areas, e.g. periorbital area, and pad with suction openings for treatment of smoother areas, e.g. cheeks.
The advantage of the device where the attachment of the pads may be provided by an adhesion layer or by a suction opening or their combination is that there is no need of any additional gripping system which would be necessary to hold the pads on the treatment area during the treatment, e.g. a band or a felt, which may cause a discomfort of the patient.
In one aspect, the suction openings may provide the heated fluid to cause heating of the patient (e.g. hot air), which may be provided instead of, or as u supplementary energy to the primary electromagnetic energy (e.g. radiofrequency energy).
Yet in another aspect, it is possible to fasten the flexible pads 4 to the face by at least one fastening mechanism, for example—a band or a felt, which may be made from an elastic material and thus adjustable for an individual face. In that case the flexible pads, which may have not the adhesive layer or suction opening, are placed on the treatment area of the patient and their position is then fastened by a band or felt to avoid deflection of the pads from the treatment areas. Alternatively, the band may be replaced by a mask, e.g. an elastic mask that covers from 5% to 100% or from 30% to 99% or from 40% to 95% or from 50% to 90% of the face and may serve to secure the flexible pads on the treatment areas. In another aspect, the mask may be rigid or semi rigid. The mask may contain one connecting part comprising conductive leads which then distributes the conductive leads to specific pads. Furthermore, it may be possible to use the combination of the pad with adhesive layer or suction opening and the fastening band, felt or mask to ensure strong attachment of the pads on the treatment areas.
Additionally, the fastening mechanism may be in the form of a textile or a garment which may be mountable on a patient's body part. In use of the device, a surface of the active element or pad 4 lays along an inner surface of the garment, while the opposite surface of the active element or pad 4 is in contact with the patient's skin, preferably by means of a skin-active element hydrogel interface.
The garment may be fastened for securement of the garment to or around a patient's body part, e.g. by hook and loop fastener, button, buckle, stud, leash or cord, magnetic-guided locking system or clamping band and the garment may be manufactured with flexible materials or fabrics that adapt to the shape of the patient's body or limb. The pad 4 may be in the same way configured to be fastened to the inner surface of the garment. The garment is preferably made of breathable materials. Non limiting examples of such materials are soft Neoprene, Nylon, polyurethane, polyester, polyamide, polypropylene, silicone, cotton or any other material which is soft and flexible. All named materials could be used as woven, non-woven, single use fabric or laminated structures.
The garment and the pad may be modular system, which means module or element of the device (pad, garment) and/or system is designed separately and independently from the rest of the modules or elements, at the same time that they are compatible with each other.
The pad 4 may be designed to be attached to or in contact with the garment, thus being carried by the garment in a stationary or fixed condition, in such a way that the pads are disposed on fixed positions of the garment. The garment ensures the correct adhesion or disposition of the pad to the patient's skin. In use of the device, the surface of one or more active elements not in contact with the garment is in contact with the patient's skin, preferably by means of a hydrogel layer that acts as pad-skin interface. Therefore, the active elements included in the pad are in contact with the patient's skin.
The optimal placement of the pad on the patient's body part, and therefore the garment which carries the pad having the active elements, is determined by a technician or clinician helping the patient.
In addition, the garment may comprise more than one pad or the patient may wear more than one garment comprising one or more pads during one treatment session.
The pad 4 contains at least one active element 13 capable of delivering energy from primary electromagnetic generator 6 or secondary generator 9 or ultrasound emitter 10. In various aspects, the active element is an electrode, an optical element, an acoustic window, an ultrasound emitter, a coil, a fluid conduit, a heating element, or other energy delivering elements known in the art. The electrode may be a radiofrequency (RF) electrode. The RF electrode may be a dielectric electrode coated with insulating (e.g. dielectric) material. The RF electrode may be monopolar, bipolar, unipolar or multipolar. The bipolar arrangement may consist of electrodes that alternate between active and return function and where the thermal gradient beneath electrodes is almost the same during treatment. Bipolar electrodes may form circular or ellipsoidal shapes, where electrodes are concentric to each other. However, a group of bipolar electrode systems may be used as well. A unipolar electrode or one or more multipolar electrodes may be used as well. The system may alternatively use monopolar electrodes, where the so-called return electrode (or neutral electrode or ground electrode or grounding electrode) has larger area than so-called active electrode. The thermal gradient beneath the active electrode is therefore higher than beneath the return electrode. The active electrode may be part of the pad and the passive electrode having larger surface area may be located at least 5 cm, 10 cm, or 20 cm from the pad. A neutral electrode may be used as the passive electrode. The neutral electrode may be on the opposite side of the patient's body than the pad is attached. A unipolar electrode may also optionally be used. During unipolar energy delivery there is one electrode, no neutral electrode, and a large field of RF emitted in an omnidirectional field around a single electrode. Capacitive and/or resistive electrodes may be used. Radiofrequency energy may provide energy flux on the surface of the RF electrode or on the surface of the treated tissue (e.g. skin) in the range of 0.001 W/cm2 to 1500 W/cm2 or 0.01 W/cm2 to 1000 W/cm2 or 0.5 W/cm2 to 500 W/cm2 or 0.5 W/cm2 to 100 W/cm2 or 1 W/cm2 to 50 W/cm2. The energy flux on the surface of the RF electrode may be calculated from the size of the RF electrode and its output value of the energy. The energy flux on the surface of the treated tissue may be calculated from the size of the treated tissue exactly below the RF electrode and its input value of the energy provided by the RF electrode. In addition, the RF electrode positioned in the pad 4 may act as an acoustic window for ultrasound energy.
The active element 13 may provide a secondary energy from secondary generator 9 in the form of an electric current or a magnetic field. By applying the secondary energy to the treated area of the body of the patient, muscle fibers stimulation (e.g. muscle contractions) may be achieved and thus increasing muscle tone, muscle strengthening, restoration of feeling the muscle, relaxation of the musculature and/or stretching musculature.
The magnetic field provided by the active element 13 (e.g. coil) used for simulation of the muscle may be in the range of 0.01 T to 7 T, or in the range of 0.015 T to 4 T or in the range of 0.02 T to 1 T or in the range of 0.05 T to 0.5 T, on the surface of the active element (e.g. coil). The maximum value of the magnetic flux density derivative may be in the range of 1 T/s to 800 kT/s or in the range of 40 T/s to 320 kT/s or in the range of 80 T/s to 250 kT/s or in the range of 100 T/s to 250 kT/s or in the range of 250 T/s to 180 kT/s or in the range of 500 T/s to 100 kT/s or in the range of 1 kT/s to 65 kT/s. The value of magnetic flux density derivative may correspond to induced current within the tissue. The pulse duration of the magnetic field may be in the range of 3 μs to 10 ms, or alternatively 3 μs to 3 ms or alternatively 3 μs to 1 ms. The active element 13 (e.g. coil) may provide pulses of magnetic field with the frequency in the range of 1 Hz to 1200 kHz or in the range of 2 Hz to 600 Hz or in the range of 3 Hz to 250 Hz or in the range of 4 Hz to 150 Hz or in the range of 4 Hz to 65 Hz.
An inductance of the active element 13 (e.g. coil) used for magnetic field generation may be in the range of 1 nH to 500 mH, or in the range of 10 nH to 50 mH, or in the range of 50 nH to 10 mH, or in the range of 500 nH to 1 mH, or in the range of 1 μH to 500 μH. Alternatively, the inductance of the active element (e.g. coil) used for magnetic field generation may be in the range of 1 nH to 100 μH, or in the range of 5 nH to 50 μH, or in the range of 10 nH to 25 μH or in the range of 45 nH to 20 μH.
The proposed device may provide an electrotherapy in case that the secondary energy delivered by the active element 13 (e.g an electrotherapy electrode or simply referred just as an electrode, which may also be the radiofrequency electrode as described above) is the electric current generated by the secondary generator 9. The main effects of electrotherapy are: analgesic, myorelaxation, iontophoresis, anti-edematous effect or muscle stimulation causing a muscle fiber contraction. Each of these effects may be achieved by one or more types of electrotherapy: galvanic current, pulse direct current and alternating current.
Galvanic current (or “continuous”) is a current that may have constant electric current and/or absolute value of the electric current is in every moment higher than 0. It may be used mostly for iontophoresis, or its trophic stimulation (hyperemic) effect is utilized. At the present invention this current may be often substituted by galvanic intermittent current. Additionally, galvanic component may be about 95% but due to interruption of the originally continuous intensity the frequency may reach 5-12 kHz or 5-10 kHz or 5-9 kHz or 5-8 kHz.
The pulse direct current (DC) is of variable intensity but only one polarity. The basic pulse shape may vary. It includes e.g. diadynamics, rectangular, triangular and exponential pulse of one polarity. Depending on the used frequency and intensity it may have stimulatory, tropic, analgesic, myorelaxation, iontophoresis, at least partial muscle contraction and anti-edematous effect and/or other.
Alternating Current (AC or biphasic) where the basic pulse shape may vary—rectangular, triangular, harmonic sinusoidal, exponential and/or other shapes and/or combination of mentioned above. It can be alternating, symmetric and/or asymmetric. Use of alternating currents in contact electrotherapy implies much lower stress on the tissue under the electrode. For these types of currents the capacitive component of skin resistance is involved, and due to that these currents are very well tolerated by the patients.
AC therapies may be differentiated into five subtypes: TENS, Classic (four-pole) Interference, Two-pole Interference, Isoplanar Interference and Dipole Vector Field. There also exists some specific electrotherapy energy variants and modularity of period, shape of the energy etc.
Due to interferential electrotherapy, different nerves and tissue structures by medium frequency may be stimulated in a range of 500 Hz to 12 kHz or in a range of 500 Hz to 8 kHz, or 500 Hz to 6 kHz, creating pulse envelopes with frequencies for stimulation of the nerves and tissues e.g. sympathetic nerves (0.1-5 Hz), parasympathetic nerves (10-150 Hz), motor nerves (10-50 Hz), smooth muscle (0.1-10 Hz), sensor nerves (90-100 Hz) nociceptive fibers (90-150 Hz).
Electrotherapy may provide stimulus with currents of frequency in the range from 0.1 Hz to 12 kHz or in the range from 0.1 Hz to 8 kHz or in the range from 0.1 Hz to 6 kHz.
Muscle fiber stimulation by electrotherapy may be important during and/or as a part of the RF treatment. Muscle stimulation increases blood flow and lymph circulation. It may improve removing of treated cells and/or prevent of hot spots creation. Moreover internal massage stimulation of adjoining tissues improves homogeneity of tissue and dispersing of the delivered energy. The muscle fiber stimulation by electrotherapy may cause muscle contractions, which may lead to improvement of a visual appearance of the patient through muscle firming and strengthening, Another beneficial effect is for example during fat removing with the RF therapy. RF therapy may change structure of the fat tissue. The muscle fiber stimulation may provide internal massage, which may be for obese patient more effective than classical massage.
Muscle stimulation may be provided by e.g. intermittent direct currents, alternating currents (e.g. medium-frequency currents, Russian currents and TENS currents), faradic current as a method for multiple stimulation and/or others.
Frequency of the currents may be in the range from 0.1 Hz to 1500 Hz or from 0.1 to 1000 Hz or from 0.1 Hz to 500 Hz or from 0.1 to 300 Hz.
Frequency of the current envelope is typically in the range from 0.1 Hz to 500 Hz or from 0.1 to 250 Hz or from 0.1 Hz to 150 Hz or from 0.1 to 140 Hz. Additionally, the current envelopes may have an envelope repetition frequency (ERF) in a range of 0.01 to 100 per second, or of 0.05 to 50 per second, or of 0.07 to 30 per second, or of 0.1 to 20 per second, or of 0.2 to 6 per second.
The electrostimulation may be provided in a combined manner where various treatments with various effects may be achieved. As an illustrative example, the electromagnetic energy with the electrostimulation may be dosed in trains of pulses of electric current where the first train of electrostimulation may achieve different effect than second or other successive train of stimulation. Therefore, the treatment may provide muscle fibers stimulation or muscle contractions followed by relaxation, during continual or pulsed radiofrequency thermal heating provided by electromagnetic energy provided by electromagnetic energy generator.
The electrostimulation may be provided by monopolar, unipolar, bipolar or multipolar mode.
Absolute value of voltage between the electrotherapy electrodes operated in bipolar, multipolar mode (electric current flow between more than two electrodes) and/or provided to at least one electrotherapy electrode may be in a range between 0.8 V and 10 kV; or in a range between 1 V and 1 kV; or in a range between 1 V and 300 V or in a range between 1 V and 100 V or in a range between 10 V and 80 V or in a range between 20 V and 60 V or in a range between 30 V and 50 V.
Current density of electrotherapy for a non-galvanic current may be in a range between 0.1 mA/cm2 and 150 mA/cm2, or in a range between 0.1 mA/cm2 and 100 mA/cm2, or in a range between 0.1 mA/cm2 and 50 mA/cm2, or in a range between 0.1 mA/cm2 and 20 mA/cm2; for a galvanic current may be preferably in a range between 0.05 mA/cm2 and 3 mA/cm2, or in a range between 0.1 mA/cm2 and 1 mA/cm2, or in a range between 0.01 mA/cm2 and 0.5 mA/cm2. The current density may be calculated on the surface of the electrode providing the electrotherapy to the patient. In one aspect, the current density of electrotherapy for a non-galvanic current may be in a range between 0.1 mA/cm2 and 200 mA/cm2, or in a range between 0.5 mA/cm2 and 150 mA/cm2, or in a range between 1 mA/cm2 and 120 mA/cm2, or in a range between 5 mA/cm2 and 100 mA/cm2.
The electric current in one pulse in case of a pulsed electric current (e.g. pulse mode) may be in the range of 0.5 mA to 150 mA, in the range of 1 mA to 100 mA, in the range of 5 mA to 75 mA, or in the range of 10 mA to 55 mA. The duration of one electric current pulse may be preferably in the range of 1 to 500 μs, in the range of 10 to 350 μs, in the range of 20 to 200 μs, in the range of 35 to 150 μs, or in the range of 50 to 100 μs.
During electrotherapy, e.g. bipolar electrotherapy, two or more electrodes may be used. If polarity of at least one electrode has a non-zero value in a group of the electrodes during bipolar mode, the group of the electrodes has to include at least one electrode with opposite polarity value. Absolute values of both electrode polarities may or may not be equal. In bipolar electrostimulation mode stimulating signal passes through the tissue between electrodes with opposite polarities.
A distance between two electrodes operating in bipolar mode may be in a range between 0.1 mm and 4 cm or in a range between 0.2 mm to 3 cm or in a range between 0.5 mm and 2 cm or in a range between 1 mm and 1 cm or in a range between 2 mm and 7 mm, or in the range of 0.1 cm and 40 cm or in a range between 1 cm and 30 cm, or in the range between 1 cm and 20 cm, wherein the distance is between the two closest points of two electrodes operating in bipolar mode.
During monopolar electrotherapy mode stimulating signal may be induced by excitement of action potential by changing polarity of one electrode that change polarization in the nerve fiber and/or neuromuscular plague.
During the electrotherapy, one of the bipolar or monopolar electrotherapy mode may be used or bipolar or monopolar electrotherapy mode may be combined.
The ultrasound emitters may provide focused or defocused ultrasound energy. The ultrasound energy may be transferred to the tissue through an acoustic window. The output power of the ultrasound energy on the surface of the active element 13 may be less than or equal to 20 W or 15 W or 10 W or 5 W. Ultrasound energy may provide energy flux on the surface of the active element 13 or on the surface of the treated tissue (e.g. skin) in the range of 0.001 W/cm2 to 250 W/cm2, or in the range of 0.005 W/cm2 to 50 W/cm2, or in the range of 0.01 W/cm2 to 25 W/cm2, or in the range of 0.05 W/cm2 to 20 W/cm2. The treatment depth of ultrasound energy may be in the range of 0.1 mm to 100 mm or 0.2 mm to 50 mm or 0.25 mm to 25 mm or 0.3 mm to 15 mm. At a depth of 5 mm the ultrasound energy may provide an energy flux in the range of 0.01 W/cm2 to 20 W/cm2 or 0.05 W/cm2 to 15 W/cm2. An ultrasound beam may have a beam non-uniformity ratio (RBN) in the range of 0.1 to 20 or 2 to 15 to 4 to 10. In addition, an ultrasound beam may have a beam non-uniformity ratio below 15 or below 10. An ultrasound beam may be divergent, convergent and/or collimated. The ultrasound energy may be transferred to the tissue through an acoustic window. It is possible that the electrode may act as the acoustic window. Furthermore, the ultrasound emitter 10 may be a part of the active element 13, thus ultrasound emitter 10 may be a part of the pad 4.
In one aspect, the ultrasound may provide heating of the patient, and the ultrasound emitter 10 may be used instead of the primary electromagnetic generator 6, which may not be presented in the device. In another aspect, the ultrasound may provide supplementary heating energy to the energy generated by the primary electromagnetic generator 6.
At least some of the active elements 13 may be capable of delivering energy from primary electromagnetic generator 6 or secondary generator 9 or ultrasound emitter 10 simultaneously (at the same time) successively or in an overlapping method or in any combination thereof. For example, the active element 13 (e.g. electrode) may be capable of delivering radiofrequency energy and electric current sequentially, which may mean that firstly the active element 13 may provide primary electromagnetic energy generated by the primary electromagnetic generator 6 and subsequently the active element 13 may provide the secondary energy generated by the secondary generator 9. Thus the active element 13 may e.g. apply radiofrequency energy to the tissue of the patient and then the same active element 13 may apply e.g. electrical current to the tissue of the patient. In one aspect, the primary electromagnetic generator may generate both, the radiofrequency energy and the electric current.
In one aspect, the proposed device 1 may provide only one treatment energy, e.g. only electric current to cause a muscle stimulation or only radiofrequency energy to cause heating of the tissue.
The active element (e.g. electrode or coil) may be cooled. A cooling member may provide cooling by any known mechanism including e.g. water cooling, sprayed coolant, presence of an active solid cooling element (e.g. thermoelectric cooler), or air flow cooling. Cooling of the active element (e.g. electrode or coil) may be provided during, before, or after the active element provides an energy to the patient. The temperature of the cooling member may be in the range of −80° C. to 36° C., in the range of −70° C. to 35° C., in the range of −60° C. to 34° C., in the range of −20° C. to 30° C., in the range of 0° C. to 27° C., in the range of 5° C. to 25° C.
Pad 4 may further comprise thermal sensors 15 enabling temperature control during the therapy, providing feedback to control unit (e.g. CPU) 11, enabling adjustment of treatment parameters of each active element and providing information to the operator. The thermal sensor 15 may be a contact sensor, contactless sensor (e.g. infrared temperature sensor) or invasive sensor (e.g. a thermocouple) for precise temperature measurement of deep layers of skin, e.g. epidermis, dermis or hypodermis. The control unit (e.g. CPU) 11 may also use algorithms to calculate the deep or upper-most temperatures. A temperature feedback system may control the temperature and based on set or pre-set limits alert the operator in human perceptible form, e.g. on the human machine interface 8 or via indicators 17. In a limit temperature condition, the device may be configured to adjust one or more treatment parameters, e.g. output power, switching mode, pulse length, etc. or stop the treatment. A human perceptible alert may be a sound, alert message shown on human machine interface 8 or indicators 17 or change of color of any part of the interconnecting block 3 or pad 4.
The pad may comprise at least one electromyography (EMG) sensing electrode configured to monitor, to record or to evaluate the electrical activity produced by skeletal muscles (e.g. twitch or contraction) in response to delivered energy (e.g. electric current). The at least one EMG sensing electrode being disposed on the pad may be electrically insulated from the active elements (e.g. electrodes used for treatment). An electromyograph detects the electric potential generated by muscle cells when these cells are electrically or neurologically activated. The signals can be analyzed to detect abnormalities, activation level, or recruitment order, or to analyze the biomechanics of the patient's movement. The EMG may be one of a surface EMG or an intramuscular EMG. The surface EMG can be recorded by a pair of electrodes or by a more complex array of multiple electrodes. EMG recordings display the potential difference (voltage difference) between two separate electrodes. Alternatively the active elements, e.g. electrodes, may be used for EMG, for example when the active element is not active (e.g. does not provide/deliver any type of energy/signal to the patient) it may be used for EMG detection/recording. The intramuscular EMG may be recorded by one (monopolar) or more needle electrodes. This may be a fine wire inserted into a muscle with a surface electrode as a reference; or more fine wires inserted into muscle referenced to each other. Muscle tissue at rest is normally electrically inactive. After the electrical activity caused by delivered energy (e.g. electric current), action potentials begin to appear. As the strength of a muscle contraction is increased, more and more muscle fibers produce action potentials. When the muscle is fully contracted, a disorderly group of action potentials of varying rates and amplitudes should appear (a complete recruitment and interference pattern).
The pad may also comprise at least one capacitive sensor for measurement of the proper contact of the pad with the patient. The capacitive sensor may be connected to at least two complementary metal-oxide-semiconductor (CMOS) integrated circuit (IC) chips, an application-specific integrated circuit (ASIC) controller and a digital signal processor (DSP) which may be part of the control unit. The capacitive sensor may detect and measure the skin based on the different dielectric properties than the air, thus when the pad is detached from the patient a change in the signal may be detected and further processed by the control unit. The capacitance sensor may be configured in a surface capacitance or in a projected capacitance configuration. For better information about the contact and for higher safety, a single pad may comprise 3 to 30 or 4 to 20 or 5 to 18 or 6 to 16 or 7 to 14 capacitance sensors.
Memory 12 may include, for example, information about the type and shape of the pad 4, its remaining lifetime, or the time of therapy that has already been performed with the pad. The memory may also provide information about the manufacturer of the pad or information about the designated area of use on the body of the patient. The memory may include RFID, MRAM, resistors, or pins.
Neutral electrode 7 may ensure proper radiofrequency energy distribution within the patient's body for mono-polar radiofrequency systems. The neutral electrode 7 is attached to the patient's skin prior to each therapy so that the energy may be distributed between active element 13 (e.g. electrode) and neutral electrode 7. In some bipolar or multipolar radiofrequency systems, there is no need to use a neutral electrode—because radiofrequency energy is distributed between multiple active elements 13 (e.g. electrodes). Neutral electrode 7 represents an optional block of the apparatus 1 as any type of radiofrequency system can be integrated. In one aspect, the neutral electrode 7 may be part of the pad 4.
Additionally, device 1 may include one or more sensors. The sensor may provide information about at least one physical quantity and its measurement may lead to feedback which may be displayed by human machine interface 8 or indicators 17. The one or more sensors may be used for sensing delivered electromagnetic energy, impedance of the skin, resistance of the skin, temperature of the treated skin, temperature of the untreated skin, temperature of at least one layer of the skin, water content of the device, the phase angle of delivered or reflected energy, the position of the active elements 13, the position of the interconnecting block 3, temperature of the cooling media, temperature of the primary electromagnetic generator 6 and secondary generator 9 and ultrasound emitter 10 or the contact with the skin. The sensor may be a thermal, acoustic, vibration, electric, magnetic, flow, positional, optical, imaging, pressure, force, energy flux, impedance, current, Hall or proximity sensor. The sensor may be a capacitive displacement sensor, acoustic proximity sensor, gyroscope, accelerometer, magnetometer, infrared camera or thermographic camera. The sensor may be invasive or contactless. The sensor may be located on or in the pad 4, in the main unit 2, in the interconnecting block 3 or may be a part of a thermal sensor 15. One sensor may measure more than one physical quantity. For example, the sensor may include a combination of a gyroscope, an accelerometer and/or a magnetometer. Additionally, the sensor may measure one or more physical quantities of the treated skin or untreated skin.
A resistance sensor may measure skin resistance, because skin resistance may vary for different patients, as well as the humidity—wetness and sweat may influence the resistance and therefore the behavior of the skin in the energy field. Based on the measured skin resistance, the skin impedance may also be calculated.
Information from one or more sensors may be used for generation of a pathway on a model e.g. a model of the human body shown on a display of human machine interface 8. The pathway may illustrate a surface or volume of already treated tissue, presently treated tissue, tissue to be treated, or untreated tissue. A model may show a temperature map of the treated tissue providing information about the already treated tissue or untreated tissue.
The sensor may provide information about the location of bones, inflamed tissue or joints. Such types of tissue may not be targeted by electromagnetic energy due to the possibility of painful treatment. Bones, joints or inflamed tissue may be detected by any type of sensor such as an imaging sensor (ultrasound sensor, IR sensor), impedance sensor, and the like. A detected presence of these tissue types may cause general human perceptible signals or interruption of generation of electromagnetic energy. Bones may be detected by a change of impedance of the tissue or by analysis of reflected electromagnetic energy.
In one aspect the active elements 13, may be used as the sensors described above. For example, the active element 13 (e.g. electrode) may measure impedance before, during or after providing the radiofrequency energy. In addition, the active element 13 (e.g. electrode) may measure the voltage or the current passing through the patient during the electric current stimulation. Based on those information it may be possible to determine proper contact of the pad 4 or active elements 13 (e.g. electrodes) with the patient.
The patient's skin over at least one treatment portion may be pre-cooled to a selected temperature for a selected duration, the selected temperature and duration for pre-cooling may be sufficient to cool the skin to at least a selected temperature below normal body temperature. The skin may be cooled to at least the selected temperature to a depth below the at least one depth for the treatment portions so that the at least one treatment portion is substantially surrounded by cooled skin. The cooling may continue during the application of energy, and the duration of the application of energy may be greater than the thermal relaxation time of the treatment portions. Cooling may be provided by any known mechanism including water cooling, sprayed coolant, presence of an active solid cooling element (e.g. thermoelectric cooler) or air flow cooling. A cooling element may act as an optical element. Alternatively, the cooling element may be a spacer. Cooling may be provided during, before or after the treatment with electromagnetic energy. Cooling before treatment may also provide an environment for sudden heat shock, while cooling after treatment may provide faster regeneration after heat shock. The temperature of the coolant may be in the range of −200° C. to 36° C. The temperature of the cooling element during the treatment may be in the range of −80° C. to 36° C. or −70° C. to 35° C. or −60° C. to 34° C. or −20° C. to 30° C. or 0° C. to 27° C. or 5° C. to 25° C. Further, where the pad is not in contact with the patient's skin, cryogenic spray cooling, gas flow or other non-contact cooling techniques may be utilized. A cooling gel on the skin surface might also be utilized, either in addition to or instead of, one of the cooling techniques indicated above.
In addition, the pad 4 may be used to treat at least partially neck, bra fat, love handles, torso, back, abdomen, buttocks, thighs, calves, legs, arms, forearms, hands, fingers or body cavities (e.g. vagina, anus, mouth, inner ear etc.).
The pad 4 may have a rectangular, oblong, square, trapezoidal form, or of the form of a convex or concave polygon wherein the pad 4 may have at least two different inner angles of the convex or concave polygon structure. Additionally, the pad 4 may form at least in part the shape of a conic section (also called conic), e.g. circle, ellipse, parabola or hyperbola. The pad 4 may have at least in part one, two, three, four, five or more curvatures of a shape of an arc with the curvature kin the range of 0.002 to 10 mm−1 or in the range of 0.004 to 5 mm−1 or in the range of 0.005 to 3 mm−1 or in the range of 0.006 to 2 mm−1. The pad 4 may have at least one, two, three, four, five or more arcs with the curvature k or may have at least two different inner angles of a convex or concave polygon structure, and may be suitable for the treatment of chin, cheeks, submental area (e.g. “banana shape 1” 4.2), for treating jaw line, perioral area, Marionette lines and nasolabial folds (e.g. “banana shape 2” 4.4), for the treatment of periorbital area (e.g. “horseshoe shape” 4.3) or other regions of face and neck. The “banana shape” pad 4.2 or 4.4 may have a convex-concave shape, which means that one side is convex and the opposite side is concave, that occupies at least 5% to 50% or 10% to 60% or 15% to 70% or 20% to 90% of a total circumference of the pad 4 seen from above, wherein the shortest distance between the endpoints 4.21a and 4.21b of the “banana shape” pad 4.2 (dashed line in
In addition, the center curve may have at least in part circular, elliptical, parabolic, hyperbolic, exponential, convex or concave curve such that the straight line connecting endpoint of the pad 4 with the middle point of the center curve forms an angle alpha with the tangent of the middle of the center curve. The angle alpha may be in a range of 0.1° to 179° or in a range of 0.2° to 170° or in a range of 0.5° to 160° or in a range of 1° to 150°.
The pad 4 whose shape has at least two concave arcs with the curvature k or has at least two concave inner angles of the polygon structure may be suitable for the treatment of the forehead like the “T shape” 4.1 in
Another possible non-limiting configuration of the pad 4 used for the treatment of the forehead is depicted in
As shown in
The forehead pad (pad 4 used for treatment of the forehead) may comprise edge active elements (e.g. electrodes) 13a, 13c, 13d and 13f and middle active elements (e.g. electrodes)—13b and 13e as shown in
The distance dedge between the closest points of the bottom edge active elements (e.g. electrodes) 13a and 13c in the
The distance ° Gil between the closest points of the upper active elements (e.g. electrodes) and the bottom active elements (e.g. electrodes) on one side (left, middle, right), e.g. the distance between active elements 13a and 13f, between active elements 13b and 13e, or between active elements 13c and 13d in
Such distances (dedge and dvert) are optimized to mitigate the edge effects (e.g. prevent creation of hot spots near edges) or leakage currents and effectively treat, e.g. the Frontalis muscle or Procerus muscle during the treatment. The edge active elements (e.g. electrodes)—13a, 13c, 13d and 13f in
The forehead pad (pad 4 used for treatment of the forehead) in
One possible non-limiting configuration of the pad 4 used for the treatment of the left cheek is depicted in
The middle active elements (e.g. electrodes) 13g, 13h, 13i and 13j in
The pad 4 used for the treatment of the right cheek may be symmetrically arranged to the left cheek pad 4 depicted in
In one aspect, the cheek pad 4 may be symmetrical as depicted in
Inter-active elements distance din& depicted in
Another possible non-limiting configuration of the pad 4, which may be used for treatment of the forehead, is shown in
The active elements (e.g. electrodes) may have the same or different surface area, or pair active elements (e.g. active elements 13q1 and 13q2) may have the same surface area, which may be different than the surface area of another pair of active elements (e.g. active elements 13r1 and 13r2). The surface area of the active element (e.g. electrode) is in the range of 1 to 10 cm2 or in the range of 2 to 6.5 cm2 or in the range of 2.3 to 6 cm2 or in the range of 2.5 to 5.5 cm2. The active elements (e.g. electrodes) may have the distances dedge and dvert between them as described above, which are optimized to mitigate the edge effects (e.g. prevent creation of hot spots near edges) or leakage currents and effectively treat e.g. the Frontalis muscle or Procerus muscle during the treatment. Some active elements (e.g. electrodes) may be also at least partially separated by the slots 43 of the pad, e.g. active elements 13r2 and 13s2 for better coupling of the pad 4 with the patient.
All non-limiting examples of the pad shown in
A treatment pad suitable for a treatment of submental area may cover the submentum as well as part of the neck. In one aspect, such a submentum pad may comprise active elements (e.g. electrodes) delivering energy suitable to provide contractions (e.g. electric current) only to the submentum (submental and submandibular triangle) and other active elements (e.g. electrodes) delivering energy suitable for heating (e.g. radiofrequency) of the submentum and/or neck (e.g. carotid triangle, muscular triangle. Such a layout of the pad may be suitable for treatment of double chin, wherein the heating is evenly distributed under the pad and the contractions are provided only to some submentum muscles (e.g. digastric, mylohyoid and/or stylohyoid muscle), which may lay above the hyoid bone. In one aspect, the submentum pad may be symmetrical.
Pads may have different sizes with the surface areas ranging from 0.1 to 150 cm2 or from 0.2 to 125 cm2 or from 0.5 to 100 cm2 or in the range of 1 to 50 cm2 or in the range of 10 to 50 cm2 or in the range of 15 to 47 cm2 or in the range of 18 to 45 cm2. The pad may occupy approximately 1 to 99% or 1 to 80% or 1 to 60% or 1 to 50% of the face. The number of active elements 13 (e.g. electrodes) within a single pad 4 ranges from 1 to 100 or from 1 to 80 or from 1 to 60 or from 2-20 or from 3 to 10 or from 4 to 9. A thickness at least in a part of the pad 4 may be in the range of 0.01 to 15 mm or in the range of 0.02 to 10 mm or in the range of 0.05 to 7 mm or in the range of 0.1 to 2 mm.
In one aspect, the pad 4 may comprise one active element 13 (e.g. electrode) that provides one or more treatments (e.g. radiofrequency energy and electric current), whereas a plurality of such pads may be used to treat the same area during one treatment. For example instead of using one pad 4 with six active elements 13 (e.g. electrodes) which may be used for treatment of a forehead, six pads 4 each with one active element 13 (e.g. electrode) may be used for the same treatment. In another aspect, the pad 4 may comprise one active element 13 (e.g. electrode) that provides one type of treatment/energy and plurality of pads 4 that provides the same or different treatment/energy may be used to treat the same area during one treatment. For example, instead of pad 4 with one active element 13 (e.g. electrode) that provides radiofrequency energy and electric current, it may be possible to use two pads 4, one with active element 13 (e.g. electrode) that provides radiofrequency energy and the other one with active element 13 (e.g. electrode) that provides electric current.
Alternatively, only one or more active elements 13 (e.g. electrodes) themselves may be used instead of the pad 4 with a substrate and the active element 13. In one aspect, the active element 13 (e.g. electrode) that provides one or more treatments (e.g. radiofrequency energy and electric current) may be used to treat a body part of the patient. In another aspect, a plurality of active elements 13 (e.g. electrodes) may be used to treat the same body part during one treatment. For example instead of using one pad 4 with six active elements 13 (e.g. electrodes) which may be used for treatment of a forehead, six individual active elements 13 (e.g. electrodes) may be used for the same treatment. In another aspect, the active element 13 (e.g. electrode) may provide one type of treatment/energy and a plurality of active elements 13 (e.g. electrodes) that provides the same or different treatment/energy may be used to treat the same area during one treatment. For example, instead of using pad 4 with at least one active element 13 (e.g. electrode) that provides radiofrequency energy and electric current, it may be possible to use at least two individual active elements (e.g. electrodes), at least one active element 13 (e.g. electrode) that provides radiofrequency energy and at least one active element 13 (e.g. electrode) that provides electric current.
In one aspect, the active elements 13 (e.g. electrodes or coils) may overlap each other at least partially. For example, the electrode may be at least partially situated under or over the coil in the pad 4.
Furthermore the pads 4 may have a shape that at least partially replicates the shape of galea aponeurotica, procerus, levatar labii superioris alaeque nasi, nasalis, lavator labii superioris, zygomaticus minor, zygomaticus major, levator angulis oris, risorius, platysma, depressor anguli oris, depressor labii inferioris, occipitofrontalis (frontal belly), currugator supercilii, orbicularis oculi, buccinator, masseter, orbicularis oris or mentalis muscle when the pad 4 is attached to the surface of the patient skin.
The pad 4 may be characterized by at least one aforementioned aspect or by a combination of more than one aforementioned aspect or by a combination of all aforementioned aspects.
The electromagnetic energy generator 6 or the secondary generator 9 inside the main case may generate an electromagnetic or secondary energy (e.g. electric current) which may be delivered via a conductive lead to at least one active element 13 (e.g. electrode) attached to the skin, respectively. The active element 13 may deliver energy through its entire surface or by means of a so-called fractional arrangement. Active element 13 may be an active electrode in a monopolar, unipolar, bipolar or multipolar radiofrequency system. In the monopolar radiofrequency system, energy is delivered between an active electrode (active element 13) and a neutral electrode 7 with a much larger surface area. Due to mutual distance and difference between the surface area of the active and neutral electrode, energy is concentrated under the active electrode enabling it to heat the treated area. In the monopolar radiofrequency system, the energy may be delivered with the frequency in the range of 100 kHz to 550 MHz or in the range of 200 kHz to 300 MHz or in the range of 250 kHz to 100 MHz or in the range of 300 kHz to 50 MHz or in the range of 350 kHz to 14 MHz. In the unipolar, bipolar or multipolar radiofrequency system, there is no need for neutral electrode 7. In the bipolar and multipolar radiofrequency system, energy is delivered between two and multiple active electrodes with similar surface area, respectively. The distance between these electrodes determines the depth of energy penetration. In the unipolar radiofrequency system, only a single active electrode is incorporated and energy is delivered to the tissue and environment surrounding the active electrode. The distance between the two nearest active elements 13 (e.g. the nearest neighboring sides of electrodes) in one pad 4 may be in the range of 0.1 to 100 mm or in the range of 0.3 to 70 mm or in the range of 0.5 to 60 mm or in the range of 0.7 to 30 mm or in the range of 1 to 10 mm or in the range of 1 to 5 mm. The distance between the two nearest neighboring sides of the electrodes may mean the distance between the two nearest points of neighboring electrodes.
A distance between the nearest point of the active element 13 (e.g. electrode) and the nearest edge of the pad 4 may be in the range of 0.1 to 10 mm or in the range of 0.5 to 5 mm or in the range of 1 to 4 mm or in the range of 1 to 3 mm.
In some aspects, active elements 13 (e.g. electrodes) may be flexible as well. A stiffness of the pad 4, the flexible substrate, or the active elements 13 (e.g. electrodes) may be in a range of shore OO10 to shore D80, in a range of shore OO30 to shore A100, in the range of shore A10 to shore A80, or in the range of shore A20 to A70. In another aspect, the pad 4 may be made of flexible substrate with rigid active elements 13 (e.g. electrodes) or some active elements 13 (e.g. electrodes) may be rigid and some may be flexible with the above mentioned shore ranges (e.g. RF electrodes may be rigid and the electrodes for electrotherapy may be flexible and vice versa).
In one aspect, active elements 13 (e.g. electrodes) suitable for one treatment (e.g. radiofrequency) may have different shapes and surface areas than the active elements 13 (e.g. electrodes) suitable for second treatment (e.g. electric current). For example, the radiofrequency electrodes may have a larger surface area than the electrotherapy electrodes.
The thickness of the active elements 13 (e.g. electrode) may be in the range of 1 μm to 500 μm, in the range of 2 μm to 400 μm, in the range of 3 μm to 300 μm, or in the range of 5 μm to 100 μm. In another aspect, the electrode thickness may be in the range of 0.2 mm to 10 mm, in the range of 0.4 mm to 8 mm, or in the range of 0.5 mm to 5 mm.
In one aspect, the active elements 13 (e.g. electrodes) may have a sandwich structure where multiple conductive materials are deposited gradually on each other, e.g. a copper-nickel-gold structure. For example the copper may be deposited on the substrate with a thickness in the range of 5 to 100 μm or in the range of 15 to 55 μm or in the range of 25 to 45 μm. The nickel may be deposited on the copper with a thickness in the range of 0.1 to 15 μm or in the range of 0.5 to 8 μm or in the range of 1 to 6 μm. And the gold may be deposited on the nickel with a thickness in the range of 25 to 200 nm or in the range of 50 to 100 nm or in the range of 60 to 90 nm. Such a sandwich structure may be made for example by an ENIG process.
In another aspect, the active elements 13 (e.g. electrodes) may be made of copper and covered with another conductive layer, e.g. silver or silver-chloride ink, carbon paste, or aluminum segments coupled to the copper by conductive glue. Yet in another aspect the electrodes may be printed e.g. by a silver ink, a silver-chloride ink, or a carbon paste with the electrode thickness in the range of 1 to 100 μm or in the range of 5 to 55 μm or in the range of 8 to 45 μm.
The active element 13 (e.g. electrode) may have a shape that has a total number of convex or concave arcs in a range of 1 to 12 or in a range of 2 to 10 or in a range of 3 to 9 or in a range of 4 to 8. Additionally, the active element (e.g. electrode) may have a number of concave inner angles in a range of 1 to 7 or in a range of 1 to 6 or in a range of 1 to 5 or in a range of 2 to 4, or the active element (e.g. electrode) may have a number of convex inner angles in a range of 1 to 10 or in a range of 1 to 9 or in a range of 2 to 8 in a range of 3 to 7. A possible arrangement of convex-concave active elements 13 (e.g. electrodes) is depicted in
The active element 13 (e.g. electrode providing radiofrequency energy and/or electric current) may be full-area electrode that has a full active surface. This means that the whole surface of the electrode facing the patient is made of conductive material deposited or integrated in the pad 4 as mentioned above.
In one aspect, the electrode (made of conductive material) facing the patient may be with e.g. one or more apertures, cutouts and/or protrusions configured for example to improve flexibility of the electrode and/or pad, and/or reduce the edge effects and/or improve homogeneity of delivered energy density and/or improve homogeneity of provided treatment. Apertures may be an opening in the body of the electrode. A cutout may be an opening in the body of the electrode along the border of the electrode. Openings in the body of the electrode may be defined by view from floor projections, which shows a view of the electrode from above. The openings, e.g. apertures, cutouts and/or areas outside of protrusions may be filed by air, dielectric material, insulation material, substrate of the pad, air or hydrogel. The electrode is therefore segmented in comparison to a regular electrode by disruption of the surface area (i.e., an electrode with no apertures or cutouts). The two or more apertures or cutouts of the one electrode may be asymmetrical. The one or more aperture and cutout may have e.g. rectangular or circular shape. The apertures and/or cutouts may have regular, irregular, symmetrical and/or asymmetrical shapes. When the electrode includes two or more apertures or cutouts, the apertures or cutouts may have the same point of symmetry and/or line of symmetry. The distance between two closest points located on the borders of two different apertures and/or cutouts of the electrode may be in a range from 1 μm to 10 mm or from 10 μm to 8 mm or from 20 μm to 5 mm or from 50 μm to 3 mm or from 100 μm to 2 mm.
The active element (e.g. electrode) with one or more openings (e.g. apertures and/or cutouts) and/or protrusions may be framed by the conductive material and the inside of the frame may have a combination of conductive material and the openings. As shown in
The thickness of the frame 801, as depicted in
In a first aspect, the total area of the electrode 800 (comprising the frame 801 and the grid lines 802) and all apertures 803 inside the frame 801 of said electrode 800 may be in the range of 1 to 15 cm2 or in the range of 2 to 8 cm2 or in the range of 2.5 to 6 cm2 or in the range of 3 to 5 cm2.
In a second aspect, the total area of the electrode 800 (comprising the frame 801 and the grid lines 802) and all apertures 803 inside the frame 801 of said electrode 800 may be in the range of 1 to 20 cm2 or in the range of 2 to 10 cm2 or in the range of 2.5 to 8 cm2 or in the range of 3.5 to 7 cm2.
In a third aspect, the total area of the electrode 800 (comprising the frame 801 and the grid lines 802) and all apertures 803 inside the frame 801 of said electrode 800 may be in the range of 1 to 10 cm2 or in the range of 2 to 6.5 cm2 or in the range of 2.3 to 6 cm2 or in the range of 2.5 to 5.5 cm2.
In a fourth aspect, the total area of the electrode 800 (comprising the frame 801 and the grid lines 802) and all apertures 803 inside the frame 801 of said electrode 800 may be in the range of 1 to 20 cm2 or in the range of 2 to 15 cm2 or in the range of 3 to 12 cm2 or in the range of 4 to 10 cm2.
A ratio of the area of the conductive material of the electrode 800 (i.e. the frame 801 and the gridlines 802) to the total area of all apertures inside the frame 801 of the electrode 800 may be in the range of 1% to 50%, or in the range of 2% to 45% or in the range of 5% to 40% or in the range of 8% to 35% or in the range of 10% to 33%. Additionally the ratio may be in the range of 1% to 20%, or in the range of 10% to 40% or in the range of 33% to 67% or in the range of 50% to 70% or in the range of 66% to 100%.
Alternatively, the electrode 800 may not be framed, e.g. it may have a form of a grid with no boundaries formed by openings 803 as shown in
With reference to
With reference to
With reference to
With reference to
The distance between two closest protrusions 808 may be illustrated as at least one circle (similarly to the circle 820 in
The protrusions 808 or cutouts 803 may have a symmetrical, asymmetrical, irregular and/or regular shape. The size, shape and/or symmetry of individual radial conductive lines may be the same and/or different across the electrode. For example each protrusion 808 may have the same shape, the same dimension, the same direction and/or symmetry. The protrusions 808 may be characterized by a thickness and a length of the protrusion, wherein the length is larger than the thickness by factor in the range of 2 to 100, or in the range of 4 to 80, or in the range of 5 to 70. The thickness of a protrusion may be in the range of 1 μm to 5 mm or in the range of 20 μm to 4 mm or in the range of 50 μm to 3 mm or in the range of 100 μm to 2.5 mm or in the range of 120 μm to 2 mm or in the range of 150 μm to 1.5 mm or in the range of 200 μm to 1 mm. The length of the protrusions may be in the range of 0.05 to 50 mm or in the range of 0.1 to 30 mm or in the range of 0.5 to 20 mm. The number of protrusions that one electrode may comprise may be in a range of 1 to 1000, or of 5 to 500, or of 10 to 300, or of 15 to 250, or of 20 to 240.
The surface area of the electrode 800 with the protrusions 808 may be in the range of 0.1 to 10 cm2 or in the range of 0.3 to 9.5 cm2 or in the range of 0.4 to 9 cm2 or in the range of 0.5 to 8.5 cm2.
In addition, all the possible electrode arrangements depicted in
The total number of apertures and/or cutouts in one electrode regardless of the parallel cuts may be in a range of 5 to 250, or of 10 to 200, or of 15 to 170, or of 20 to 150, or of 300 to 1500, or of 400 to 1400, or of 500 to 1300, or of 600 to 1200.
In one aspect, where one or more active elements are in the form of an electrode, which is grated (
In another aspect, where one or more active elements are in the form of an electrode with openings and/or protrusions (
As shown in
In another aspect, the active elements 13 (e.g. electrodes) may be embedded in the flexible substrate 42 such, that the underside of the substrate 401 and the underside of the active elements 13A-D are in one plane, as shown in
Another possible arrangement of the active elements (e.g. electrodes) in the pad 4 is represented in
Alternatively, the active element (e.g. electrode) may be fully embedded in the substrate and protrude from its top side or underside. Thus, the thickness of the active element (e.g. electrode) may be bigger than the thickness of the substrate.
In addition, combinations of pad 4 structures mentioned above may be possible, e.g. one active element (e.g. first electrode) is deposited on the underside of the pad 4 and another active element (e.g. second electrode) is embedded in the pad 4.
In case of a single conductive lead connection, the active elements 13 (e.g. electrode) may be partially embedded inside the flexible substrate 42 or adhesive layer 40 or in the interface of the flexible substrate layer 42 and adhesive layer 40, and the active elements 13 (e.g. electrode) may be connected via single conductive lead 41b which may be situated in the flexible substrate 42 or at the interface of the flexible substrate 42 and adhesive layer 40, as shown in
Additionally, the active elements 13 (e.g. electrode) may be partially embedded within the flexible substrate 42 and the adhesive layer 40 may surround the active elements 13 such that a surface of active elements 13 may be at least partially in direct contact with the surface of a treatment area.
Moreover, the top side of the pad 4 may be protected by a cover layer 410, which is shown for simplicity only in
In one aspect, all the layers from top to the bottom may be configured as depicted in
In other aspects, the layers may be different and it may be possible to remove or add more layers to the structure of the pad 420 that is shown in
A pad 4 may include flexible substrate 500, which may comprise a central part 501 and one or more segments 502, which may move at least partially independently from each other as shown in
Conventional therapy pads have routinely been made on a single non-segmented substrate which in some cases includes a flexible metal material or a polymeric material with a layer of metallic material deposited thereon.
As seen in
As shown in
The shapes and positions of the segments 502 and/or the slots 503 may be provided in different configurations from those illustrated in
Each segment 502 of the substrate 500 may comprise an active element 13 (e.g. electrode) on a portion of, or the entirety of, the segment 502.
The central part 501 may have a proximal end 504 and a distal end 505, wherein the proximal end 504 of the central part 501 may pass or may be connected to the connecting part 507. The central part 501 is connected to the connecting part 507 in the area of a dotted circle in
The connecting part 507 may be flexible or partially elastic. The connecting part may be made of flexible PCB with the cover layer as an isolation layer on the top side and/or the underside of the connecting part 507.
In one aspect, the connecting part 507 may be printed on the substrate, which is made of the same material as the substrate 500 of the pad, and it may be printed (e.g. by metal ink) on the underside of the substrate 500 and covered by the cover layer, so it does not come into a contact with the patient.
The connecting part may have a connector at its ends, which may be rigid. The connector may be one of a USB type A, USB type B, USB type C, USB Micro B, DC power cord, AC power cord, computer power cable, firewire, RJ11, fiber connector, USB 3.0, mini display, pin connector, SMA, DVI, BNC, IDE, PS/2, RCA, display port, PSU, SATA, mSATA, DB9, RJ45, RS232 or any other connector know in the art. The pin connector may have number of pins in a range of 5 to 60 or in a range of 10 to 44 or in a range of 15 to 36 or in a range of 20 to 34. Alternatively, the connector may be made on the flexible PCB with an attached stiffener underneath used to stiffen the connector against out of plane deformation. The stiffener may be made of a non-conductive material including but not limited to plastic or fiberglass. The stiffener may have a thickness in a range of 0.1 to 5 mm or in a range of 0.5 to 2 mm or in a range of 1 to 1.5 mm. The flexible PCB connector may comprise a number of contacts in the range of 5 to 60 or in a range of 10 to 44 or in a range of 15 to 36 or in a range of 20 to 34.
In one aspect, the pad 4, the connecting part 507 and the connector may all be part of the applicator.
The interconnecting block 3 or the main unit 2 may comprise one or more sockets configured to connect the connecting part via the connector on the opposite side to the side where the pad 4 is situated, wherein the one or more sockets are configured to connect an arbitrary pad and/or applicator. Alternatively, the interconnecting block or the main unit may comprise multiple sockets, each socket configured to connect one specific pad and/or applicator for a specific treatment area. The socket may be configured such that it will automatically determine a currently connected pad and/or applicator. The information about the connected pad and/or applicator may be read out from the memory of the pad. Alternatively, the memory may be part of the connector. After the connection, the connector may be linked with the control unit 11 (e.g. CPU). The control unit 11 (e.g. CPU) may provide one or more predetermined treatment protocols to the user via the human machine interface 8 after the detection of the pad in the socket. For example if only a forehead pad is connected, the system may automatically detect this specific pad and propose only a treatment of a forehead of the patient, not allowing the user to set a treatment of other body parts of the patient. Furthermore, the connector may comprise cutouts, grooves, slots, holes and/or notches for locking the connector in the socket. The socket may also comprise a safeguard preventing unintentional connection of the connector in the socket.
In one aspect, the connector may comprise a symbol indicating on which body part the pad and/or the applicator is designated to treat.
In addition, a supplementary connection may be used between the main unit 2 and the connecting part; or between the interconnecting block 3 and the connecting part in order to extend the connection between the main unit 3 and the pad 4 or interconnecting block 3 and the pad 4.
Average pad thickness may be in the range of 10 μm to 2000 μm or in the range of 50 μm to 1000 μm or in the range of 80 μm to 300 μm or in the range of 100 μm to 200 μm.
The apparatus configured in a fractional arrangement may have the active element 13 (e.g. electrode) comprising a matrix formed by active points of defined size. These points are separated by inactive (and therefore untreated) areas that allow faster tissue healing. The surface containing active points may make up from 1 to 99% or from 2 to 90% or from 3 to 80% or from 4 to 75% of the whole active element area (active and inactive area). The active points may have blunt ends at the tissue contact side that do not penetrate the tissue, wherein the surface contacting tissue may have a surface area in the range of 500 μm2 to 250 000 μm2 or in the range of 1000 μm2 to 200 000 μm2 or in the range of 200 μm2 to 180 000 μm2 or in the range of 5000 μm2 to 160 000 μm2. The blunt end may have a radius of curvature of at least 0.05 mm. A diameter of the surface contacting tissue of one active point may be in the range of 25 μm to 1500 μm or in the range of 50 μm to 1000 μm or in the range of 80 μm to 800 μm or in the range of 100 μm to 600 μm.
Additionally, the device may employ a safety system comprising thermal sensors and a circuit capable of adjusting the therapy parameters based on the measured values. One or more thermal sensors, depending on the number and distribution of active elements 13 (e.g. electrodes), may be integrated onto pad 4 to collect data from different points so as to ensure homogeneity of heating. The data may be collected directly from the treatment area or from the active elements 13 (e.g. electrodes). If uneven heating or overheating is detected, the device may notify the operator and at the same time adjust the therapy parameters to avoid burns to the patient. Treatment parameters of one or more active elements (e.g. electrodes) might be adjusted. The main therapy parameters are power, duty cycle and time period regulating switching between multiple active elements 13 (e.g. electrodes). Therapy may be automatically stopped if the temperature rises above the safe threshold.
Furthermore, impedance measurement may be incorporated in order to monitor proper active element 13 (e.g. electrodes) to skin contact. If the impedance value is outside the allowed limits, the therapy may be automatically suspended and the operator may be informed about potential contact issues. In that case, the active element (e.g. electrode) may act as an impedance sensor itself. The impedance may be measured by one or more active elements (e.g. electrodes) of the pad before, during or after the treatment.
In one aspect, the measurement of the voltage pulses and/or the current pulses and/or phase shift may be used to monitor the course of the electric current therapy. As one non-limiting example, the electric current pulses may have a rectangular shape and the corresponding measured voltage pulses may have a shape depending on the amount of the current passing through the patient. Thus, it may be possible to determine the correct contact of the active element 13 (e.g. electrode) with the patient based on the measurement of the voltage pulses.
Control unit 11 (e.g. CPU) may be incorporated onto the pad 4 itself or it may form a separate part conductively connected to the pad 4. In addition to the control mechanism, control unit 11 (e.g. CPU) may also contain main indicators (e.g. ongoing therapy, actual temperature and active element to skin contact).
It is possible to switch between multiple active elements 13 (e.g. electrodes) within the single pad 4 in such a way so that the multiple active elements 13 deliver energy simultaneously, successively or in an overlapping method or any combination thereof. For example, in the case of two active elements: in the simultaneous method, both active elements (e.g. electrodes) are used simultaneously during the time interval e.g., 1-20 s. In the successive method, the first active element (e.g. first electrode) is used during the first time interval e.g., from 1 s to 10 s. The first active element is then stopped and the second active element (e.g. second electrode) is immediately used in a subsequent time interval e.g., from 10 s to 20 s. This successive step may be repeated. In the overlapping method, the first active element (e.g. first electrode) is used during a time interval for e.g., 1-10 s, and the second active element (e.g. second electrode) is used in a second overlapping time interval for e.g., 1-10 s, wherein during the second time interval the first active element and the second active element are overlapping e.g., with total overlapping method time of 0.1-9.9 s. Active elements 13 (e.g. electrodes) may deliver energy sequentially in predefined switching order or randomly as set by operator via human machine interface 8. Schema I in
The control unit (e.g. CPU) may be configured to control the stimulation device and provide treatment by at least one treatment protocol improving of visual appearance. Treatment protocol is set of parameters of the primary electromagnetic energy and the secondary energy ensuring the desired treatment effect. Each pad may be controlled by the control unit (e.g. CPU) to provide same or alternatively different protocol. Pair areas or areas where symmetrical effect is desired may be treated by the same treatment protocol. Each protocol may include one or several sections or steps.
As a non-limiting example: in case of applying the radiofrequency energy by the active elements (e.g. electrodes) one by one as shown in Schema III and IV in
In case of the treatment when more than one pad is used, the sequential switching of the active elements (e.g. electrodes) providing radiofrequency treatment may be provided within each pad independently of the other pads or active elements (e.g. electrodes) may deliver energy sequentially through all pads.
As an example for three dependent pads, each with two active elements (e.g. electrodes): first step—the radiofrequency energy may be provided by active element one in the first pad, wherein other active elements are turned off,
second step—the active element two of the first pad is turned on and the rest of the active elements are turned off,
third step—the active element one of the second pad is turned on and the rest of the active elements are turned off,
fourth step—the active element two of the second pad is turned on and the rest of the active elements are turned off,
fifth step—the active element one of the third pad is turned on and the rest of the active elements are turned off,
sixth step—the active element two of the third pad is turned on and the rest of the active elements are turned off.
Another non-limiting example may be:
first step—the radiofrequency energy may be provided by active element one in the first pad, wherein other active elements are turned off,
second step—the active element one of the second pad is turned on and the rest of the active elements are turned off,
third step—the active element one of the third pad is turned on and the rest of the active elements are turned off,
fourth step—the active element two of the first pad is turned on and the rest of the active elements are turned off,
fifth step—the active element two of the second pad is turned on and the rest of the active elements are turned off,
sixth step—the active element two of the third pad is turned on and the rest of the active elements are turned off.
In case that the pads are treating pair areas (e.g. cheeks, thighs or buttocks), where symmetrical effect is desired, the pair pads may be driven by the same protocol at the same time.
An example of treatment protocol for one pad delivering the radiofrequency energy for heating of the patient and the electric current causing the muscle contractions is as follow. The protocol may include a first section where electrodes in one pad may be treated such that the electrodes provide an electric current pulses modulated in an envelope of increasing amplitude modulation (increasing envelope) followed by constant amplitude (rectangle envelope) followed by decreasing amplitude modulation (decreasing envelope), all these three envelopes may create together a trapezoidal amplitude modulation (trapezoidal envelope). The trapezoidal envelope may last 1 to 10 seconds or 1.5 to 7 seconds or 2 to 5 seconds. The increasing, rectangle, or decreasing envelope may last for 0.1 to 5 seconds or 0.1 to 4 seconds or 0.1 to 3 seconds. The increasing and decreasing envelope may last for the same time, thus creating a symmetrical trapezoid envelope. Alternatively, the electric current may be modulated to a sinusoidal envelope or rectangular envelope or triangular envelope. The respective envelopes causing muscle contractions may be separated by time of no or low current stimulation, such that no muscle contraction is achieved or by a radiofrequency energy causing the heating of the tissue. During this time of no muscle contraction, the pressure massage by suction openings may be provided, which may cause the relaxation of the muscles. The first section may be preprogrammed such that electrodes on various places of the pad may be switched in time to provide alternating current pulses wherein some other electrodes in the pad may not provide any alternating current pulses but only RF pulses causing heating of the tissue. All electrodes in the pad may ensure providing (be switched by the switching circuitry 14 that is controlled by the control unit 11 to provide) RF pulses for heating the tissue during the section of protocol or protocol, while only a limited amount of the electrodes may provide (be switched by the switching circuitry 14 to provide) alternating currents for muscle contracting during the section of protocol or protocol. The device may be configured such that the first section lasts for 1-5 minutes.
A second section may follow the first section. The second section may be preprogrammed such that different electrodes than the ones used in the first section on various places of the pad may be switched in time to provide alternating current pulses wherein some other electrodes (same or different electrodes than the ones used in the first section) in the pad may not provide any alternating current pulses but only RF pulses causing heating of the tissue.
A third section may follow the second section. The third section may be preprogrammed such that different electrodes than the ones used in the second section on various places of the pad may be switched in time to provide alternating current pulses wherein some other electrodes (same or different electrodes than the ones used in the second section) in the pad may not provide any alternating current pulses but only RF pulses causing heating of the tissue.
An example of a treatment protocol for three dependent pads, e.g. one pad for treatment of the forehead (forehead pad) and two pads for treatment of the left and right cheeks (left and right cheek pad), delivering radiofrequency energy for heating of the patient and electric current causing muscle contractions is as follows: The first pad, e.g. for treatment of the forehead, may have six active elements, e.g. electrodes E1-E6; the second pad, e.g. for treatment of the left cheek, may comprise seven active elements, e.g. electrodes E7-E13; and the third pad, e.g. for treatment of the right cheek, may comprise seven active elements, e.g. electrodes E14-E20. Some electrodes may be configured to provide radiofrequency energy and some electrodes may be configured to provide both radiofrequency energy and electric current.
The radiofrequency energy may be a monopolar radiofrequency energy with a frequency in the range of 100 kHz to 550 MHz or in the range of 250 kHz to 500 MHz or in the range of 350 kHz to 100 MHz or in the range of 350 kHz to 14 MHz. The radiofrequency energy may be delivered with a rectangular envelope which may last for 200 to 3000 ms or for 250 to 2000 ms or for 300 to 1800 ms or for 350 to 1500 ms. Alternatively, the radiofrequency envelope (hereinafter RF envelope) may be modulated to a sinusoidal envelope or triangular envelope or trapezoidal envelope.
The electric current may be a bipolar (biphasic) rectangular AC TENS current with a frequency in the range of 10 Hz to 10 kHz or in the range of 25 Hz to 1 kHz or in the range of 50 to 500 Hz or in the range of 100 to 300 Hz modulated to a trapezoidal envelope, which may last 1 to 10 seconds or 1.5 to 7 seconds or 2 to 5 seconds. An increasing, rectangular, or decreasing envelope of the trapezoidal envelope may last for 0.1 to 5 seconds or 0.1 to 4 seconds or 0.1 to 3 seconds. The increasing and decreasing envelopes may have the same duration, thus creating a symmetrical trapezoidal envelope. Alternatively, the electric current envelope (hereinafter EC envelope) may be modulated to a sinusoidal envelope or rectangular envelope or triangular envelope.
The protocol may have a cycle that includes sections. The number of protocol sections in one cycle may be the same number as the total number of used electrodes within all pads used for the treatment or may be different. The number of sections per pad may be in the range of 1 to 100, or of 1 to 80, or of 1 to 60, or of 2 to 20, or of 3 to 10, or of 4 to 9. The number of sections per cycle may be in the range of 1 to 100, or of 1 to 80, or of 1 to 60, or of 2 to 40, or of 3 to 35, or of 4 to 30. Each protocol section may follow the previous protocol section, e.g. the second section follows the first section. Each protocol section may last for 200 to 3000 ms or for 250 to 2000 ms or for 300 to 1800 ms or for 350 to 1500 ms. The cycle may repeat from 30 to 300, or from 50 to 250, or from 80 to 220, or from 100 to 200, times per treatment. Alternatively, the cycle may repeat from 150 to 600, or from 190 to 550, or from 200 to 520, or from 210 to 500 times per treatment. In one aspect the treatment protocol may repeat the same cycle. In another aspect the treatment protocol may repeat different cycles, wherein the cycles may be different in the number of sections, and/or duration of sections, and/or sequence of activating and/or deactivating the electrodes, and/or parameters set for RF and/or EC envelopes (e.g. shape of envelope, amplitude, frequency, duration and so on), and/or parameters set for radiofrequency and/or parameters of electric current.
An example of a cycle including 20 sections may be as follows:
In the first section, the electrode E2 delivers the RF envelope.
In the second section, the electrode E7 delivers the RF envelope.
In the third section, the electrode E14 delivers the RF envelope.
In the fourth section, the electrode E5 delivers the RF envelope.
In the fifth section, the electrode E8 delivers the RF envelope.
Throughout the first to fifth sections, the electrode pairs E1-E4, E3-E6, E9-E10, E11-E12, E16-E17 and electrode pair E18-E19 deliver the EC envelope causing muscle contractions under the first, second and third pads, e.g. under the forehead pad, the left cheek pad and the right cheek pad.
In the sixth section, the electrode E15 delivers the RF envelope.
In the seventh section, the electrode E13 delivers the RF envelope.
In the eighth section, the electrode E20 delivers the RF envelope.
In the ninth section, the electrode E1 delivers the RF envelope.
In the tenth section, the electrode E3 delivers the RF envelope.
Throughout the sixth to tenth sections, the electrode pairs E9-E10, E11-E12, E16-E17 and electrode pair E18-E19 deliver the EC envelope causing muscle contractions under the second and third pads, e.g. under the left and right cheek pads.
In the eleventh section, the electrode E6 delivers the RF envelope.
In the twelfth section, the electrode E4 delivers the RF envelope.
In the thirteenth section, the electrode E9 delivers the RF envelope.
In the fourteenth section, the electrode E16 delivers the RF envelope.
In the fifteenth section, the electrode E12 delivers the RF envelope.
Throughout the eleventh to fifteenth sections, no electrode pairs deliver the EC envelope, causing the muscles to relax.
In the sixteenth section, the electrode E19 delivers the RF envelope.
In the seventeenth section, the electrode E10 delivers the RF envelope.
In the eighteenth section, the electrode E17 delivers the RF envelope.
In the nineteenth section, the electrode E11 delivers the RF envelope.
In the twentieth section, the electrode E18 delivers the RF envelope.
Throughout the sixteenth to twentieth sections, the electrode pairs E1-E4 and E3-E6 deliver the EC envelope causing muscle contractions under the first pad, e.g. under the forehead pad.
Another example of a treatment protocol for three dependent pads 4 controlled by the control unit 11, e.g. one pad for treatment of the forehead (forehead pad) and two pads for treatment of the left and right cheeks (left and right cheek pad), delivering radiofrequency energy for heating of the patient and electric current causing muscle contractions is as follows: The first pad, e.g. for treatment of the forehead, may have six active elements, e.g. electrodes E1-E6; the second pad, e.g. for treatment of the left cheek, may comprise six active elements, e.g. electrodes E7-E12; and the third pad, e.g. for treatment of the right cheek, may comprise six active elements, e.g. electrodes E13-E18. Some active elements may be configured to provide either electromagnetic energy (e.g. radiofrequency energy) or secondary energy (e.g. electric current), and some active elements may be configured to provide both electromagnetic energy and secondary energy. Alternatively, each active element may be part of one pad 4 (thus using eighteen pads instead of three) or it may be possible to use just the active elements (e.g. electrodes without the substrate of the pad) attached to treated areas. Each protocol section may last for 200 to 3000 ms or for 250 to 2000 ms or for 300 to 1800 ms or for 350 to 1500 ms. The cycle may repeat from 30 to 300, or from 50 to 250, or from 80 to 220, or from 100 to 200, times per treatment/treatment protocol. Alternatively, the cycle may repeat from 150 to 600, or from 190 to 550, or from 200 to 520, or from 210 to 500 times per treatment. In one aspect the treatment protocol may repeat the same cycle. In another aspect the treatment protocol may repeat different cycles, wherein the cycles may be different in the number of sections, and/or duration of sections, and/or sequence of activating and/or deactivating the active elements, and/or parameters set for electromagnetic energy and/or secondary energy (e.g. shape of envelope, amplitude, frequency, duration and so on).
A cycle of the exemplary treatment protocol executed by the control unit 11 may comprise one or more sections from the following list:
In one section, the electrode E10 delivers the RF envelope.
In another section, the electrode E18 delivers the RF envelope.
In another section, the electrode E11 delivers the RF envelope.
In another section, the electrode E15 delivers the RF envelope.
In another section, the electrode E12 delivers the RF envelope.
In another section, the electrode E1 delivers the RF envelope.
In another section, the electrode E14 delivers the RF envelope.
In another section, the electrode E7 delivers the RF envelope.
In another section, the electrode E13 delivers the RF envelope.
In another section, the electrode E8 delivers the RF envelope.
In another section, the electrode E4 delivers the RF envelope.
In another section, the electrode E3 delivers the RF envelope.
In another section, none electrode delivers the RF envelope.
In another section, the electrode E6 delivers the RF envelope.
In another section, the electrode E5 delivers the RF envelope.
In another section, the electrode E16 delivers the RF envelope.
In another section, the electrode E9 delivers the RF envelope.
In another section, the electrode E17 delivers the RF envelope.
In another section, the electrode E2 delivers the RF envelope.
The sections may be arranged one after another in specific order, wherein each section may be included in the cycle one or more times. In one aspect some sections may not be included in the cycle (e.g. a section when none electrode delivers the RF envelope). Each protocol section may last for 200 to 3000 ms or for 250 to 2000 ms or for 300 to 1800 ms or for 350 to 1500 ms and some sections of the cycle may last for time t1, some sections may last for time t2, wherein the t2 is higher than t1. In addition, some sections may last for time t3, which is higher than t1 and t2. For example, the sections may be arranged such that the electrode following the previous electrode is from different pad that the previous electrode.
The cycle may further comprise delivering of electric current (e.g. one or more EC envelopes) by the electrode pairs of the first pad (e.g. E3-E5 and E4-E6) for a time duration of one or more sections in a row, e.g. one to seven sections, two to six sections, three to five sections, or four to five sections in a row, causing muscle contractions under the first pads, e.g. under the forehead pad. Therefore, the electric current may be delivered by the electrode pairs of the first pad (e.g. E3-E5 and E4-E6) for a time duration of 200 ms to 21 s, 250 ms to 12 s, 900 ms to 9 s, 1.4 s to 7.5 s.
The cycle may further comprise delivering of electric current (e.g. one or more EC envelopes) by the electrode pairs of the first, second and third pad (e.g. E3-E5, E4-E6, E9-E11, E10-E12, E15-E17 and E16-E18) for a time duration of one or more sections in a row, e.g. one to seven sections, two to six sections, three to five sections, or four to five sections in a row, causing muscle contractions under the first, second and third pads, e.g. under the forehead pad and left and right cheek pads. Therefore, the electric current may be delivered by the electrode pairs of the first, second and third pad (e.g. E3-E5, E4-E6, E9-E11, E10-E12, E15-E17 and E16-E18) for a time duration of 200 ms to 21 s, 250 ms to 12 s, 900 ms to 9 s, 1.4 s to 7.5 s.
The cycle may further comprise delivering of electric current (e.g. one or more EC envelopes) by the electrode pairs of the second and third pads (e.g. E9-E11, E10-E12, E15-E17 and E16-E18) for a time duration of one or more sections in a row, e.g. one to seven sections, two to six sections, three to five sections, or four to five sections in a row, causing muscle contractions under the second and third pads, e.g. under the left and right cheek pads. Therefore, the electric current may be delivered by the electrode pairs of the second and third pad (e.g E9-E11, E10-E12, E15-E17 and E16-E18) for a time duration of 200 ms to 21 s, 250 ms to 12 s, 900 ms to 9 s, 1.4 s to 7.5 s.
Throughout some sections of the cycle no electrode pairs deliver the EC envelope, causing the muscles to relax.
The treatment protocol may be preprogrammed such that each electrode used during the treatment may deliver the RF envelope once per cycle and some electrode pairs (e.g. E1-E4) may deliver EC envelope twice per cycle. Alternatively, each electrode may deliver the RF envelope 2 to 10, or 2 to 8, or 2 to 5 times per cycle; and some electrode pairs may deliver the EC envelope 1 to 10, or 1 to 8, or 1 to 5 times per cycle.
In one aspect, the treatment protocol may be preprogrammed such that only one electrode delivers the RF envelope per section. In another aspect, 2 to 20, or 2 to 15, or 2 to 10, or 2 to 5, or 2 to 3 electrodes deliver RF envelopes in each section simultaneously, wherein the RF envelopes may be the same or may be different and wherein the electrodes delivering RF envelopes may be from different pads. In another aspect, no RF envelopes may be delivered during at least one section.
The treatment protocol may be preprogrammed such that during a single treatment the RF envelopes are delivered 25 to 300, or 50 to 250, or 80 to 200, or 100 to 180 times by each electrode with an RF pause time between each delivery of the RF envelope. The RF pause time—the time during which the electrode is not providing a radiofrequency energy to the patient between two consecutive deliveries of RF envelopes—may be in the range of 0.5 to 20 s, or of 1 to 15 s, or of 1.5 to 12 s, or of 2 to 10 s.
In one aspect, the radiofrequency energy may be controlled by a control unit (e.g. CPU) in order to provide a constant heating radiofrequency power (CHRP) on each electrode, which means that each electrode provides homogenous heating of the patient. A CHRP setting may be preprogrammed in the treatment protocol for each specific electrode in each specific pad based on the dimensions of the electrode and/or its position in the pad and/or its position on the body area of the patient. In another aspect, the radio frequency power may be controlled by the control unit based on feedback from at least one thermal sensor measuring the temperature of the treated body area and/or the temperature of the electrode providing the radiofrequency energy such, that when the desired temperature is reached, the electrodes are controlled to keep the temperature at this desired level. A typical treatment temperature of the body area under the electrode is in the range of 37.5° C. to 55° C. or in the range of 38° C. to 53° C. or in the range of 39° C. to 52° C. or in the range of 40° C. to 50° C. or in the range of 41° C. to 45° C.
The treatment protocol may be preprogrammed such that during a single treatment the EC envelopes are delivered 25 to 1000, or 50 to 900, or 100 to 750, or 120 to 600, or 150 to 500 times by at least one pair of electrodes with an EC pause time between each delivery of the EC envelope. The EC pause time—the time when the electrode pair is not providing electric current to the patient between two consecutive deliveries of EC envelopes—may be in the range of 0.5 to 20 s, or of 1 to 15 s, or of 1.5 to 12 s, or of 2 to 10 s. Alternatively, the electrode pair may deliver EC envelopes one after another without the EC pause time.
The treatment protocol may be preprogrammed such that during at least one section the active element 13 (e.g. electrode) provides 1 to 900 electric pulses, 2 to 700 electric pulses, 10 to 500 electric pulses, 25 to 400 electric pulses, 50 to 375 electric pulses, or 100 to 200 electric pulses.
In another aspect, radiofrequency energy may be delivered constantly through all electrodes during the whole treatment and only the EC envelopes may be delivered sequentially.
Another non limiting example of a cycle of the treatment protocol executed by the control unit 11 for three pads 4 providing a muscle contractions may be as follows:
The cycle may comprise delivering of electric current (e.g. one or more EC envelopes) by the electrode pairs of the first pad (e.g. E3-E5 and E4-E6) for a time duration of one or more sections in a row, e.g. one to seven sections, two to six sections, three to five sections, or four to five sections in a row, causing muscle contractions under the first pads, e.g. under the forehead pad. Therefore, the electric current may be delivered by the electrode pairs of the first pad (e.g. E3-E5 and E4-E6) for a time duration of 200 ms to 21 s, 250 ms to 12 s, 900 ms to 9 s, 1.4 s to 7.5 s.
The cycle may further comprise delivering of electric current (e.g. one or more EC envelopes) by the electrode pairs of the first, second and third pad (e.g. E3-E5, E4-E6, E9-E11, E10-E12, E15-E17 and E16-E18) for a time duration of one or more sections in a row, e.g. one to seven sections, two to six sections, three to five sections, or four to five sections in a row, causing muscle contractions under the first, second and third pads, e.g. under the forehead pad and left and right cheek pads. Therefore, the electric current may be delivered by the electrode pairs of the first, second and third pad (e.g. E3-E5, E4-E6, E9-E11, E10-E12, E15-E17 and E16-E18) for a time duration of 200 ms to 21 s, 250 ms to 12 s, 900 ms to 9 s, 1.4 s to 7.5 s.
The cycle may further comprise delivering of electric current (e.g. one or more EC envelopes) by the electrode pairs of the second and third pads (e.g. E9-E11, E10-E12, E15-E17 and E16-E18) for a time duration of one or more sections in a row, e.g. one to seven sections, two to six sections, three to five sections, or four to five sections in a row, causing muscle contractions under the second and third pads, e.g. under the left and right cheek pads. Therefore, the electric current may be delivered by the electrode pairs of the second and third pad (e.g E9-E11, E10-E12, E15-E17 and E16-E18) for a time duration of 200 ms to 21 s, 250 ms to 12 s, 900 ms to 9 s, 1.4 s to 7.5 s.
Throughout some sections of the cycle, no electrode pairs deliver the EC envelope, causing the muscles to relax.
In one aspect the treatment protocol may be preprogramed such that each active element 13 (e.g. electrode, coil, heating element, fluid conduit) used during the treatment may provide heating once per cycle and some active elements 13 (e.g. electrode, coil) may provide muscle contractions one or more times per cycle. Alternatively, each active element 13 may provide heating 2 to 10, 2 to 8, or 2 to 5 times per cycle, and some active elements 13 may provide muscle contractions 1 to 10, 1 to 8, or 1 to 5 times per cycle.
In one aspect, the treatment protocol may be preprogrammed such that only one active element 13 provides heating per section (e.g. by radiofrequency energy). In another aspect, 2 to 20, or 2 to 15, or 2 to 10, or 2 to 5, or 2 to 3 active elements 13 provide heating in each section simultaneously, wherein the heating temperature may be the same or may be different. In another aspect, heating may not be provided during at least one section. Each protocol section may last for 200 to 3000 ms or for 250 to 2000 ms or for 300 to 1800 ms or for 350 to 1500 ms and some sections of the cycle may last for time t1, some sections may last for time t2, wherein the t2 is higher than t1. In addition, some sections may last for time t3, which is higher than t1 and t2.
In one aspect, the treatment protocol may be preprogrammed such that during a single treatment the heating (e.g. by radiofrequency energy) is provided 25 to 300, or 50 to 250, or 80 to 200, or 100 to 180 times by one or more active elements 13 with a pause time between each heating. The heating pause time—the time during which non active element 13 is providing a heating of the patient between two consecutive heating—may be in the range of 20 ms to 10 s, or of 50 ms to 5 s, or of 100 ms to 2 s, or of 250 ms to 1 s.
In one aspect, the active elements 13 may be controlled by a control unit (e.g. CPU) to keep the temperature at a desired level. A typical treatment temperature of the body area under the active elements 13 is in the range of 37.5° C. to 55° C. or in the range of 38° C. to 53° C. or in the range of 39° C. to 52° C. or in the range of 40° C. to 50° C. or in the range of 41° C. to 45° C.
The treatment protocol may be preprogrammed such that during a single treatment the muscle contractions are provided 25 to 1000, or 50 to 900, or 100 to 750, or 120 to 600, or 150 to 500 times by at least one active element 13 (e.g. by providing the electric current) or at least one pair of active elements 13 with contraction pause time between each muscle contractions. One contraction may last for a duration in range of 0.1 to 15 seconds or in the range of 0.5 to 12 seconds or in the range of 1 to 10 seconds or in the range of 2 to 8 seconds. The contraction pause time—the time when the at least one active element 13 or at least one pair of active elements 13 is not providing a muscle contraction between two consecutive contractions may be in the range of 0.5 to 20 s, or of 1 to 15 s, or of 1.5 to 12 s, or of 2 to 10 s. Alternatively the at least one active element 13 or at least one pair of active elements 13 may provide contractions one after another without the contraction pause time.
The treatment protocol may be preprogrammed such that during at least one section the active element 13 (e.g. electrode or coil) provides 1 to 900 secondary energy pulses or 2 to 700 secondary energy pulses or 10 to 500 secondary energy pulses or 25 to 400 secondary energy pulses or 50 to 375 secondary energy pulses or 100 to 200 secondary energy pulses. Furthermore, the treatment protocol may be preprogrammed such that during the treatment the active element 13 (e.g. electrode or coil) provides secondary energy envelopes 25 to 1000, or 50 to 900, or 100 to 750, or 120 to 600, or 150 to 500 times.
In another aspect, heating may be provided constantly through all active elements 13 the whole treatment and only the contractions may be provided sequentially, for example, with contraction pause time between each muscle contraction.
Yet in another aspect, the treatment or the cycle may comprise at least one section when no energy/signal is provided to the tissue.
In one aspect, the pad may comprise one or more active elements 13 (e.g. electrode or coil) that provides more than one energy, or the pad may comprise more different active elements 13 (e.g. electrode and coil) that provides more than one energy. For example radiofrequency energy, electric current and magnetic field, or radiofrequency energy, electric current and ultrasound. Alternatively, the pad may be configured to produce more than two therapies, for example, heating of the skin (e.g. by radiofrequency energy), contraction of muscles (e.g. by electric current) and massage/relaxation of the tissue (e.g. by pressure pulses).
A single treatment may last for 1 to 60 min, or for 5 to 45 min, or for 10 to 30 min, or for 15 to 25 min, or for 18 to 23 min based on the number of pads used during the treatment. The number of pads used in single treatment may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or up to 100. The protocol may be preprogrammed such, that the electrodes providing the electric current causing the muscle contractions are switched to provide radiofrequency heating after they produce one, two, three, four or five contractions on maximum.
The respective sections are assembled by the control unit (CPU) in the treatment protocol to provide at least 60-900 contractions or 90-800 contractions, or 150-700 contractions by a single pad per treatment.
In addition, the respective electrode pairs providing electric current to the patient are controlled by the control unit (CPU) to provide at least 50-1000 contractions or 60-900 contractions or 90-800 contractions, or 100-450 contractions per treatment.
The forehead pad may include a layout of electrodes such that the anatomical area 1 and anatomical area 2 are stimulated by alternating currents which may cause muscle contractions while anatomical area 3 is not stimulated by alternating currents causing muscle contraction as shown in
The pad used for a treatment of the cheek (either side of the face below the eye) may include a layout of electrodes such that the anatomical area comprising the Buccinator muscle, the Masseter muscle, the Zygomaticus muscles or the Risorius muscle are stimulated by electrical currents, which may cause muscle contractions, wherein the other anatomical area may be only heated by the radiofrequency energy. A cheek pad may also be used for contraction of the Lavator labii superioris.
On the contrary the pad may be configured such that the layout of electrodes close to the eyes (e.g. body part comprising Orbicularis oculi muscles) or teeth (e.g. body part comprising Orbicularis oris muscles) may not provide energy causing muscle contractions.
The pad used for a treatment of the submentum or submental area may include a layout of electrodes such that the anatomical area comprising the Mylohyoid muscle or the Digastric muscle is stimulated with electrical current, which may cause muscle contractions, wherein the other anatomical area may only be heated by the radiofrequency energy. In one aspect, a submentum pad (pad used for treatment of the submentum) may not provide electric current to an Adam's apple, but may provide heating with radiofrequency energy to the Adam's apple.
The treatment device may be configured such, that in each section or step the impedance sensor provides the information about the contact of the pad or active element (e.g. electrode) with the patient to the control unit (e.g. CPU). The impedance may be measured by the active element (e.g. electrode) itself. The control unit (e.g. CPU) may determine based on the pre-set conditions if the contact of the pad or active element (e.g. electrode) with the patient is sufficient or not. In case of sufficient contact, the control unit (e.g. CPU) may allow the treatment protocol to continue. In case that the contact is inappropriate, the valuated pad or active element (e.g. electrode) is turned off and the treatment protocol continues to consecutive pad or active element (e.g. electrode) or the treatment is terminated. The determination of proper contact of the pad or active element (e.g. electrode) may be displayed on the human machine interface 8.
The impedance measurement may be made at the beginning of the section/step, during the section/step or at the end of the section/step. The impedance measurement and/or the proper contact evaluation may be determined only on the active electrodes for the given section/step or may be made on all electrodes of all pads used during the section/step.
In one aspect, the impedance may be monitored through all active elements (e.g. electrodes) while the therapy is being provided to the patient. The device monitors the impedance between the active element (e.g. electrode) and the skin of the patient while the treatment energy (e.g. radiofrequency or electric current) is being delivered to the patient, analyzes the monitored impedance at two or more different time instances in order to determine a change in the size of the electrode-skin contact area, and if the change in the monitored impedance reaches a pre-determined threshold, alters the stimulation being delivered to the patient or terminates the treatment. The change in the impedance value at a given time may be quantified by an impedance ratio between the impedance value at that time and a baseline impedance, which is a first impedance value from the history of impedance measurement of a given active element (e.g. electrode).
The device may further comprise a billing system. The billing system may be based on a reader and an information medium (e.g. card) that has recorded number of therapies. The information medium (e.g. card) may be put into the reader, or may work on a contactless principle, and then the amount of recorded number of therapies is subtracted based on the amount of used pads during the therapy. New information medium (e.g. card) may contain recorded number of therapies in a range of 1 to 100 or in a range of 2 to 80 or in a range of 5 to 50 or in a range of 10 to 40. When the information medium (e.g. card) has no more recorded number of therapies, the user may order a new information medium (e.g. card). If the pads or applicators are disposable, then the information medium may be a part of the new pads or applicators order and the amount of the recorded number of therapies may be equal to the amount of the ordered pads or applicators. For example, if the user of the device orders 30 disposable pads, the amount of recorded therapies on the information medium (e.g. card, which is also a part of the order) is also 30. The reader may be part of the main unit 2, or the interconnecting block 3 or the applicator
Main unit 2 may include a primary electromagnetic generator 6 which may generate one or more forms of electromagnetic radiation wherein the electromagnetic radiation may be e.g., in the form of incoherent light or in the form of coherent light (e.g. laser light) of predetermined wavelength. The electromagnetic field may be primarily generated by a laser, laser diode module, LED, flash lamp or incandescent light bulb. The electromagnetic radiation may be such that it may be at least partially absorbed under the surface of the skin of the patient. The wavelength of the applied radiation may be in the range of 100 to 15000 nm or in the range of 200 to 12000 nm or in the range of 300 to 11000 nm or in the range of 400 to 10600 nm or it may be in the form of second, third, fourth, fifth, sixth, seventh or eighth harmonic wavelengths of the above mentioned wavelength ranges. Main unit 2 may further comprise a human machine interface 8 represented by display, buttons, keyboard, touchpad, touch panel or other control members enabling an operator to check and adjust therapy and other device parameters. The power supply 5 located in the main unit may include a transformer, disposable battery, rechargeable battery, power plug or standard power cord. The output power of the power supply 5 may be in the range of 10 W to 600 W, or in the range of 50 W to 500 W, or in the range of 80 W to 450 W. Indicators 17 may provide additional information about the current status of the device independently on human machine interface 8. Indicators 17 may be realized through the display, LEDs, acoustic signals, vibrations or other forms capable of adequate notice.
Delivery head 19 may be interconnected with the main unit via arm 21 which may form the main optical and electrical pathway. Arm 21 may comprise transmission media, for example wires or waveguide, e.g. mirrors or fiber optic cables, for electromagnetic radiation in the form of light or additional electric signals needed for powering the delivery head 19. The control unit (e.g. CPU) 11 controls the primary electromagnetic generator 6 which may generate a continuous electromagnetic energy (CM) or a pulses, having a fluence in the range of 0.1 pJ/cm2 to 1000 J/cm2 or in the range of 0.5 pJ/cm2 to 800 J/cm2 or in the range of 0.8 pJ/cm2 to 700 J/cm2 or in the range of 1 pJ/cm2 to 600 J/cm2 on the output of the electromagnetic generator. The CM mode may be operated for a time interval in the range of 0.1 s to 24 hours or in the range of 0.2 s to 12 hours or in the range of 0.5 s to 6 hours or in the range of 1 s to 3 hours. The pulse duration of the electromagnetic radiation operated in the pulse regime may be in the range of 0.1 fs to 2000 ms or in the range of 0.5 fs to 1500 ms or in the range of 1 fs to 1200 ms or in the range of 1 fs to 1000 ms. Alternatively the pulse duration may be in the range of 0.1 fs to 1000 ns or in the range of 0.5 fs to 800 ns or in the range of 1 fs to 500 ns or in the range of 1 fs to 300 ns. Alternatively, the pulse duration may be in the range of 0.3 to 5000 ps or in the range of 1 to 4000 ps or in the range of 5 to 3500 ps or in the range of 10 to 3000 ps. Or alternatively the pulse duration may be in the range of 0.05 to 2000 ms or in the range of 0.1 to 1500 ms or in the range of 0.5 to 1250 ms or in the range of 1 to 1000 ms. The primary electromagnetic generator 6 in the pulse regime may be operated by control unit (e.g. CPU) 11 in a single shot mode or in a repetition mode or in a burst mode. The frequency of the repetition mode or the burst mode may be in the range of 0.05 to 10 000 Hz or in the range of 0.1 to 5000 Hz or in the range of 0.3 to 2000 Hz or in the range of 0.5 to 1000 Hz. Alternatively the frequency of the repetition mode or the burst mode may be in the range of 0.1 kHz to 200 MHz or in the range of 0.5 kHz to 150 MHz or in the range of 0.8 kHz to 100 MHz or in the range of 1 kHz to 80 MHz. The single shot mode may be configured to generate a single electromagnetic energy of specific parameters (e.g. intensity, duration, etc.) for irradiation of a single treatment area. The repetition mode may be configured to generate an electromagnetic energy, which may have one or more specific parameters (e.g. intensity, duration, etc.), with a repetition rate of the above-mentioned frequency for irradiation of a single treatment area. The burst mode may be configured to generate multiple consecutive electromagnetic energies, which may have variable parameters (e.g. intensity, duration, delay etc.), during one sequence, wherein the sequences are repeated with the above-mentioned frequency and wherein the sequence may include the same or different sets of consecutive electromagnetic energies.
Alternatively, the device may contain more than one primary electromagnetic generator 6 for generation of the same or a different electromagnetic energy, e.g. one primary electromagnetic generator is for generation of an ablative electromagnetic energy and the other is for generation of a non-ablative electromagnetic energy. In this case, it is possible for an operator to select which primary electromagnetic generators may be used for a given treatment or the clinician can choose a required treatment through the human machine interface 8 and the control unit (e.g. CPU) 11 will select which primary electromagnetic generators will be used. It is possible to operate one or more primary electromagnetic generators of the device 100 simultaneously, successively or in an overlapping method. For example in the case of two primary electromagnetic generators: in the simultaneous method, both primary electromagnetic generators are used simultaneously during a time interval e.g., 1-20 ps. In the successive method, the first primary electromagnetic generator is used during the first time interval e.g., from 1 to 10 ps. The first primary electromagnetic generator is then stopped and the second primary electromagnetic generator is immediately used in a subsequent time interval e.g., from 10 to 20 ps. Such a sequence of two or more successive steps may be repeated. In the overlapping method, the first primary electromagnetic generator is used during a time interval, e.g., 1-10 ps, and the second primary electromagnetic generator is used in a second overlapping time interval for e.g., 2-11 ps, wherein during the second time interval the first primary electromagnetic generator and the second primary electromagnetic generator are overlapping e.g., with total overlapping method time for 2-10 ps. In the case of more than two primary electromagnetic generators, the activating and deactivating of the primary electromagnetic generators in a successive or overlap method may be driven by control unit (e.g. CPU) 11 in the order which is suitable for a given treatment, e.g. first activating the pre-heating primary electromagnetic generator, then the ablation primary electromagnetic generator and then the non-ablative primary electromagnetic generator.
The active elements 13 in the delivery head 19 may be in the form of optical elements, which may be represented by one or more optical windows, lenses, mirrors, fibers or diffraction elements. The optical element representing active element 13 may be connected to or may contain primary electromagnetic generator 6 inside the delivery head 19. The optical element may produce one beam of electromagnetic energy, which may provide an energy spot having an energy spot size defined as a surface of tissue irradiated by one beam of light. One optical element may provide one or more energy spots e.g. by splitting one beam into a plurality of beams. The energy spot size may be in the range of 0.001 cm2 to 1000 cm2, or in the range of 0.005 cm2 to 700 cm2, or in the range of 0.01 cm2 to 300 cm2, or in the range of 0.03 cm2 to 80 cm2. Energy spots of different or the same wavelength may be overlaid or may be separated. Two or more beams of light may be applied to the same spot at the same time or with a time gap ranging from 0.1 μs to 30 seconds. Energy spots may be separated by at least 1% of their diameter, and in addition, energy spots may closely follow each other or may be separated by a gap ranging from 0.01 mm to 20 mm or from 0.05 mm to 15 mm or from 0.1 mm to 10 mm.
The control unit (e.g. CPU) may be further responsible for switching between active elements 13 or for moving the active elements 13 within the delivery head 19 so that the electromagnetic radiation may be delivered homogeneously into the whole treatment area marked with aiming beam 18. The rate of switching between active elements 13 may be dependent on the amount of delivered energy, pulse length, etc. and the speed of control unit (e.g. CPU) or other mechanism responsible for switching or moving the active elements 13 (e.g. scanner). Additionally, a device may be configured to switch between multiple active elements 13 in such a way that they deliver energy simultaneously, successively or in an overlapping method. For example, in the case of two active elements: in the simultaneous method, both active elements are used simultaneously during the time interval e.g., 1-20 ps. In the successive method, the first active element is used during the first time interval e.g., from 1 to 10 ps. The first active element is then stopped and the second active element is immediately used in a subsequent time interval e.g., from 10 to 20 ps. This successive step may be repeated. In the overlapping method, the first active element is used during a time interval for e.g., 1-10 ps, and the second active element is used in a second overlapping time interval for e.g., 2-11 ps, wherein during the second time interval the first active element and the second active element are overlapping e.g., with total overlapping method time for 2-10 ps.
The aiming beam 18 has no clinical effect on the treated tissue and may serve as a tool to mark the area to be treated so that the operator knows which exact area will be irradiated and the control unit 11 (e.g. CPU) may set and adjust treatment parameters accordingly. An aiming beam may be generated by a separate electromagnetic generator or by the primary electromagnetic generator 6. Aiming beam 18 may deliver energy at a wavelength in a range of 300-800 nm and may supply energy at a maximum power of 10 mW.
In addition, the pad may contain a control unit 11 (e.g. CPU) driven distance sensor 22 for measuring a distance from active element 13 to the treated point within the treated area marked by aiming beam 18. The measured value may be used by CPU 11 as a parameter for adjusting one or more treatment parameters which may depend on the distance between the active element and a treating point, e.g. fluence. Information from distance sensor 22 may be provided to control unit 11 (e.g. CPU) before every switch/movement of an active element 13 so that the delivered energy will remain the same across the treated area independent of its shape or unevenness.
The patient's skin may be pre-cooled to a selected temperature for a selected duration over at least one treatment portion, the selected temperature and duration for pre-cooling preferably being sufficient to cool the skin to at least a selected temperature below normal body temperature. The skin may be cooled to at least the selected temperature to a depth below the at least one depth for the treatment portions so that the at least one treatment portion is substantially surrounded by cooled skin. The cooling may continue during the application of radiation, wherein the duration of the application of radiation may be greater than the thermal relaxation time of the treatment portions. Cooling may be provided by any known mechanism including water cooling, sprayed coolant, presence of an active solid cooling element (e.g. thermoelectric cooler) or air flow cooling. A cooling element may act as an optical element. Alternatively, a spacer may serve as a cooling element. Cooling may be provided during, before or after the treatment with electromagnetic energy. Cooling before treatment may also provide an environment for sudden heat shock, while cooling after treatment may provide faster regeneration after heat shock. The temperature of the coolant may be in the range of −200° C. to 36° C. The temperature of the cooling element during the treatment may be in the range of −80° C. to 36° C. or −70° C. to 35° C. or −60° C. to 34° C. or −20° C. to 30° C. or 0° C. to 27° C. or 5° C. to 25° C. Further, where the pad is not in contact with the patient's skin, cryogenic spray cooling, gas flow or other non-contact cooling techniques may be utilized. A cooling gel on the skin surface might also be utilized, either in addition to or instead of, one of the cooling techniques indicated above.
Additionally, device 100 may include one or more sensors. The sensor may provide information about at least one physical quantity and its measurement may lead to feedback which may be displayed by human machine interface 8 or indicators 17. The one or more sensors may be used for sensing a variety of physical quantities, including but not limited to the energy of the delivered electromagnetic radiation or backscattered electromagnetic radiation from the skin, impedance of the skin, resistance of the skin, temperature of the treated skin, temperature of the untreated skin, temperature of at least one layer of the skin, water content of the device, the phase angle of delivered or reflected energy, the position of the active elements 13, the position of the delivery element 19, temperature of the cooling media or temperature of the primary electromagnetic generator 6. The sensor may be a temperature, acoustic, vibration, electric, magnetic, flow, positional, optical, imaging, pressure, force, energy flux, impedance, current, Hall or proximity sensor. The sensor may be a capacitive displacement sensor, acoustic proximity sensor, gyroscope, accelerometer, magnetometer, infrared camera or thermographic camera. The sensor may be invasive or contactless. The sensor may be located on the delivery element 19 or in the main unit 2 or may be a part of a distance sensor 22. One sensor may measure more than one physical quantity. For example, a sensor may include a combination of a gyroscope, an accelerometer or a magnetometer. Additionally, the sensor may measure one or more physical quantities of the treated skin or untreated skin.
The thermal sensor measures and monitors the temperature of the treated skin. The temperature can be analyzed by a control unit 11 (e.g. CPU). The thermal sensor may be a contactless sensor (e.g. infrared temperature sensor). The control unit 11 (e.g. CPU) may also use algorithms to calculate a temperature below the surface of the skin based on the surface temperature of the skin and one or more additional parameters. A temperature feedback system may control the temperature and based on set or pre-set limits alert the operator in human perceptible form e.g. on the human machine interface 8 or via indicators 17. In a limit temperature condition, the device may be configured to adjust treatment parameters of each active element, e.g. output power, activate cooling or stop the treatment. Human perceptible form may be a sound, alert message shown on human machine interface 8 or indicators 17 or change of color of any part of the device 100.
A resistance sensor may measure the skin resistance, since it may vary for different patients, as well as the humidity—wetness and sweat may influence the resistance and therefore the behavior of the skin in the energy field. Based on the measured skin resistance, the skin impedance may also be calculated.
Information from one or more sensors may be used for generation of a pathway on a convenient model e.g. a model of the human body shown on a display of human machine interface 8. The pathway may illustrate a surface or volume of already treated tissue, presently treated tissue, tissue to be treated, or untreated tissue. A convenient model may show a temperature map of the treated tissue providing information about the already treated tissue or untreated tissue.
The sensor may provide information about the location of bones, inflamed tissue or joints. Such types of tissue may not be targeted by electromagnetic radiation due to the possibility of painful treatment. Bones, joints or inflamed tissue may be detected by any type of sensor such as an imaging sensor (ultrasound sensor, IR sensor), impedance and the like. A detected presence of these tissue types may cause general human perceptible signals or interruption of generation of electromagnetic radiation. Bones may be detected for example by a change of impedance of the tissue or by analysis of reflected electromagnetic radiation.
Furthermore, the device 100 may include an emergency stop button 16 so that the patient can stop the therapy immediately anytime during the treatment.
It may be part of the invention that the method of treatment includes the following steps: preparation of the tissue; positioning the proposed device; selecting or setting up the treatment parameters; and application of the energy. More than one step may be executed simultaneously.
Preparation of the tissue may include removing make-up or cleansing the patient's skin. For higher target temperatures, anesthetics may be applied topically or in an injection.
Positioning the device may include selecting the correct shape of the pad according to the area to be treated and affixing the pad or the neutral electrode to the patient, for example with an adhesive layer, vacuum suction, band or mask, and verifying proper contact with the treated tissue in the case of contact therapy. In the case of contactless therapy, positioning of the device may include adjusting the aiming beam of proposed device so that the device can measure the distance of the active element(s) from the treatment area and adjust the treatment parameters accordingly.
Selecting or setting up the treatment parameters may include adjusting treatment time, power, duty cycle, delivery time and mode (CM or pulsed), active points surface density/size for fractional arrangement and mode of operation. Selecting the mode of operation may mean choosing simultaneous, successive or overlapping methods or selecting the switching order of active elements or groups of active elements or selecting the proper preprogrammed protocol.
Application of the energy may include providing at least one type of energy in the form of RF energy, electric current, ultrasound energy or electromagnetic energy in the form of polychromatic or monochromatic light, or their combination. The energy may be provided from at least one active element into the skin by proposed device. Energy may be delivered and regulated automatically by the control unit (e.g. CPU) according to information from thermal sensors and impedance measurements and, in the case of contactless therapy, distance sensors. All automatic adjustments and potential impacts on the therapy may be indicated on the device display. Either the operator or the patient may suspend therapy at any time during treatment. A typical treatment might have a duration of about 1 to 60 min or 2 to 50 min or 3 to 40 min or 5 to 30 min or 8 to 25 min or 10 to 20 min depending on the treated area and the size and number of active elements located within one or more pads. A typical treatment with 1, 2, 3, 4, 5 or up to 10 pads may have a total duration of about 1 to 60 minutes or 2 to 50 minutes or 3 to 40 minutes 5 to 30 minutes or 8 to 25 minutes or 10 to 20 minutes. A typical treatment with one pad may have a total duration of about 1 to 30 minutes or 2 to 25 minutes or 3 to 22 minutes 5 to 20 minutes or 5 to 15 minutes or 5 to 12 minutes.
In one example, application of energy to the tissue may include providing radiofrequency energy and/or electric current and/or ultrasound energy or any combination of these, from the active elements embedded in the pad, to the skin of the patient. In such embodiment, active elements providing radiofrequency energy are capacitive or resistive RF electrodes and the RF energy may cause heating, coagulation or ablation of the skin. The electric current is provided by the RF electrodes and may cause muscle contractions. Ultrasound energy may be provided through an acoustic window and may rise the temperature in the depth which may suppress the gradient loss of RF energy and thus the desired temperature in a germinal layer may be reach. In addition, the RF electrode may act as an acoustic window for ultrasound energy.
Alternatively, the application of the energy to the tissue may include providing electromagnetic energy in the form of polychromatic or monochromatic light from the active elements into the skin of the patient. In such case, active elements providing the electromagnetic energy may comprise optical elements described in the proposed device. Optical elements may be represented by an optical window, lens, mirror, fiber or electromagnetic field generator, e.g. LED, laser, flash lamp, incandescent light bulb or other light sources known in the state of art. The electromagnetic energy in the form of polychromatic or monochromatic light may entail the heating, coagulation or ablation of the skin in the treated area.
After reaching the required temperature and therapy time the therapy is terminated, the device accessories may be removed and a cleansing of the patient's skin may be provided.
This application is a continuation of U.S. application Ser. No. 17/941,777, filed Sep. 9, 2022, now pending, which is a continuation of U.S. application Ser. No. 17/664,161, filed May 19, 2022, now pending, which is a continuation-in-part of U.S. application Ser. No. 17/518,243, filed Nov. 3, 2021, now pending, which is a continuation-in-part of International Application No. PCT/IB2021/000300, filed May 3, 2021, now pending, which claims priority to U.S. Provisional Application No. 63/019,619, filed on May 4, 2020, all of which are incorporated herein by reference in their entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 1973387 | Neymann et al. | Sep 1934 | A |
| 2021676 | Wood et al. | Nov 1935 | A |
| 3163161 | Jacques et al. | Dec 1964 | A |
| 3566877 | Smith et al. | Mar 1971 | A |
| 3658051 | MacLean et al. | Apr 1972 | A |
| 3709228 | Barker | Jan 1973 | A |
| 3841306 | Hallgren et al. | Oct 1974 | A |
| 3915151 | Kraus | Oct 1975 | A |
| 3946349 | Haldeman, III | Mar 1976 | A |
| 3952751 | Yarger | Apr 1976 | A |
| 3971387 | Mantell | Jul 1976 | A |
| 4068292 | Berry et al. | Jan 1978 | A |
| 4143661 | LaForge et al. | Mar 1979 | A |
| 4197851 | Fellus | Apr 1980 | A |
| 4237898 | Whalley | Dec 1980 | A |
| 4305115 | Armitage | Dec 1981 | A |
| 4315503 | Ryaby et al. | Feb 1982 | A |
| 4392040 | Rand et al. | Jul 1983 | A |
| 4454883 | Fellus | Jun 1984 | A |
| 4456001 | Pescatore | Jun 1984 | A |
| 4550714 | Talish et al. | Nov 1985 | A |
| 4556056 | Fischer et al. | Dec 1985 | A |
| 4665898 | Costa et al. | May 1987 | A |
| 4674482 | Waltonen et al. | Jun 1987 | A |
| 4674505 | Pauli et al. | Jun 1987 | A |
| 4723536 | Rauscher et al. | Feb 1988 | A |
| 4850959 | Findl | Jul 1989 | A |
| 4889526 | Rauscher et al. | Dec 1989 | A |
| 4957480 | Morenings | Sep 1990 | A |
| 4989604 | Fang | Feb 1991 | A |
| 4993413 | McLeod et al. | Feb 1991 | A |
| 5061234 | Chaney | Oct 1991 | A |
| 5067940 | Liboff et al. | Nov 1991 | A |
| 5085626 | Frey | Feb 1992 | A |
| 5143063 | Fellner | Sep 1992 | A |
| 5156587 | Montone | Oct 1992 | A |
| 5181902 | Erickson et al. | Jan 1993 | A |
| 5199951 | Spears | Apr 1993 | A |
| 5246438 | Langberg | Sep 1993 | A |
| 5334181 | Rubinsky et al. | Aug 1994 | A |
| 5344384 | Ostrow et al. | Sep 1994 | A |
| 5401233 | Erickson et al. | Mar 1995 | A |
| 5415617 | Kraus | May 1995 | A |
| 5419344 | Dewitt | May 1995 | A |
| 5433737 | Aimone | Jul 1995 | A |
| 5433740 | Yamaguchi | Jul 1995 | A |
| 5562706 | Lauterbach et al. | Oct 1996 | A |
| 5584863 | Rauch et al. | Dec 1996 | A |
| 5620463 | Drolet | Apr 1997 | A |
| 5660836 | Knowlton | Aug 1997 | A |
| 5674218 | Rubinsky et al. | Oct 1997 | A |
| 5690692 | Fleming | Nov 1997 | A |
| 5691873 | Masaki | Nov 1997 | A |
| 5718662 | Jalinous | Feb 1998 | A |
| 5725471 | Davey et al. | Mar 1998 | A |
| 5755753 | Knowlton | May 1998 | A |
| 5766124 | Polson | Jun 1998 | A |
| 5782743 | Russell | Jul 1998 | A |
| 5807232 | Espinoza et al. | Sep 1998 | A |
| 5857957 | Lin | Jan 1999 | A |
| 5908444 | Azure | Jun 1999 | A |
| 5919219 | Knowlton | Jul 1999 | A |
| 5968527 | Litovitz | Oct 1999 | A |
| 5984854 | Ishikawa et al. | Nov 1999 | A |
| 6017337 | Pira | Jan 2000 | A |
| 6032675 | Rubinsky | Mar 2000 | A |
| 6038485 | Axelgaard | Mar 2000 | A |
| 6047215 | McClure et al. | Apr 2000 | A |
| 6063108 | Salansky et al. | May 2000 | A |
| 6067474 | Schulman et al. | May 2000 | A |
| 6086525 | Davey et al. | Jul 2000 | A |
| 6094599 | Bingham et al. | Jul 2000 | A |
| 6099459 | Jacobson | Aug 2000 | A |
| 6099523 | Kim et al. | Aug 2000 | A |
| 6117066 | Abrams et al. | Sep 2000 | A |
| 6132361 | Epstein et al. | Oct 2000 | A |
| 6141985 | Cluzeau et al. | Nov 2000 | A |
| 6155966 | Parker | Dec 2000 | A |
| 6161757 | Morris | Dec 2000 | A |
| 6179769 | Ishikawa et al. | Jan 2001 | B1 |
| 6179770 | Mould | Jan 2001 | B1 |
| 6179771 | Mueller | Jan 2001 | B1 |
| 6200259 | March | Mar 2001 | B1 |
| 6213933 | Lin | Apr 2001 | B1 |
| 6223750 | Ishikawa et al. | May 2001 | B1 |
| 6246905 | Mogul | Jun 2001 | B1 |
| 6255815 | Davey | Jul 2001 | B1 |
| 6261301 | Knesch et al. | Jul 2001 | B1 |
| 6273862 | Privitera et al. | Aug 2001 | B1 |
| 6273884 | Altshuler et al. | Aug 2001 | B1 |
| 6280376 | Holcomb | Aug 2001 | B1 |
| 6282448 | Katz et al. | Aug 2001 | B1 |
| D447806 | Davey et al. | Sep 2001 | S |
| 6311090 | Knowlton | Oct 2001 | B1 |
| 6324430 | Zarinetchi et al. | Nov 2001 | B1 |
| 6324432 | Rigaux et al. | Nov 2001 | B1 |
| 6334069 | George et al. | Dec 2001 | B1 |
| 6334074 | Spertell | Dec 2001 | B1 |
| 6350276 | Knowlton | Feb 2002 | B1 |
| 6366814 | Boveja et al. | Apr 2002 | B1 |
| 6402678 | Fischell et al. | Jun 2002 | B1 |
| 6413255 | Stern | Jul 2002 | B1 |
| 6418345 | Tepper et al. | Jul 2002 | B1 |
| 6424864 | Matsuura | Jul 2002 | B1 |
| 6425852 | Epstein et al. | Jul 2002 | B1 |
| 6443883 | Ostrow et al. | Sep 2002 | B1 |
| 6445955 | Michelson et al. | Sep 2002 | B1 |
| 6447440 | Markoll | Sep 2002 | B1 |
| 6453202 | Knowlton | Sep 2002 | B1 |
| 6461375 | Baudry et al. | Oct 2002 | B1 |
| 6491620 | Davey | Dec 2002 | B1 |
| 6500110 | Davey et al. | Dec 2002 | B1 |
| 6520903 | Yamashiro | Feb 2003 | B1 |
| 6527694 | Ishikawa et al. | Mar 2003 | B1 |
| 6527695 | Davey et al. | Mar 2003 | B1 |
| 6537197 | Ruohonen et al. | Mar 2003 | B1 |
| 6569078 | Ishikawa et al. | May 2003 | B2 |
| 6591138 | Fischell et al. | Jul 2003 | B1 |
| 6605080 | Altshuler et al. | Aug 2003 | B1 |
| 6635053 | Lalonde et al. | Oct 2003 | B1 |
| 6658301 | Loeb et al. | Dec 2003 | B2 |
| 6662054 | Kreindel et al. | Dec 2003 | B2 |
| 6663556 | Barker | Dec 2003 | B2 |
| 6663659 | McDaniel | Dec 2003 | B2 |
| 6701185 | Burnett et al. | Mar 2004 | B2 |
| 6735481 | Bingham et al. | May 2004 | B1 |
| 6738667 | Deno et al. | May 2004 | B2 |
| 6749624 | Knowlton | Jun 2004 | B2 |
| 6827681 | Tanner et al. | Dec 2004 | B2 |
| 6849040 | Ruohonen et al. | Feb 2005 | B2 |
| 6860852 | Schonenberger et al. | Mar 2005 | B2 |
| 6871099 | Whitehurst et al. | Mar 2005 | B1 |
| 6879859 | Boveja | Apr 2005 | B1 |
| 6889090 | Kreindel | May 2005 | B2 |
| 6920883 | Bessette et al. | Jul 2005 | B2 |
| 6926660 | Miller | Aug 2005 | B2 |
| 6939287 | Ardizzone et al. | Sep 2005 | B1 |
| 6939344 | Kreindel | Sep 2005 | B2 |
| 6960202 | Cluzeau et al. | Nov 2005 | B2 |
| 6990427 | Kirsch et al. | Jan 2006 | B2 |
| 7008370 | Tanner et al. | Mar 2006 | B2 |
| 7024239 | George et al. | Apr 2006 | B2 |
| 7030764 | Smith et al. | Apr 2006 | B2 |
| 7041100 | Kreindel | May 2006 | B2 |
| 7083580 | Bernabei | Aug 2006 | B2 |
| 7104947 | Riehl | Sep 2006 | B2 |
| 7153256 | Riehl et al. | Dec 2006 | B2 |
| 7186209 | Jacobson et al. | Mar 2007 | B2 |
| 7217265 | Hennings et al. | May 2007 | B2 |
| 7238183 | Kreindel | Jul 2007 | B2 |
| 7276020 | Becker et al. | Oct 2007 | B2 |
| 7276058 | Altshuler et al. | Oct 2007 | B2 |
| 7294101 | Fischell et al. | Nov 2007 | B2 |
| 7309309 | Wang et al. | Dec 2007 | B2 |
| 7318821 | Lalonde et al. | Jan 2008 | B2 |
| 7320664 | Riehl et al. | Jan 2008 | B2 |
| 7351252 | Altshuler et al. | Apr 2008 | B2 |
| 7367341 | Anderson et al. | May 2008 | B2 |
| 7367936 | Myers et al. | May 2008 | B2 |
| 7369895 | Hurtado | May 2008 | B2 |
| 7372271 | Roozen et al. | May 2008 | B2 |
| 7376460 | Bernabei | May 2008 | B2 |
| 7396326 | Ghiron et al. | Jul 2008 | B2 |
| 7407478 | Zangen et al. | Aug 2008 | B2 |
| 7494458 | Fischell et al. | Feb 2009 | B2 |
| 7496401 | Bernabei | Feb 2009 | B2 |
| 7520848 | Schneider et al. | Apr 2009 | B2 |
| 7520849 | Simon | Apr 2009 | B1 |
| 7520875 | Bernabei | Apr 2009 | B2 |
| 7532926 | Bernabei | May 2009 | B2 |
| 7560058 | Riehl et al. | Jul 2009 | B2 |
| 7571003 | Pozzato | Aug 2009 | B2 |
| 7591776 | Phillips et al. | Sep 2009 | B2 |
| 7601115 | Riehl | Oct 2009 | B2 |
| 7601116 | Fischell et al. | Oct 2009 | B2 |
| 7608035 | Farone | Oct 2009 | B2 |
| 7614996 | Riehl et al. | Nov 2009 | B2 |
| 7618429 | Mulholland | Nov 2009 | B2 |
| 7630774 | Karni et al. | Dec 2009 | B2 |
| 7643883 | Kreindel | Jan 2010 | B2 |
| 7651459 | Cameron et al. | Jan 2010 | B2 |
| 7697998 | Axelgaard | Apr 2010 | B2 |
| 7699768 | Kishawi et al. | Apr 2010 | B2 |
| 7706885 | Farone | Apr 2010 | B2 |
| 7711431 | Tanner et al. | May 2010 | B2 |
| 7740574 | Pilla et al. | Jun 2010 | B2 |
| 7744523 | Epstein | Jun 2010 | B2 |
| 7753836 | Peterchev | Jul 2010 | B2 |
| 7783348 | Gill et al. | Aug 2010 | B2 |
| 7785358 | Lach | Aug 2010 | B2 |
| 7824324 | Riehl et al. | Nov 2010 | B2 |
| 7854232 | Aho et al. | Dec 2010 | B2 |
| 7854754 | Ting et al. | Dec 2010 | B2 |
| 7857746 | Riehl | Dec 2010 | B2 |
| 7857775 | Rosenberg et al. | Dec 2010 | B2 |
| 7901373 | Tavger | Mar 2011 | B2 |
| 7909786 | Bonnefin et al. | Mar 2011 | B2 |
| 7914469 | Torbati | Mar 2011 | B2 |
| 7925066 | Ruohonen et al. | Apr 2011 | B2 |
| 7945321 | Bernabei | May 2011 | B2 |
| 7946973 | Peterchev | May 2011 | B2 |
| 7953500 | Bingham et al. | May 2011 | B2 |
| 7963903 | Ghiron et al. | Jun 2011 | B2 |
| 7976451 | Zangen et al. | Jul 2011 | B2 |
| 7998053 | Aho | Aug 2011 | B2 |
| 8035385 | Tomiha et al. | Oct 2011 | B2 |
| 8052591 | Mishelevich et al. | Nov 2011 | B2 |
| RE43007 | Lalonde et al. | Dec 2011 | E |
| 8088058 | Juliana et al. | Jan 2012 | B2 |
| 8105254 | Guantera et al. | Jan 2012 | B2 |
| 8118722 | Riehl et al. | Feb 2012 | B2 |
| 8128549 | Testani et al. | Mar 2012 | B2 |
| 8133191 | Rosenberg et al. | Mar 2012 | B2 |
| 8137258 | Dennis et al. | Mar 2012 | B1 |
| 8170643 | Turner et al. | May 2012 | B2 |
| 8172835 | Leyh et al. | May 2012 | B2 |
| 8177702 | Riehl et al. | May 2012 | B2 |
| 8192474 | Levinson | Jun 2012 | B2 |
| 8204446 | Scheer et al. | Jun 2012 | B2 |
| 8246529 | Riehl et al. | Aug 2012 | B2 |
| 8251986 | Chornenky et al. | Aug 2012 | B2 |
| 8262556 | Fischell et al. | Sep 2012 | B2 |
| 8265763 | Fahey | Sep 2012 | B2 |
| 8265910 | Mishelevich et al. | Sep 2012 | B2 |
| 8267850 | Schneider et al. | Sep 2012 | B2 |
| 8271090 | Hartman et al. | Sep 2012 | B1 |
| 8275442 | Allison | Sep 2012 | B2 |
| 8277371 | Zangen et al. | Oct 2012 | B2 |
| 8285390 | Levinson et al. | Oct 2012 | B2 |
| 8303478 | Lebosse et al. | Nov 2012 | B2 |
| 8335566 | Muller et al. | Dec 2012 | B2 |
| 8337539 | Ting et al. | Dec 2012 | B2 |
| 8366756 | Tucek et al. | Feb 2013 | B2 |
| 8376825 | Guinn et al. | Feb 2013 | B2 |
| 8376925 | Dennis et al. | Feb 2013 | B1 |
| 8388510 | Zangen et al. | Mar 2013 | B2 |
| 8428735 | Littlewood et al. | Apr 2013 | B2 |
| 8454591 | Leyh et al. | Jun 2013 | B2 |
| 8457751 | Pozzato | Jun 2013 | B2 |
| 8465408 | Phillips et al. | Jun 2013 | B2 |
| 8475354 | Phillips et al. | Jul 2013 | B2 |
| 8480554 | Phillips et al. | Jul 2013 | B2 |
| 8493286 | Agrama | Jul 2013 | B1 |
| 8506468 | Ghiron et al. | Aug 2013 | B2 |
| 8517908 | Riehl et al. | Aug 2013 | B2 |
| 8523753 | Schneider et al. | Sep 2013 | B2 |
| 8523927 | Levinson et al. | Sep 2013 | B2 |
| 8548599 | Zarsky et al. | Oct 2013 | B2 |
| 8565888 | Buhlmann et al. | Oct 2013 | B2 |
| 8579953 | Dunbar et al. | Nov 2013 | B1 |
| 8585568 | Phillips et al. | Nov 2013 | B2 |
| 8585617 | Mashiach et al. | Nov 2013 | B2 |
| 8588930 | Diubaldi et al. | Nov 2013 | B2 |
| 8593245 | Zeng et al. | Nov 2013 | B2 |
| 8603073 | Allison | Dec 2013 | B2 |
| 8608634 | Zangen et al. | Dec 2013 | B2 |
| 8646239 | Rulon | Feb 2014 | B2 |
| 8657731 | Riehl et al. | Feb 2014 | B2 |
| 8666492 | Muller et al. | Mar 2014 | B2 |
| 8676338 | Levinson | Mar 2014 | B2 |
| 8684901 | Zabara | Apr 2014 | B1 |
| 8700176 | Azar et al. | Apr 2014 | B2 |
| 8702774 | Baker et al. | Apr 2014 | B2 |
| 8723628 | Mishelevich et al. | May 2014 | B2 |
| 8725270 | Towe | May 2014 | B2 |
| 8740765 | Fischell et al. | Jun 2014 | B1 |
| 8768454 | Sham et al. | Jul 2014 | B2 |
| 8771163 | Zangen et al. | Jul 2014 | B2 |
| 8771326 | Myeong et al. | Jul 2014 | B2 |
| 8777831 | Aho | Jul 2014 | B2 |
| 8788060 | Nebrigic et al. | Jul 2014 | B2 |
| 8795148 | Schneider et al. | Aug 2014 | B2 |
| 8801589 | Peterchev et al. | Aug 2014 | B2 |
| 8825166 | John | Sep 2014 | B2 |
| 8834547 | Anderson et al. | Sep 2014 | B2 |
| 8840608 | Anderson et al. | Sep 2014 | B2 |
| 8845508 | Schneider et al. | Sep 2014 | B2 |
| 8864641 | Riehl et al. | Oct 2014 | B2 |
| 8868177 | Simon et al. | Oct 2014 | B2 |
| 8870737 | Phillips et al. | Oct 2014 | B2 |
| 8888672 | Phillips et al. | Nov 2014 | B2 |
| 8888673 | Phillips et al. | Nov 2014 | B2 |
| 8906009 | Nebrigic et al. | Dec 2014 | B2 |
| 8909342 | Lozano | Dec 2014 | B2 |
| 8915948 | Altshuler et al. | Dec 2014 | B2 |
| 8926490 | Phillips et al. | Jan 2015 | B2 |
| 8932338 | Lim et al. | Jan 2015 | B2 |
| 8956273 | Mishelevich et al. | Feb 2015 | B2 |
| 8956274 | Schneider et al. | Feb 2015 | B2 |
| 8961386 | Phillips et al. | Feb 2015 | B2 |
| 8979727 | Ron et al. | Mar 2015 | B2 |
| 8985331 | Guenter et al. | Mar 2015 | B2 |
| 8998791 | Ron Edoute et al. | Apr 2015 | B2 |
| 9002477 | Burnett | Apr 2015 | B2 |
| 9008793 | Cosman, Sr. et al. | Apr 2015 | B1 |
| 9015057 | Phillips et al. | Apr 2015 | B2 |
| 9028469 | Jones et al. | May 2015 | B2 |
| 9031659 | Campbell et al. | May 2015 | B2 |
| 9033861 | Fischell et al. | May 2015 | B2 |
| 9037247 | Simon et al. | May 2015 | B2 |
| 9044595 | Araya et al. | Jun 2015 | B2 |
| 9061128 | Hall et al. | Jun 2015 | B2 |
| 9067052 | Moses et al. | Jun 2015 | B2 |
| 9072891 | Rao | Jul 2015 | B1 |
| 9078634 | Gonzales et al. | Jul 2015 | B2 |
| 9089719 | Simon et al. | Jul 2015 | B2 |
| 9101524 | Aghion | Aug 2015 | B2 |
| 9132031 | Levinson et al. | Sep 2015 | B2 |
| 9149650 | Shanks et al. | Oct 2015 | B2 |
| 9168096 | Kreindel | Oct 2015 | B2 |
| 9233207 | Polyakov et al. | Jan 2016 | B2 |
| 9233257 | Zabara | Jan 2016 | B1 |
| 9254395 | Shambayati | Feb 2016 | B1 |
| 9261574 | Boskamp et al. | Feb 2016 | B2 |
| 9265690 | Kriksunov et al. | Feb 2016 | B2 |
| 9308120 | Anderson et al. | Apr 2016 | B2 |
| 9314368 | Allison et al. | Apr 2016 | B2 |
| 9326910 | Eckhouse et al. | May 2016 | B2 |
| 9339641 | Rajguru et al. | May 2016 | B2 |
| 9358068 | Schomacker et al. | Jun 2016 | B2 |
| 9358149 | Anderson et al. | Jun 2016 | B2 |
| 9375345 | Levinson et al. | Jun 2016 | B2 |
| 9387339 | Sham et al. | Jul 2016 | B2 |
| 9398975 | Müller et al. | Jul 2016 | B2 |
| 9408745 | Levinson et al. | Aug 2016 | B2 |
| 9414759 | Lang et al. | Aug 2016 | B2 |
| 9433797 | Pilla et al. | Sep 2016 | B2 |
| 9439805 | Gonzales et al. | Sep 2016 | B2 |
| 9446258 | Schwarz et al. | Sep 2016 | B1 |
| 9468774 | Arsk et al. | Oct 2016 | B2 |
| 9526912 | Fischell et al. | Dec 2016 | B1 |
| 9532832 | Ron Edoute et al. | Jan 2017 | B2 |
| 9545523 | Nanda | Jan 2017 | B2 |
| 9561357 | Hall et al. | Feb 2017 | B2 |
| 9561384 | Fischell et al. | Feb 2017 | B1 |
| 9586048 | Ternes et al. | Mar 2017 | B2 |
| 9586057 | Ladman et al. | Mar 2017 | B2 |
| 9596920 | Shalev et al. | Mar 2017 | B2 |
| 9610429 | Harris et al. | Apr 2017 | B2 |
| 9610459 | Burnett et al. | Apr 2017 | B2 |
| 9615854 | Matsushita | Apr 2017 | B2 |
| 9636516 | Schwarz | May 2017 | B2 |
| 9636519 | Ladman | May 2017 | B2 |
| 9649220 | Anderson et al. | May 2017 | B2 |
| 9655770 | Levinson et al. | May 2017 | B2 |
| 9675800 | Li et al. | Jun 2017 | B2 |
| 9675815 | Fischell et al. | Jun 2017 | B1 |
| 9694194 | Ron Edoute et al. | Jul 2017 | B2 |
| 9707121 | Hyde et al. | Jul 2017 | B2 |
| 9713567 | Guantera et al. | Jul 2017 | B2 |
| 9724533 | Fischell et al. | Aug 2017 | B1 |
| 9737238 | Wright et al. | Aug 2017 | B2 |
| 9737434 | Allison | Aug 2017 | B2 |
| 9757584 | Burnett | Sep 2017 | B2 |
| 9782324 | Crunick et al. | Oct 2017 | B2 |
| 9814897 | Ron Edoute et al. | Nov 2017 | B2 |
| 9844460 | Weber et al. | Dec 2017 | B2 |
| 9844461 | Levinson et al. | Dec 2017 | B2 |
| 9849299 | Sham et al. | Dec 2017 | B2 |
| 9855166 | Anderson et al. | Jan 2018 | B2 |
| 9861421 | O'Neil et al. | Jan 2018 | B2 |
| 9861520 | Baker et al. | Jan 2018 | B2 |
| 9867996 | Zarsky et al. | Jan 2018 | B2 |
| 9901743 | Ron Edoute et al. | Feb 2018 | B2 |
| 9919161 | Schwarz et al. | Mar 2018 | B2 |
| 9937358 | Schwarz et al. | Apr 2018 | B2 |
| 9962553 | Schwarz et al. | May 2018 | B2 |
| 9968797 | Sham et al. | May 2018 | B2 |
| 9974519 | Schwarz et al. | May 2018 | B1 |
| 9974684 | Anderson et al. | May 2018 | B2 |
| 9980765 | Avram et al. | May 2018 | B2 |
| 9981143 | Ron Edoute et al. | May 2018 | B2 |
| 9999780 | Weyh et al. | Jun 2018 | B2 |
| 10029112 | Fischell et al. | Jul 2018 | B1 |
| 10037867 | Godyak | Jul 2018 | B2 |
| 10039929 | Schwarz et al. | Aug 2018 | B1 |
| 10080906 | Schwarz | Sep 2018 | B2 |
| 10092346 | Levinson | Oct 2018 | B2 |
| 10111770 | Harris et al. | Oct 2018 | B2 |
| 10111774 | Gonzales et al. | Oct 2018 | B2 |
| 10124187 | Schwarz et al. | Nov 2018 | B2 |
| 10183172 | Ghiron et al. | Jan 2019 | B2 |
| 10195010 | Sanders | Feb 2019 | B2 |
| 10195427 | Kent et al. | Feb 2019 | B2 |
| 10195453 | Schwarz et al. | Feb 2019 | B2 |
| 10195454 | Yamashiro | Feb 2019 | B2 |
| 10195456 | Cabrerizo et al. | Feb 2019 | B2 |
| 10201380 | Debenedictis et al. | Feb 2019 | B2 |
| 10245439 | Schwarz et al. | Apr 2019 | B1 |
| 10271900 | Marchitto et al. | Apr 2019 | B2 |
| 10279185 | Meadows et al. | May 2019 | B2 |
| 10342988 | Midorikawa et al. | Jul 2019 | B2 |
| 10363419 | Simon et al. | Jul 2019 | B2 |
| 10413745 | Riehl | Sep 2019 | B2 |
| 10463869 | Ron Edoute et al. | Nov 2019 | B2 |
| 10471269 | Schwarz et al. | Nov 2019 | B1 |
| 10471271 | John | Nov 2019 | B1 |
| 10478588 | Walpole et al. | Nov 2019 | B2 |
| 10478633 | Schwarz et al. | Nov 2019 | B2 |
| 10478634 | Schwarz et al. | Nov 2019 | B2 |
| 10493293 | Schwarz et al. | Dec 2019 | B2 |
| 10518098 | Hong et al. | Dec 2019 | B2 |
| 10549109 | Schwarz et al. | Feb 2020 | B2 |
| 10549110 | Schwarz et al. | Feb 2020 | B1 |
| 10556121 | Gurfein | Feb 2020 | B2 |
| 10556122 | Schwarz et al. | Feb 2020 | B1 |
| 10569094 | Schwarz et al. | Feb 2020 | B2 |
| 10569095 | Schwarz et al. | Feb 2020 | B1 |
| 10583287 | Schwarz | Mar 2020 | B2 |
| 10596366 | Sama | Mar 2020 | B2 |
| 10596386 | Schwarz et al. | Mar 2020 | B2 |
| 10610696 | Peled | Apr 2020 | B1 |
| 10632321 | Schwarz et al. | Apr 2020 | B2 |
| 10639490 | Simon et al. | May 2020 | B2 |
| 10661093 | Ron Edoute et al. | May 2020 | B2 |
| 10675819 | Li et al. | Jun 2020 | B2 |
| 10688310 | Tomás et al. | Jun 2020 | B2 |
| 10695575 | Schwarz et al. | Jun 2020 | B1 |
| 10695576 | Schwarz et al. | Jun 2020 | B2 |
| 10709894 | Schwarz et al. | Jul 2020 | B2 |
| 10709895 | Schwarz et al. | Jul 2020 | B2 |
| 10806943 | Sokolowski | Oct 2020 | B2 |
| 10821295 | Schwarz et al. | Nov 2020 | B1 |
| 10849784 | Jurna et al. | Dec 2020 | B2 |
| 10946195 | Strohl | Mar 2021 | B2 |
| 11141219 | Schwarz | Oct 2021 | B1 |
| 11185690 | Schwarz | Nov 2021 | B2 |
| 11207540 | Zangen et al. | Dec 2021 | B2 |
| 11247039 | Schwarz et al. | Feb 2022 | B2 |
| 11420061 | Caparso et al. | Aug 2022 | B2 |
| 11478638 | Toong et al. | Oct 2022 | B2 |
| 11484263 | Leaper | Nov 2022 | B2 |
| 11484725 | Schwarz et al. | Nov 2022 | B2 |
| 11529514 | Bolea et al. | Dec 2022 | B2 |
| 20010018547 | Mechlenburg et al. | Aug 2001 | A1 |
| 20010031906 | Ishikawa et al. | Oct 2001 | A1 |
| 20020010414 | Coston et al. | Jan 2002 | A1 |
| 20020049483 | Knowlton | Apr 2002 | A1 |
| 20020082466 | Han | Jun 2002 | A1 |
| 20020128686 | Minogue et al. | Sep 2002 | A1 |
| 20020143365 | Herbst | Oct 2002 | A1 |
| 20020143373 | Courtnage et al. | Oct 2002 | A1 |
| 20020160436 | Markov et al. | Oct 2002 | A1 |
| 20020165590 | Crowe et al. | Nov 2002 | A1 |
| 20030028072 | Fischell et al. | Feb 2003 | A1 |
| 20030032900 | Ella | Feb 2003 | A1 |
| 20030032950 | Altshuler et al. | Feb 2003 | A1 |
| 20030050527 | Fox et al. | Mar 2003 | A1 |
| 20030074037 | Moore et al. | Apr 2003 | A1 |
| 20030078646 | Axelgaard | Apr 2003 | A1 |
| 20030093133 | Crowe et al. | May 2003 | A1 |
| 20030130711 | Pearson et al. | Jul 2003 | A1 |
| 20030139789 | Tvinnereim et al. | Jul 2003 | A1 |
| 20030149451 | Chomenky et al. | Aug 2003 | A1 |
| 20030153958 | Yamazaki et al. | Aug 2003 | A1 |
| 20030158585 | Burnett | Aug 2003 | A1 |
| 20030216729 | Marchitto et al. | Nov 2003 | A1 |
| 20030220674 | Anderson et al. | Nov 2003 | A1 |
| 20030236487 | Knowlton | Dec 2003 | A1 |
| 20040015163 | Buysse et al. | Jan 2004 | A1 |
| 20040034346 | Stern et al. | Feb 2004 | A1 |
| 20040039279 | Ruohonen | Feb 2004 | A1 |
| 20040073079 | Altshuler et al. | Apr 2004 | A1 |
| 20040077977 | Ella et al. | Apr 2004 | A1 |
| 20040093042 | Altshuler et al. | May 2004 | A1 |
| 20040102768 | Cluzeau et al. | May 2004 | A1 |
| 20040162583 | Bingham et al. | Aug 2004 | A1 |
| 20040193000 | Riehl | Sep 2004 | A1 |
| 20040193003 | Mechlenburg et al. | Sep 2004 | A1 |
| 20040206365 | Knowlton | Oct 2004 | A1 |
| 20040210214 | Knowlton | Oct 2004 | A1 |
| 20040210282 | Flock et al. | Oct 2004 | A1 |
| 20040210287 | Greene | Oct 2004 | A1 |
| 20040230226 | Bingham et al. | Nov 2004 | A1 |
| 20050004632 | Benedict | Jan 2005 | A1 |
| 20050038313 | Ardizzone | Feb 2005 | A1 |
| 20050049543 | Anderson et al. | Mar 2005 | A1 |
| 20050075701 | Shafer | Apr 2005 | A1 |
| 20050075702 | Shafer | Apr 2005 | A1 |
| 20050085866 | Tehrani | Apr 2005 | A1 |
| 20050085874 | Davis et al. | Apr 2005 | A1 |
| 20050090814 | Lalonde et al. | Apr 2005 | A1 |
| 20050107656 | Jang et al. | May 2005 | A1 |
| 20050134193 | Myers et al. | Jun 2005 | A1 |
| 20050187599 | Sharkey et al. | Aug 2005 | A1 |
| 20050203504 | Wham et al. | Sep 2005 | A1 |
| 20050215987 | Slatkine | Sep 2005 | A1 |
| 20050216062 | Herbst | Sep 2005 | A1 |
| 20050251120 | Anderson et al. | Nov 2005 | A1 |
| 20060004244 | Phillips et al. | Jan 2006 | A1 |
| 20060020236 | Ben-Nun | Jan 2006 | A1 |
| 20060036300 | Kreindel | Feb 2006 | A1 |
| 20060094924 | Riehl | May 2006 | A1 |
| 20060106375 | Werneth et al. | May 2006 | A1 |
| 20060152301 | Rohwedder | Jul 2006 | A1 |
| 20060184214 | McDaniel | Aug 2006 | A1 |
| 20060187607 | Mo | Aug 2006 | A1 |
| 20060195168 | Dunbar et al. | Aug 2006 | A1 |
| 20060199992 | Eisenberg et al. | Sep 2006 | A1 |
| 20060206103 | Altshuler et al. | Sep 2006 | A1 |
| 20060206180 | Alcidi | Sep 2006 | A1 |
| 20060253176 | Caruso et al. | Nov 2006 | A1 |
| 20060259102 | Slatkine | Nov 2006 | A1 |
| 20060271028 | Altshuler et al. | Nov 2006 | A1 |
| 20060287566 | Zangen et al. | Dec 2006 | A1 |
| 20060293719 | Naghavi | Dec 2006 | A1 |
| 20070010766 | Gil et al. | Jan 2007 | A1 |
| 20070010861 | Anderson et al. | Jan 2007 | A1 |
| 20070016274 | Boveja et al. | Jan 2007 | A1 |
| 20070027411 | Ella et al. | Feb 2007 | A1 |
| 20070083237 | Teruel | Apr 2007 | A1 |
| 20070088413 | Weber et al. | Apr 2007 | A1 |
| 20070088419 | Fiorina et al. | Apr 2007 | A1 |
| 20070135811 | Hooven | Jun 2007 | A1 |
| 20070142886 | Fischell et al. | Jun 2007 | A1 |
| 20070173749 | Williams et al. | Jul 2007 | A1 |
| 20070173805 | Weinberg et al. | Jul 2007 | A1 |
| 20070179534 | Firlik et al. | Aug 2007 | A1 |
| 20070198071 | Ting et al. | Aug 2007 | A1 |
| 20070232966 | Applebaum et al. | Oct 2007 | A1 |
| 20070244530 | Ren | Oct 2007 | A1 |
| 20070255355 | Altshuler et al. | Nov 2007 | A1 |
| 20070255362 | Levinson et al. | Nov 2007 | A1 |
| 20070260107 | Mishelevich et al. | Nov 2007 | A1 |
| 20070270795 | Francischelli et al. | Nov 2007 | A1 |
| 20070270925 | Levinson | Nov 2007 | A1 |
| 20070282156 | Konings | Dec 2007 | A1 |
| 20070293911 | Crowe et al. | Dec 2007 | A1 |
| 20070293918 | Thompson et al. | Dec 2007 | A1 |
| 20080009885 | Del Giglio | Jan 2008 | A1 |
| 20080046053 | Wagner et al. | Feb 2008 | A1 |
| 20080077201 | Levinson et al. | Mar 2008 | A1 |
| 20080077202 | Levinson | Mar 2008 | A1 |
| 20080077211 | Levinson et al. | Mar 2008 | A1 |
| 20080082094 | McPherson et al. | Apr 2008 | A1 |
| 20080082153 | Gadsby et al. | Apr 2008 | A1 |
| 20080103565 | Altshuler et al. | May 2008 | A1 |
| 20080114199 | Riehl et al. | May 2008 | A1 |
| 20080132971 | Pille et al. | Jun 2008 | A1 |
| 20080161636 | Hurme et al. | Jul 2008 | A1 |
| 20080177128 | Riehl et al. | Jul 2008 | A1 |
| 20080183251 | Azar et al. | Jul 2008 | A1 |
| 20080188915 | Mills et al. | Aug 2008 | A1 |
| 20080195181 | Cole | Aug 2008 | A1 |
| 20080228520 | Day et al. | Sep 2008 | A1 |
| 20080234534 | Mikas et al. | Sep 2008 | A1 |
| 20080249350 | Marchitto et al. | Oct 2008 | A1 |
| 20080255572 | Zeller et al. | Oct 2008 | A1 |
| 20080255637 | Oishi | Oct 2008 | A1 |
| 20080262287 | Dussau | Oct 2008 | A1 |
| 20080262574 | Briefs et al. | Oct 2008 | A1 |
| 20080287839 | Rosen et al. | Nov 2008 | A1 |
| 20080287948 | Newton et al. | Nov 2008 | A1 |
| 20080306325 | Burnett et al. | Dec 2008 | A1 |
| 20080306326 | Epstein | Dec 2008 | A1 |
| 20080312647 | Knopp et al. | Dec 2008 | A1 |
| 20090005631 | Simenhaus et al. | Jan 2009 | A1 |
| 20090018384 | Boyden et al. | Jan 2009 | A1 |
| 20090018623 | Levinson et al. | Jan 2009 | A1 |
| 20090018624 | Levinson et al. | Jan 2009 | A1 |
| 20090018625 | Levinson et al. | Jan 2009 | A1 |
| 20090018626 | Levinson et al. | Jan 2009 | A1 |
| 20090018627 | Levinson et al. | Jan 2009 | A1 |
| 20090018628 | Burns et al. | Jan 2009 | A1 |
| 20090024192 | Mulholland | Jan 2009 | A1 |
| 20090024193 | Altshuler et al. | Jan 2009 | A1 |
| 20090036958 | Mehta | Feb 2009 | A1 |
| 20090043185 | McAdams et al. | Feb 2009 | A1 |
| 20090043293 | Pankratov et al. | Feb 2009 | A1 |
| 20090099405 | Schneider et al. | Apr 2009 | A1 |
| 20090108969 | Sims et al. | Apr 2009 | A1 |
| 20090118722 | Ebbers et al. | May 2009 | A1 |
| 20090118790 | Van Herk | May 2009 | A1 |
| 20090149300 | Chen | Jun 2009 | A1 |
| 20090149929 | Levinson et al. | Jun 2009 | A1 |
| 20090149930 | Schenck | Jun 2009 | A1 |
| 20090156958 | Mehta et al. | Jun 2009 | A1 |
| 20090198144 | Phillips et al. | Aug 2009 | A1 |
| 20090209840 | Axelgaard | Aug 2009 | A1 |
| 20090221938 | Rosenberg et al. | Sep 2009 | A1 |
| 20090227830 | Pillutla et al. | Sep 2009 | A1 |
| 20090227831 | Burnett et al. | Sep 2009 | A1 |
| 20090234423 | Vetanze | Sep 2009 | A1 |
| 20090240096 | Riehl et al. | Sep 2009 | A1 |
| 20090248004 | Altshuler et al. | Oct 2009 | A1 |
| 20090254154 | De Taboada et al. | Oct 2009 | A1 |
| 20090270945 | Markoll et al. | Oct 2009 | A1 |
| 20090284339 | Choi et al. | Nov 2009 | A1 |
| 20090306648 | Podhajsky et al. | Dec 2009 | A1 |
| 20090326571 | Mulholland | Dec 2009 | A1 |
| 20100004536 | Rosenberg | Jan 2010 | A1 |
| 20100004715 | Fahey | Jan 2010 | A1 |
| 20100016761 | Rosenberg | Jan 2010 | A1 |
| 20100016850 | Ron Edoute et al. | Jan 2010 | A1 |
| 20100036191 | Walter et al. | Feb 2010 | A1 |
| 20100036368 | England et al. | Feb 2010 | A1 |
| 20100049188 | Nelson et al. | Feb 2010 | A1 |
| 20100069704 | Peterchev | Mar 2010 | A1 |
| 20100081971 | Allison | Apr 2010 | A1 |
| 20100087699 | Peterchev | Apr 2010 | A1 |
| 20100087816 | Roy | Apr 2010 | A1 |
| 20100121131 | Mathes | May 2010 | A1 |
| 20100130945 | Laniado et al. | May 2010 | A1 |
| 20100145399 | Johari et al. | Jun 2010 | A1 |
| 20100152522 | Roth et al. | Jun 2010 | A1 |
| 20100152824 | Allison | Jun 2010 | A1 |
| 20100160712 | Burnett et al. | Jun 2010 | A1 |
| 20100168501 | Burnett et al. | Jul 2010 | A1 |
| 20100179372 | Glassman | Jul 2010 | A1 |
| 20100185042 | Schneider et al. | Jul 2010 | A1 |
| 20100210894 | Pascual-Leone et al. | Aug 2010 | A1 |
| 20100217253 | Mehta | Aug 2010 | A1 |
| 20100222629 | Burnett et al. | Sep 2010 | A1 |
| 20100228075 | Lu | Sep 2010 | A1 |
| 20100228250 | Brogna | Sep 2010 | A1 |
| 20100256438 | Mishelevich et al. | Oct 2010 | A1 |
| 20100256439 | Schneider et al. | Oct 2010 | A1 |
| 20100261992 | Axelgaard | Oct 2010 | A1 |
| 20100274327 | Carroll et al. | Oct 2010 | A1 |
| 20100274329 | Bradley et al. | Oct 2010 | A1 |
| 20100280582 | Baker et al. | Nov 2010 | A1 |
| 20100286470 | Schneider et al. | Nov 2010 | A1 |
| 20100286691 | Kerr et al. | Nov 2010 | A1 |
| 20100298623 | Mishelevich et al. | Nov 2010 | A1 |
| 20100309689 | Coulson | Dec 2010 | A1 |
| 20100324611 | Deming et al. | Dec 2010 | A1 |
| 20100331602 | Mishelevich et al. | Dec 2010 | A1 |
| 20100331603 | Szecsi | Dec 2010 | A1 |
| 20100331604 | Okamoto et al. | Dec 2010 | A1 |
| 20110004261 | Sham et al. | Jan 2011 | A1 |
| 20110007745 | Schultz et al. | Jan 2011 | A1 |
| 20110009737 | Manstein | Jan 2011 | A1 |
| 20110015464 | Riehl et al. | Jan 2011 | A1 |
| 20110021863 | Burnett et al. | Jan 2011 | A1 |
| 20110046432 | Simon et al. | Feb 2011 | A1 |
| 20110046523 | Altshuler et al. | Feb 2011 | A1 |
| 20110060179 | Aho et al. | Mar 2011 | A1 |
| 20110066216 | Ting et al. | Mar 2011 | A1 |
| 20110077451 | Marchitto et al. | Mar 2011 | A1 |
| 20110082383 | Cory et al. | Apr 2011 | A1 |
| 20110087312 | Shanks et al. | Apr 2011 | A1 |
| 20110105826 | Mishelevich et al. | May 2011 | A1 |
| 20110112520 | Michael | May 2011 | A1 |
| 20110118722 | Lischinsky et al. | May 2011 | A1 |
| 20110125203 | Simon et al. | May 2011 | A1 |
| 20110130618 | Ron et al. | Jun 2011 | A1 |
| 20110130713 | Dufay | Jun 2011 | A1 |
| 20110130796 | Louise | Jun 2011 | A1 |
| 20110152967 | Simon et al. | Jun 2011 | A1 |
| 20110172735 | Johari | Jul 2011 | A1 |
| 20110172752 | Bingham et al. | Jul 2011 | A1 |
| 20110190569 | Simon et al. | Aug 2011 | A1 |
| 20110196438 | Mnozil et al. | Aug 2011 | A1 |
| 20110202058 | Eder et al. | Aug 2011 | A1 |
| 20110218464 | Iger | Sep 2011 | A1 |
| 20110224761 | Manstein | Sep 2011 | A1 |
| 20110237921 | Askin, III et al. | Sep 2011 | A1 |
| 20110238050 | Allison et al. | Sep 2011 | A1 |
| 20110238051 | Levinson et al. | Sep 2011 | A1 |
| 20110245900 | Turner et al. | Oct 2011 | A1 |
| 20110263925 | Bratton | Oct 2011 | A1 |
| 20110273251 | Mishelevich et al. | Nov 2011 | A1 |
| 20110275881 | Aho | Nov 2011 | A1 |
| 20110275927 | Wagner et al. | Nov 2011 | A1 |
| 20110276108 | Crowe et al. | Nov 2011 | A1 |
| 20110300079 | Martens et al. | Dec 2011 | A1 |
| 20110306943 | Dunbar et al. | Dec 2011 | A1 |
| 20110319700 | Schneider | Dec 2011 | A1 |
| 20120016177 | Mishelevich et al. | Jan 2012 | A1 |
| 20120016359 | Podhajsky | Jan 2012 | A1 |
| 20120022518 | Levinson | Jan 2012 | A1 |
| 20120029264 | Roth et al. | Feb 2012 | A1 |
| 20120029394 | Babaev | Feb 2012 | A1 |
| 20120035608 | Marchitto et al. | Feb 2012 | A1 |
| 20120046598 | Kardos et al. | Feb 2012 | A1 |
| 20120046653 | Welches et al. | Feb 2012 | A1 |
| 20120053449 | Moses et al. | Mar 2012 | A1 |
| 20120101326 | Simon et al. | Apr 2012 | A1 |
| 20120101366 | Ruohonen et al. | Apr 2012 | A1 |
| 20120108883 | Peterchev | May 2012 | A1 |
| 20120108884 | Bechler et al. | May 2012 | A1 |
| 20120109241 | Rauscher | May 2012 | A1 |
| 20120116271 | Caruso et al. | May 2012 | A1 |
| 20120150079 | Rosenberg | Jun 2012 | A1 |
| 20120157747 | Rybski et al. | Jun 2012 | A1 |
| 20120158100 | Schomacker | Jun 2012 | A1 |
| 20120172653 | Chornenky et al. | Jul 2012 | A1 |
| 20120195100 | Saitoh et al. | Aug 2012 | A1 |
| 20120197361 | Gonzales et al. | Aug 2012 | A1 |
| 20120203054 | Riehl et al. | Aug 2012 | A1 |
| 20120215210 | Brown et al. | Aug 2012 | A1 |
| 20120226272 | Chernov et al. | Sep 2012 | A1 |
| 20120226330 | Kolen et al. | Sep 2012 | A1 |
| 20120239123 | Weber et al. | Sep 2012 | A1 |
| 20120240940 | Paraschac et al. | Sep 2012 | A1 |
| 20120245483 | Lundqvist | Sep 2012 | A1 |
| 20120253098 | George et al. | Oct 2012 | A1 |
| 20120259382 | Trier et al. | Oct 2012 | A1 |
| 20120271206 | Shalev et al. | Oct 2012 | A1 |
| 20120271294 | Barthe et al. | Oct 2012 | A1 |
| 20120277587 | Adanny et al. | Nov 2012 | A1 |
| 20120302821 | Burnett | Nov 2012 | A1 |
| 20120303076 | Fahey | Nov 2012 | A1 |
| 20120310033 | Muntermann | Dec 2012 | A1 |
| 20120310035 | Schneider et al. | Dec 2012 | A1 |
| 20120310311 | Elkah | Dec 2012 | A1 |
| 20120323232 | Wolf et al. | Dec 2012 | A1 |
| 20120330090 | Sham et al. | Dec 2012 | A1 |
| 20130006039 | Sadler | Jan 2013 | A1 |
| 20130012755 | Slayton | Jan 2013 | A1 |
| 20130030239 | Weyh et al. | Jan 2013 | A1 |
| 20130035745 | Ahmed et al. | Feb 2013 | A1 |
| 20130053620 | Susedik et al. | Feb 2013 | A1 |
| 20130066309 | Levinson | Mar 2013 | A1 |
| 20130079684 | Rosen et al. | Mar 2013 | A1 |
| 20130085317 | Feinstein | Apr 2013 | A1 |
| 20130096363 | Schneider et al. | Apr 2013 | A1 |
| 20130103127 | Muller et al. | Apr 2013 | A1 |
| 20130116758 | Levinson et al. | May 2013 | A1 |
| 20130116759 | Levinson et al. | May 2013 | A1 |
| 20130123568 | Hamilton et al. | May 2013 | A1 |
| 20130123629 | Rosenberg et al. | May 2013 | A1 |
| 20130123764 | Zarsky et al. | May 2013 | A1 |
| 20130123765 | Zarsky et al. | May 2013 | A1 |
| 20130131764 | Grove | May 2013 | A1 |
| 20130137918 | Phillips et al. | May 2013 | A1 |
| 20130144106 | Phillips et al. | Jun 2013 | A1 |
| 20130144280 | Eckhouse et al. | Jun 2013 | A1 |
| 20130150651 | Phillips et al. | Jun 2013 | A1 |
| 20130150653 | Borsody | Jun 2013 | A1 |
| 20130158440 | Allison | Jun 2013 | A1 |
| 20130158634 | Ron et al. | Jun 2013 | A1 |
| 20130158636 | Ting et al. | Jun 2013 | A1 |
| 20130178693 | Neuvonen et al. | Jul 2013 | A1 |
| 20130178764 | Eckhouse et al. | Jul 2013 | A1 |
| 20130184693 | Neev | Jul 2013 | A1 |
| 20130190744 | Avram et al. | Jul 2013 | A1 |
| 20130238043 | Beardall et al. | Sep 2013 | A1 |
| 20130238061 | Ron et al. | Sep 2013 | A1 |
| 20130238062 | Ron Edoute et al. | Sep 2013 | A1 |
| 20130245731 | Allison | Sep 2013 | A1 |
| 20130253384 | Anderson et al. | Sep 2013 | A1 |
| 20130253493 | Anderson et al. | Sep 2013 | A1 |
| 20130253494 | Anderson et al. | Sep 2013 | A1 |
| 20130253495 | Anderson et al. | Sep 2013 | A1 |
| 20130253496 | Anderson et al. | Sep 2013 | A1 |
| 20130261374 | Elder | Oct 2013 | A1 |
| 20130261683 | Soikum et al. | Oct 2013 | A1 |
| 20130267759 | Jin | Oct 2013 | A1 |
| 20130267760 | Jin | Oct 2013 | A1 |
| 20130267943 | Hancock | Oct 2013 | A1 |
| 20130289433 | Jin et al. | Oct 2013 | A1 |
| 20130303904 | Barthe et al. | Nov 2013 | A1 |
| 20130304159 | Simon et al. | Nov 2013 | A1 |
| 20130317281 | Schneider et al. | Nov 2013 | A1 |
| 20130317282 | Ron Edoute et al. | Nov 2013 | A1 |
| 20130331637 | Greff | Dec 2013 | A1 |
| 20130338424 | Pascual-Leone et al. | Dec 2013 | A1 |
| 20130338483 | Neuvonen et al. | Dec 2013 | A1 |
| 20140005758 | Ben-Yehuda et al. | Jan 2014 | A1 |
| 20140005759 | Fahey et al. | Jan 2014 | A1 |
| 20140005760 | Levinson et al. | Jan 2014 | A1 |
| 20140012064 | Riehl et al. | Jan 2014 | A1 |
| 20140018767 | Harris et al. | Jan 2014 | A1 |
| 20140025033 | Mirkov et al. | Jan 2014 | A1 |
| 20140025142 | Zarksy et al. | Jan 2014 | A1 |
| 20140046114 | Nishikawa et al. | Feb 2014 | A1 |
| 20140046232 | Sham et al. | Feb 2014 | A1 |
| 20140046423 | Rajguru et al. | Feb 2014 | A1 |
| 20140066786 | Naghavi et al. | Mar 2014 | A1 |
| 20140067025 | Levinson et al. | Mar 2014 | A1 |
| 20140081359 | Sand | Mar 2014 | A1 |
| 20140121446 | Phillips et al. | May 2014 | A1 |
| 20140135565 | Schneider | May 2014 | A9 |
| 20140148870 | Burnett | May 2014 | A1 |
| 20140179980 | Phillips et al. | Jun 2014 | A1 |
| 20140194958 | Chabal et al. | Jul 2014 | A1 |
| 20140200388 | Schneider et al. | Jul 2014 | A1 |
| 20140221725 | Mishelevich et al. | Aug 2014 | A1 |
| 20140221990 | Kreindel | Aug 2014 | A1 |
| 20140235926 | Zangen et al. | Aug 2014 | A1 |
| 20140235927 | Zangen et al. | Aug 2014 | A1 |
| 20140235928 | Zangen et al. | Aug 2014 | A1 |
| 20140235929 | Rohan | Aug 2014 | A1 |
| 20140243933 | Ginggen | Aug 2014 | A1 |
| 20140249352 | Zangen et al. | Sep 2014 | A1 |
| 20140249353 | Pesola et al. | Sep 2014 | A1 |
| 20140249355 | Martinez | Sep 2014 | A1 |
| 20140249601 | Bachinski et al. | Sep 2014 | A1 |
| 20140249609 | Zarsky et al. | Sep 2014 | A1 |
| 20140257071 | Curran et al. | Sep 2014 | A1 |
| 20140257443 | Baker et al. | Sep 2014 | A1 |
| 20140276248 | Hall et al. | Sep 2014 | A1 |
| 20140276693 | Altshuler et al. | Sep 2014 | A1 |
| 20140277219 | Nanda | Sep 2014 | A1 |
| 20140277302 | Weber et al. | Sep 2014 | A1 |
| 20140303425 | Pilla et al. | Oct 2014 | A1 |
| 20140303525 | Sitharaman | Oct 2014 | A1 |
| 20140303696 | Anderson et al. | Oct 2014 | A1 |
| 20140303697 | Anderson et al. | Oct 2014 | A1 |
| 20140316188 | Peterchev et al. | Oct 2014 | A1 |
| 20140316393 | Levinson | Oct 2014 | A1 |
| 20140324120 | Bogie et al. | Oct 2014 | A1 |
| 20140330067 | Jordan | Nov 2014 | A1 |
| 20140343351 | Tojo et al. | Nov 2014 | A1 |
| 20140350438 | Papirov et al. | Nov 2014 | A1 |
| 20140357935 | Ilmoniemi et al. | Dec 2014 | A1 |
| 20140364841 | Kornstein | Dec 2014 | A1 |
| 20140371515 | John | Dec 2014 | A1 |
| 20140378875 | Ron Edoute et al. | Dec 2014 | A1 |
| 20150005569 | Missoli | Jan 2015 | A1 |
| 20150005759 | Welches et al. | Jan 2015 | A1 |
| 20150018667 | Radman et al. | Jan 2015 | A1 |
| 20150018692 | Neuvonen et al. | Jan 2015 | A1 |
| 20150025299 | Ron et al. | Jan 2015 | A1 |
| 20150038768 | Saitoh et al. | Feb 2015 | A1 |
| 20150080769 | Lotsch | Mar 2015 | A1 |
| 20150087888 | Hurme et al. | Mar 2015 | A1 |
| 20150088105 | Fatemi | Mar 2015 | A1 |
| 20150094788 | Pierenkemper | Apr 2015 | A1 |
| 20150112118 | Mishelevich et al. | Apr 2015 | A1 |
| 20150112412 | Anderson et al. | Apr 2015 | A1 |
| 20150119849 | Aronhalt et al. | Apr 2015 | A1 |
| 20150123661 | Yui et al. | May 2015 | A1 |
| 20150127075 | Ward et al. | May 2015 | A1 |
| 20150133717 | Ghiron et al. | May 2015 | A1 |
| 20150133718 | Schneider et al. | May 2015 | A1 |
| 20150141877 | Feldman | May 2015 | A1 |
| 20150148858 | Kaib | May 2015 | A1 |
| 20150151137 | Hynninen et al. | Jun 2015 | A1 |
| 20150157873 | Sokolowski | Jun 2015 | A1 |
| 20150157874 | Aho et al. | Jun 2015 | A1 |
| 20150165226 | Simon et al. | Jun 2015 | A1 |
| 20150165232 | Altshuler et al. | Jun 2015 | A1 |
| 20150165238 | Slayton et al. | Jun 2015 | A1 |
| 20150174002 | Burbank et al. | Jun 2015 | A1 |
| 20150190648 | Fischell et al. | Jul 2015 | A1 |
| 20150196772 | Ghiron et al. | Jul 2015 | A1 |
| 20150202454 | Burnett | Jul 2015 | A1 |
| 20150216719 | Debenedictis et al. | Aug 2015 | A1 |
| 20150216720 | Debenedictis et al. | Aug 2015 | A1 |
| 20150216816 | O'Neil et al. | Aug 2015 | A1 |
| 20150217127 | Fischell et al. | Aug 2015 | A1 |
| 20150223975 | Anderson et al. | Aug 2015 | A1 |
| 20150227680 | Mainkar et al. | Aug 2015 | A1 |
| 20150238248 | Thompson et al. | Aug 2015 | A1 |
| 20150238771 | Zarsk et al. | Aug 2015 | A1 |
| 20150246238 | Moses et al. | Sep 2015 | A1 |
| 20150272776 | Gonzales et al. | Oct 2015 | A1 |
| 20150283022 | Lee et al. | Oct 2015 | A1 |
| 20150283025 | Ledany | Oct 2015 | A1 |
| 20150297909 | Peashock | Oct 2015 | A1 |
| 20150314133 | Yamashiro | Nov 2015 | A1 |
| 20150328077 | Levinson | Nov 2015 | A1 |
| 20150328475 | Kim et al. | Nov 2015 | A1 |
| 20150342661 | Ron Edoute | Dec 2015 | A1 |
| 20150342780 | Levinson et al. | Dec 2015 | A1 |
| 20150360045 | Fischell et al. | Dec 2015 | A1 |
| 20150367141 | Goetz et al. | Dec 2015 | A1 |
| 20150375005 | Segal | Dec 2015 | A1 |
| 20160001092 | Solehmainen | Jan 2016 | A1 |
| 20160008619 | Pell et al. | Jan 2016 | A1 |
| 20160015588 | Tamiya et al. | Jan 2016 | A1 |
| 20160015995 | Leung et al. | Jan 2016 | A1 |
| 20160016013 | Capelli et al. | Jan 2016 | A1 |
| 20160020070 | Kim et al. | Jan 2016 | A1 |
| 20160022349 | Woloszko et al. | Jan 2016 | A1 |
| 20160030763 | Midorikawa et al. | Feb 2016 | A1 |
| 20160045755 | Chun et al. | Feb 2016 | A1 |
| 20160051401 | Yee et al. | Feb 2016 | A1 |
| 20160051827 | Ron et al. | Feb 2016 | A1 |
| 20160059027 | Zangen et al. | Mar 2016 | A1 |
| 20160066977 | Neal, II et al. | Mar 2016 | A1 |
| 20160066994 | Shanks | Mar 2016 | A1 |
| 20160067516 | Schneider et al. | Mar 2016 | A1 |
| 20160067517 | Burnett | Mar 2016 | A1 |
| 20160067518 | Mishelevich et al. | Mar 2016 | A1 |
| 20160089550 | Debenedictis et al. | Mar 2016 | A1 |
| 20160096032 | Schneider | Apr 2016 | A9 |
| 20160106982 | Cakmak et al. | Apr 2016 | A1 |
| 20160106995 | Järnefelt et al. | Apr 2016 | A1 |
| 20160121112 | Azar | May 2016 | A1 |
| 20160129273 | Park | May 2016 | A1 |
| 20160129274 | Park | May 2016 | A1 |
| 20160136462 | Lewis, Jr. et al. | May 2016 | A1 |
| 20160150494 | Tabet et al. | May 2016 | A1 |
| 20160151637 | Abe et al. | Jun 2016 | A1 |
| 20160158574 | Eckhouse et al. | Jun 2016 | A1 |
| 20160175193 | Jung | Jun 2016 | A1 |
| 20160175605 | Borsody | Jun 2016 | A1 |
| 20160184601 | Gleich et al. | Jun 2016 | A1 |
| 20160193466 | Burnett | Jul 2016 | A1 |
| 20160206895 | Zangen et al. | Jul 2016 | A1 |
| 20160206896 | Zangen et al. | Jul 2016 | A1 |
| 20160213924 | Coleman et al. | Jul 2016 | A1 |
| 20160220834 | Schwarz | Aug 2016 | A1 |
| 20160220837 | Jin | Aug 2016 | A1 |
| 20160228698 | Horton et al. | Aug 2016 | A1 |
| 20160236004 | Fischell et al. | Aug 2016 | A1 |
| 20160250494 | Sakaki et al. | Sep 2016 | A1 |
| 20160256702 | Schwarz et al. | Sep 2016 | A1 |
| 20160256703 | Schwarz et al. | Sep 2016 | A1 |
| 20160270951 | Martins et al. | Sep 2016 | A1 |
| 20160303393 | Riehl et al. | Oct 2016 | A1 |
| 20160317346 | Kovach | Nov 2016 | A1 |
| 20160317827 | Schwarz et al. | Nov 2016 | A1 |
| 20160324684 | Levinson et al. | Nov 2016 | A1 |
| 20160346561 | Ron Edoute et al. | Dec 2016 | A1 |
| 20160354035 | Reihl et al. | Dec 2016 | A1 |
| 20160354237 | Gonzales et al. | Dec 2016 | A1 |
| 20170001024 | Prouza | Jan 2017 | A1 |
| 20170001025 | Schwarz et al. | Jan 2017 | A1 |
| 20170001026 | Schwarz et al. | Jan 2017 | A1 |
| 20170001027 | Ladman et al. | Jan 2017 | A1 |
| 20170001028 | Ladman et al. | Jan 2017 | A1 |
| 20170001029 | Pribula et al. | Jan 2017 | A1 |
| 20170001030 | Pribula et al. | Jan 2017 | A1 |
| 20170007309 | Debenedictis et al. | Jan 2017 | A1 |
| 20170021188 | Lu | Jan 2017 | A1 |
| 20170028212 | Roth et al. | Feb 2017 | A1 |
| 20170036019 | Matsushita | Feb 2017 | A1 |
| 20170043177 | Ron Edoute et al. | Feb 2017 | A1 |
| 20170050019 | Ron Edoute et al. | Feb 2017 | A1 |
| 20170072212 | Ladman et al. | Mar 2017 | A1 |
| 20170087373 | Schwarz | Mar 2017 | A1 |
| 20170100585 | Hall et al. | Apr 2017 | A1 |
| 20170105869 | Frangineas, Jr. | Apr 2017 | A1 |
| 20170106201 | Schwarz et al. | Apr 2017 | A1 |
| 20170106203 | Schneider et al. | Apr 2017 | A1 |
| 20170113058 | Schneider | Apr 2017 | A1 |
| 20170120066 | Phillips et al. | May 2017 | A1 |
| 20170120067 | Prouza | May 2017 | A1 |
| 20170143958 | Shalev et al. | May 2017 | A1 |
| 20170151436 | Flaherty et al. | Jun 2017 | A1 |
| 20170151443 | Mishelevich et al. | Jun 2017 | A1 |
| 20170156907 | Harris et al. | Jun 2017 | A1 |
| 20170173347 | Schwarz et al. | Jun 2017 | A1 |
| 20170182334 | Altshuler et al. | Jun 2017 | A1 |
| 20170182335 | Altshuler et al. | Jun 2017 | A1 |
| 20170189707 | Zabara | Jul 2017 | A1 |
| 20170196731 | Debenedictis et al. | Jul 2017 | A1 |
| 20170203117 | Biginton et al. | Jul 2017 | A1 |
| 20170209708 | Schwarz | Jul 2017 | A1 |
| 20170232267 | Riehl et al. | Aug 2017 | A1 |
| 20170239079 | Root et al. | Aug 2017 | A1 |
| 20170239467 | Shalev et al. | Aug 2017 | A1 |
| 20170259077 | Jin | Sep 2017 | A1 |
| 20170266460 | Upton et al. | Sep 2017 | A1 |
| 20170280889 | Koch | Oct 2017 | A1 |
| 20170291036 | Pell et al. | Oct 2017 | A1 |
| 20170296838 | Asahina et al. | Oct 2017 | A1 |
| 20170304642 | Ron Edoute et al. | Oct 2017 | A1 |
| 20170312536 | Phillips et al. | Nov 2017 | A1 |
| 20170319378 | Anderson et al. | Nov 2017 | A1 |
| 20170325992 | Debenedictis et al. | Nov 2017 | A1 |
| 20170325993 | Jimenez et al. | Nov 2017 | A1 |
| 20170326042 | Zeng et al. | Nov 2017 | A1 |
| 20170326346 | Jimenez et al. | Nov 2017 | A1 |
| 20170326357 | Sacristan et al. | Nov 2017 | A1 |
| 20170326377 | Neuvonen et al. | Nov 2017 | A1 |
| 20170333705 | Schwarz | Nov 2017 | A1 |
| 20170340894 | Rohan | Nov 2017 | A1 |
| 20170348143 | Rosen et al. | Dec 2017 | A1 |
| 20170348539 | Schwarz et al. | Dec 2017 | A1 |
| 20170354530 | Shagdar et al. | Dec 2017 | A1 |
| 20170361095 | Mueller et al. | Dec 2017 | A1 |
| 20170372006 | Mainkar et al. | Dec 2017 | A1 |
| 20180000347 | Perez et al. | Jan 2018 | A1 |
| 20180001106 | Schwarz | Jan 2018 | A1 |
| 20180001107 | Schwarz et al. | Jan 2018 | A1 |
| 20180021565 | Dar et al. | Jan 2018 | A1 |
| 20180028831 | Ron Edoute et al. | Feb 2018 | A1 |
| 20180036548 | Nusse | Feb 2018 | A1 |
| 20180043151 | Ejiri et al. | Feb 2018 | A1 |
| 20180056083 | Jin | Mar 2018 | A1 |
| 20180064952 | Zangen et al. | Mar 2018 | A1 |
| 20180071544 | Ghiron et al. | Mar 2018 | A1 |
| 20180071545 | Saitoh et al. | Mar 2018 | A1 |
| 20180103991 | Linhart et al. | Apr 2018 | A1 |
| 20180125416 | Schwarz et al. | May 2018 | A1 |
| 20180126184 | Phillips et al. | May 2018 | A1 |
| 20180133498 | Chornenky et al. | May 2018 | A1 |
| 20180140860 | Ledany | May 2018 | A1 |
| 20180153736 | Mills et al. | Jun 2018 | A1 |
| 20180153760 | Rosen et al. | Jun 2018 | A1 |
| 20180154165 | Schneider | Jun 2018 | A1 |
| 20180161197 | Baker et al. | Jun 2018 | A1 |
| 20180177996 | Gozani et al. | Jun 2018 | A1 |
| 20180178026 | Riehl et al. | Jun 2018 | A1 |
| 20180185081 | O'Neil et al. | Jul 2018 | A1 |
| 20180185189 | Weber et al. | Jul 2018 | A1 |
| 20180214300 | Anderson et al. | Aug 2018 | A1 |
| 20180228646 | Gonzales et al. | Aug 2018 | A1 |
| 20180229048 | Sikora et al. | Aug 2018 | A1 |
| 20180229049 | Phillips et al. | Aug 2018 | A1 |
| 20180236254 | Schwarz et al. | Aug 2018 | A1 |
| 20180250056 | Avram et al. | Sep 2018 | A1 |
| 20180250521 | Wölfel et al. | Sep 2018 | A1 |
| 20180263677 | Hilton et al. | Sep 2018 | A1 |
| 20180264245 | Edwards et al. | Sep 2018 | A1 |
| 20180271767 | Jimenez et al. | Sep 2018 | A1 |
| 20180280711 | Sekino et al. | Oct 2018 | A1 |
| 20180296831 | Matsushita | Oct 2018 | A1 |
| 20180310950 | Yee et al. | Nov 2018 | A1 |
| 20180345012 | Schwarz et al. | Dec 2018 | A1 |
| 20180345032 | Lu | Dec 2018 | A1 |
| 20180353767 | Biginton | Dec 2018 | A1 |
| 20180369601 | Saitoh et al. | Dec 2018 | A1 |
| 20190000524 | Rosen et al. | Jan 2019 | A1 |
| 20190000529 | Kothare et al. | Jan 2019 | A1 |
| 20190000663 | Anderson et al. | Jan 2019 | A1 |
| 20190029876 | Anderson et al. | Jan 2019 | A1 |
| 20190030356 | Schwarz | Jan 2019 | A1 |
| 20190053871 | Moosmann et al. | Feb 2019 | A1 |
| 20190053941 | Samson | Feb 2019 | A1 |
| 20190053967 | Moosmann et al. | Feb 2019 | A1 |
| 20190060659 | Ginhoux et al. | Feb 2019 | A1 |
| 20190070428 | Phillips et al. | Mar 2019 | A1 |
| 20190111255 | Errico et al. | Apr 2019 | A1 |
| 20190111273 | Ghiron et al. | Apr 2019 | A1 |
| 20190117965 | Iger et al. | Apr 2019 | A1 |
| 20190134414 | Schwarz | May 2019 | A1 |
| 20190151655 | Hall et al. | May 2019 | A1 |
| 20190160286 | Yang et al. | May 2019 | A1 |
| 20190168012 | Biginton | Jun 2019 | A1 |
| 20190183562 | Widgerow | Jun 2019 | A1 |
| 20190192219 | Kreindel | Jun 2019 | A1 |
| 20190192853 | Kim et al. | Jun 2019 | A1 |
| 20190192872 | Schwarz et al. | Jun 2019 | A1 |
| 20190192873 | Schwarz et al. | Jun 2019 | A1 |
| 20190192875 | Schwarz et al. | Jun 2019 | A1 |
| 20190201280 | Bak et al. | Jul 2019 | A1 |
| 20190201705 | Schwarz et al. | Jul 2019 | A1 |
| 20190201706 | Schwarz et al. | Jul 2019 | A1 |
| 20190206545 | Mainkar et al. | Jul 2019 | A1 |
| 20190209836 | Yakoub et al. | Jul 2019 | A1 |
| 20190224490 | Goadsby et al. | Jul 2019 | A1 |
| 20190247654 | Alyagon et al. | Aug 2019 | A1 |
| 20190255346 | Ghiron | Aug 2019 | A1 |
| 20190269909 | Gozani et al. | Sep 2019 | A1 |
| 20190269931 | Riehl et al. | Sep 2019 | A1 |
| 20190275320 | Kim et al. | Sep 2019 | A1 |
| 20190290928 | Biginton | Sep 2019 | A1 |
| 20190299018 | Chornenky et al. | Oct 2019 | A1 |
| 20190314629 | Kreindel | Oct 2019 | A1 |
| 20190314638 | Kreindel | Oct 2019 | A1 |
| 20190328478 | Schuele | Oct 2019 | A1 |
| 20190329065 | Gandel | Oct 2019 | A1 |
| 20190336783 | Sokolowski | Nov 2019 | A1 |
| 20190344091 | Fischer | Nov 2019 | A1 |
| 20190350646 | Kreindel | Nov 2019 | A1 |
| 20190365462 | Casalino | Dec 2019 | A1 |
| 20190388697 | Pell et al. | Dec 2019 | A1 |
| 20190388698 | Schwarz et al. | Dec 2019 | A1 |
| 20200001103 | Schwarz et al. | Jan 2020 | A1 |
| 20200016422 | Ron Edoute et al. | Jan 2020 | A1 |
| 20200016423 | Ron Edoute et al. | Jan 2020 | A1 |
| 20200030622 | Weyh et al. | Jan 2020 | A1 |
| 20200038674 | John | Feb 2020 | A1 |
| 20200038675 | Neuvonen et al. | Feb 2020 | A1 |
| 20200054395 | Marchitto et al. | Feb 2020 | A1 |
| 20200054890 | Schwarz et al. | Feb 2020 | A1 |
| 20200061385 | Schwarz et al. | Feb 2020 | A1 |
| 20200061386 | Schwarz et al. | Feb 2020 | A1 |
| 20200078599 | Chen et al. | Mar 2020 | A1 |
| 20200086134 | Johnson et al. | Mar 2020 | A1 |
| 20200093297 | Dennewald | Mar 2020 | A1 |
| 20200094066 | Heath | Mar 2020 | A1 |
| 20200100932 | Hermanson et al. | Apr 2020 | A1 |
| 20200101308 | Ilmoniemi et al. | Apr 2020 | A1 |
| 20200114160 | Blendermann | Apr 2020 | A1 |
| 20200121984 | Sama | Apr 2020 | A1 |
| 20200129759 | Schwarz | Apr 2020 | A1 |
| 20200139148 | Schwarz et al. | May 2020 | A1 |
| 20200155221 | Marchitto et al. | May 2020 | A1 |
| 20200155866 | Lu | May 2020 | A1 |
| 20200171297 | Kirson et al. | Jun 2020 | A1 |
| 20200197696 | Nagel et al. | Jun 2020 | A1 |
| 20200206522 | Riehl et al. | Jul 2020 | A1 |
| 20200206524 | Katznelson et al. | Jul 2020 | A1 |
| 20200230431 | Saitoh et al. | Jul 2020 | A1 |
| 20200237424 | Hunziker et al. | Jul 2020 | A1 |
| 20200246617 | Errico et al. | Aug 2020 | A1 |
| 20200251203 | Mainkar et al. | Aug 2020 | A1 |
| 20200281642 | Kreindel | Sep 2020 | A1 |
| 20200289837 | Lowin et al. | Sep 2020 | A1 |
| 20200289838 | Schwarz et al. | Sep 2020 | A1 |
| 20200306554 | Ron Edoute et al. | Oct 2020 | A1 |
| 20200324133 | Schwarz et al. | Oct 2020 | A1 |
| 20200330782 | Zabara | Oct 2020 | A1 |
| 20200352633 | Treen et al. | Nov 2020 | A1 |
| 20200353244 | Yamazaki | Nov 2020 | A1 |
| 20200353273 | Zucco | Nov 2020 | A1 |
| 20200360681 | Lay | Nov 2020 | A1 |
| 20200398055 | Flaherty et al. | Dec 2020 | A1 |
| 20200398070 | Phillips et al. | Dec 2020 | A1 |
| 20200406050 | Casanova et al. | Dec 2020 | A1 |
| 20210008369 | Crosson | Jan 2021 | A1 |
| 20210008382 | Vaidya | Jan 2021 | A1 |
| 20210023364 | Shalev et al. | Jan 2021 | A1 |
| 20210038891 | Goldfarb | Feb 2021 | A1 |
| 20210038894 | Mowery et al. | Feb 2021 | A1 |
| 20210052893 | Suri et al. | Feb 2021 | A1 |
| 20210093858 | Thakkar et al. | Apr 2021 | A1 |
| 20210106842 | Zangen et al. | Apr 2021 | A1 |
| 20210146119 | Prouza et al. | May 2021 | A1 |
| 20210146150 | Frangineas, Jr. et al. | May 2021 | A1 |
| 20210146151 | Phillips et al. | May 2021 | A1 |
| 20210162211 | Chase et al. | Jun 2021 | A1 |
| 20210178174 | Lowin et al. | Jun 2021 | A1 |
| 20210205631 | Ghiron et al. | Jul 2021 | A1 |
| 20210228898 | Ghiron | Jul 2021 | A1 |
| 20210235901 | Dennewald | Aug 2021 | A1 |
| 20210260369 | Steier | Aug 2021 | A1 |
| 20210260398 | Bilston et al. | Aug 2021 | A1 |
| 20210268299 | Casalino et al. | Sep 2021 | A1 |
| 20210275747 | Sobel et al. | Sep 2021 | A1 |
| 20210275825 | Kreindel | Sep 2021 | A1 |
| 20210283395 | Kreindel | Sep 2021 | A1 |
| 20210283412 | Neuvonen et al. | Sep 2021 | A1 |
| 20210299420 | Sobel et al. | Sep 2021 | A1 |
| 20210330102 | Monico | Oct 2021 | A1 |
| 20210330987 | Sun et al. | Oct 2021 | A1 |
| 20210361938 | Gershonowitz | Nov 2021 | A1 |
| 20210361967 | Cohen et al. | Nov 2021 | A1 |
| 20220003112 | Leach et al. | Jan 2022 | A1 |
| 20220016413 | John et al. | Jan 2022 | A1 |
| 20220031408 | Cai et al. | Feb 2022 | A1 |
| 20220032052 | Kent | Feb 2022 | A1 |
| 20220032079 | Riehl et al. | Feb 2022 | A1 |
| 20220036584 | Sun et al. | Feb 2022 | A1 |
| 20220080217 | Peterchev et al. | Mar 2022 | A1 |
| 20220161043 | Phillips et al. | May 2022 | A1 |
| 20220161044 | Phillips et al. | May 2022 | A1 |
| 20220168584 | Schwarz et al. | Jun 2022 | A1 |
| 20220176142 | Ghiron et al. | Jun 2022 | A1 |
| 20220184379 | Lindenthaler et al. | Jun 2022 | A1 |
| 20220184409 | Schwarz et al. | Jun 2022 | A1 |
| 20220192580 | Toth et al. | Jun 2022 | A1 |
| 20220212006 | Rondoni et al. | Jul 2022 | A1 |
| 20220241604 | Lee | Aug 2022 | A1 |
| 20220249836 | Schwarz et al. | Aug 2022 | A1 |
| 20220288409 | Järnefelt | Sep 2022 | A1 |
| 20220370006 | Zieger | Nov 2022 | A1 |
| 20220370814 | Epshtein et al. | Nov 2022 | A1 |
| 20220379114 | Kent | Dec 2022 | A1 |
| 20220395681 | Martinot | Dec 2022 | A1 |
| 20220401256 | Durand | Dec 2022 | A1 |
| 20230125236 | Sandell et al. | Apr 2023 | A1 |
| 20230128482 | Gayes et al. | Apr 2023 | A1 |
| 20230130856 | Sandell et al. | Apr 2023 | A1 |
| Number | Date | Country |
|---|---|---|
| 747678 | May 2002 | AU |
| 2011265424 | Jul 2014 | AU |
| 2012200610 | Jul 2014 | AU |
| 2012244313 | Nov 2014 | AU |
| 2014203094 | Jul 2015 | AU |
| 2013207657 | Nov 2015 | AU |
| PI0701434 | Nov 2008 | BR |
| PI0812502 | Jun 2015 | BR |
| 2484880 | Apr 2006 | CA |
| 2845438 | May 2014 | CA |
| 2604112 | Jul 2016 | CA |
| 3019140 | Oct 2017 | CA |
| 3019410 | Oct 2017 | CA |
| 3023821 | Nov 2017 | CA |
| 714113 | Mar 2019 | CH |
| 86204070 | Sep 1987 | CN |
| 87203746 | Dec 1987 | CN |
| 87215926 | Jul 1988 | CN |
| 1026953 | Dec 1994 | CN |
| 1027958 | Mar 1995 | CN |
| 2192348 | Mar 1995 | CN |
| 1206975 | Jun 2005 | CN |
| 101234231 | Aug 2008 | CN |
| 101327358 | Dec 2008 | CN |
| 201906360 | Jul 2011 | CN |
| 102319141 | Jan 2012 | CN |
| 102711706 | Oct 2012 | CN |
| 102847231 | Jan 2013 | CN |
| 202637725 | Jan 2013 | CN |
| 203169831 | Sep 2013 | CN |
| 102319141 | Aug 2014 | CN |
| 106540375 | Mar 2017 | CN |
| 107613914 | Jan 2018 | CN |
| 108882992 | Nov 2018 | CN |
| 109310516 | Feb 2019 | CN |
| 208511024 | Feb 2019 | CN |
| 110180083 | Aug 2019 | CN |
| 209221337 | Aug 2019 | CN |
| 209221338 | Aug 2019 | CN |
| 110339480 | Oct 2019 | CN |
| 210770219 | Jun 2020 | CN |
| 211357457 | Aug 2020 | CN |
| 111728712 | Oct 2020 | CN |
| 111840804 | Oct 2020 | CN |
| 112023270 | Dec 2020 | CN |
| 112221015 | Jan 2021 | CN |
| 212416683 | Jan 2021 | CN |
| 112472506 | Mar 2021 | CN |
| 112582159 | Mar 2021 | CN |
| 212700107 | Mar 2021 | CN |
| 113041500 | Jun 2021 | CN |
| 213432603 | Jun 2021 | CN |
| 214099374 | Aug 2021 | CN |
| 113499542 | Oct 2021 | CN |
| 113647936 | Nov 2021 | CN |
| 215081635 | Dec 2021 | CN |
| 215084285 | Dec 2021 | CN |
| 215309722 | Dec 2021 | CN |
| 216091887 | Mar 2022 | CN |
| 216169399 | Apr 2022 | CN |
| 216986082 | Jul 2022 | CN |
| 217526108 | Oct 2022 | CN |
| 115364376 | Nov 2022 | CN |
| 217908621 | Nov 2022 | CN |
| 115454185 | Dec 2022 | CN |
| 217960287 | Dec 2022 | CN |
| 218129587 | Dec 2022 | CN |
| 115591124 | Jan 2023 | CN |
| 115639868 | Jan 2023 | CN |
| 115645737 | Jan 2023 | CN |
| 115645748 | Jan 2023 | CN |
| 718637 | Mar 1942 | DE |
| 1118902 | Dec 1961 | DE |
| 2748780 | May 1978 | DE |
| 3205048 | Aug 1983 | DE |
| 3340974 | May 1985 | DE |
| 3610474 | Oct 1986 | DE |
| 3825165 | Jan 1990 | DE |
| 3340974 | Jul 1994 | DE |
| 69318706 | Jan 1999 | DE |
| 10062050 | Apr 2002 | DE |
| 102004006192 | Sep 2005 | DE |
| 60033756 | Jun 2007 | DE |
| 102009023855 | Dec 2010 | DE |
| 102009050010 | May 2011 | DE |
| 102010004307 | Jul 2011 | DE |
| 102006024467 | Apr 2012 | DE |
| 102011014291 | Sep 2012 | DE |
| 102013211859 | Jul 2015 | DE |
| 102016116399 | Mar 2018 | DE |
| 202019100373 | Mar 2019 | DE |
| 202016008884 | Jul 2020 | DE |
| 102010014157 | Feb 2021 | DE |
| 0633008 | Mar 1999 | DK |
| 000494 | Aug 1999 | EA |
| 002087 | Dec 2001 | EA |
| 002179 | Feb 2002 | EA |
| 003851 | Oct 2003 | EA |
| 007347 | Aug 2006 | EA |
| 007975 | Feb 2007 | EA |
| 0048451 | Mar 1982 | EP |
| 0039206 | Oct 1984 | EP |
| 0209246 | Jan 1987 | EP |
| 0459101 | Dec 1991 | EP |
| 0459401 | Dec 1991 | EP |
| 0633008 | Jan 1995 | EP |
| 0788813 | Aug 1997 | EP |
| 0633008 | May 1998 | EP |
| 0692993 | Sep 1999 | EP |
| 1022034 | Jul 2000 | EP |
| 1916013 | Apr 2008 | EP |
| 2069014 | Jun 2009 | EP |
| 1883447 | Sep 2009 | EP |
| 2139560 | Jan 2010 | EP |
| 2124800 | Nov 2010 | EP |
| 1917935 | Jan 2011 | EP |
| 2308559 | Apr 2011 | EP |
| 2139560 | May 2012 | EP |
| 2461765 | Jun 2012 | EP |
| 1863569 | May 2013 | EP |
| 2069014 | Jun 2013 | EP |
| 1850781 | Jul 2013 | EP |
| 2614807 | Jul 2013 | EP |
| 2676700 | Dec 2013 | EP |
| 2694159 | Feb 2014 | EP |
| 2749259 | Jul 2014 | EP |
| 2814445 | Dec 2014 | EP |
| 2856986 | Apr 2015 | EP |
| 2878336 | Jun 2015 | EP |
| 2564894 | Nov 2015 | EP |
| 3009167 | Apr 2016 | EP |
| 2501352 | Jul 2016 | EP |
| 3209246 | Aug 2017 | EP |
| 3342379 | Jul 2018 | EP |
| 3389532 | Oct 2018 | EP |
| 3434323 | Jan 2019 | EP |
| 3721939 | Oct 2020 | EP |
| 2118925 | Oct 1998 | ES |
| 2300569 | Jun 2008 | ES |
| 2305698 | Nov 2008 | ES |
| 2359581 | May 2011 | ES |
| 2533145 | Apr 2015 | ES |
| 2533145 | Jul 2016 | ES |
| 2533145 | Oct 2018 | ES |
| 2970656 | Jun 2014 | FR |
| 3041881 | Apr 2017 | FR |
| 3061012 | Jun 2018 | FR |
| 260116 | Oct 1926 | GB |
| 304587 | Mar 1930 | GB |
| 390500 | Apr 1933 | GB |
| 871672 | Jun 1961 | GB |
| 2176009 | Dec 1986 | GB |
| 2188238 | Sep 1987 | GB |
| 2176009 | Dec 1989 | GB |
| 2261820 | Jun 1993 | GB |
| 2286660 | Aug 1995 | GB |
| 2395907 | Dec 2004 | GB |
| 2504984 | Feb 2014 | GB |
| 2521240 | Jun 2015 | GB |
| 2521609 | Jul 2015 | GB |
| 2552004 | Jan 2018 | GB |
| 2552810 | Feb 2018 | GB |
| 2554043 | Mar 2018 | GB |
| 2555809 | May 2018 | GB |
| 2567872 | May 2019 | GB |
| 2568051 | May 2019 | GB |
| 2591692 | Aug 2021 | GB |
| 2602603 | Jul 2022 | GB |
| 3027678 | Nov 1998 | GR |
| 1217550 | Mar 1990 | IT |
| RE20120010 | Aug 2013 | IT |
| UB20159823 | Jul 2017 | IT |
| H09276418 | Oct 1997 | JP |
| 2003085523 | Mar 2003 | JP |
| 2003305131 | Oct 2003 | JP |
| 2005245585 | Sep 2005 | JP |
| 2006130055 | May 2006 | JP |
| 4178762 | Nov 2008 | JP |
| 4324673 | Sep 2009 | JP |
| 2010063007 | Mar 2010 | JP |
| 2010207268 | Sep 2010 | JP |
| 2010533054 | Oct 2010 | JP |
| 2011194176 | Oct 2011 | JP |
| 4837723 | Dec 2011 | JP |
| 2013012285 | Jan 2013 | JP |
| 2013063285 | Apr 2013 | JP |
| 2013066597 | Apr 2013 | JP |
| 2013116271 | Jun 2013 | JP |
| 3192971 | Sep 2014 | JP |
| 2017518857 | Jul 2017 | JP |
| 2018501927 | Jan 2018 | JP |
| 2018018650 | Feb 2018 | JP |
| 2018187510 | Nov 2018 | JP |
| 200261417 | Mar 2002 | KR |
| 20030065126 | Aug 2003 | KR |
| 100484618 | Apr 2005 | KR |
| 100491988 | May 2005 | KR |
| 200407524 | Jan 2006 | KR |
| 100556230 | Mar 2006 | KR |
| 200410065 | Mar 2006 | KR |
| 100841596 | Jun 2008 | KR |
| 20090063618 | Jun 2009 | KR |
| 20090095143 | Sep 2009 | KR |
| 100936914 | Jan 2010 | KR |
| 20100026107 | Mar 2010 | KR |
| 101022244 | Mar 2011 | KR |
| 20110123831 | Nov 2011 | KR |
| 20120037011 | Apr 2012 | KR |
| 101233286 | Feb 2013 | KR |
| 101233287 | Feb 2013 | KR |
| 20130072244 | Jul 2013 | KR |
| 101292289 | Aug 2013 | KR |
| 20130128391 | Nov 2013 | KR |
| 101413022 | Jul 2014 | KR |
| 101415141 | Jul 2014 | KR |
| 101447532 | Oct 2014 | KR |
| 101511444 | Apr 2015 | KR |
| 20150049386 | May 2015 | KR |
| 20150058102 | May 2015 | KR |
| 101539633 | Jul 2015 | KR |
| 20150079619 | Jul 2015 | KR |
| 20150106379 | Sep 2015 | KR |
| 101650155 | Aug 2016 | KR |
| 101673182 | Nov 2016 | KR |
| 20170090654 | Aug 2017 | KR |
| 20170107603 | Sep 2017 | KR |
| 101794269 | Nov 2017 | KR |
| 20180059114 | Jun 2018 | KR |
| 20180059114 | Jun 2018 | KR |
| 20180092020 | Aug 2018 | KR |
| 101941863 | Jan 2019 | KR |
| 20190005981 | Jan 2019 | KR |
| 101955542 | May 2019 | KR |
| 102000971 | Jul 2019 | KR |
| 20190001779 | Jul 2019 | KR |
| 200491572 | May 2020 | KR |
| 20200000889 | May 2020 | KR |
| 20200052602 | May 2020 | KR |
| 20200056692 | May 2020 | KR |
| 20200056693 | May 2020 | KR |
| 20200056801 | May 2020 | KR |
| 20200056802 | May 2020 | KR |
| 20200057154 | May 2020 | KR |
| 20210002973 | Jan 2021 | KR |
| 20210002974 | Jan 2021 | KR |
| 2012012158 | Apr 2014 | MX |
| 7510644 | Mar 1977 | NL |
| 1037451 | May 2011 | NL |
| 2212909 | Sep 2003 | RU |
| 2226115 | Mar 2004 | RU |
| 2281128 | Aug 2006 | RU |
| 2373971 | Nov 2009 | RU |
| 2392979 | Jun 2010 | RU |
| 2395267 | Jul 2010 | RU |
| 2496532 | Oct 2013 | RU |
| 2529471 | Sep 2014 | RU |
| 2596053 | Aug 2016 | RU |
| 2637104 | Nov 2017 | RU |
| 2645923 | Feb 2018 | RU |
| 24921 | Aug 2016 | SI |
| 510797 | Nov 2002 | TW |
| 200423986 | Nov 2004 | TW |
| 201825045 | Jul 2018 | TW |
| WO-9312835 | Jul 1993 | WO |
| WO-9521655 | Aug 1995 | WO |
| WO-9527533 | Oct 1995 | WO |
| WO-9932191 | Jul 1999 | WO |
| WO-0013749 | Mar 2000 | WO |
| WO-0044346 | Aug 2000 | WO |
| WO-0107111 | Feb 2001 | WO |
| WO-0112089 | Feb 2001 | WO |
| WO-0193797 | Dec 2001 | WO |
| WO-0225675 | Mar 2002 | WO |
| WO 02096514 | Dec 2002 | WO |
| WO-03078596 | Sep 2003 | WO |
| WO-03079916 | Oct 2003 | WO |
| WO-03090863 | Nov 2003 | WO |
| WO-03103769 | Dec 2003 | WO |
| WO-2004078255 | Sep 2004 | WO |
| WO 2004080526 | Sep 2004 | WO |
| WO 2004080527 | Sep 2004 | WO |
| WO-2004087255 | Oct 2004 | WO |
| WO-2004095385 | Nov 2004 | WO |
| WO-2004095835 | Nov 2004 | WO |
| WO-2004096343 | Nov 2004 | WO |
| WO-2004108211 | Dec 2004 | WO |
| WO-2005032660 | Apr 2005 | WO |
| WO-2005107866 | Nov 2005 | WO |
| WO-2006115120 | Nov 2006 | WO |
| WO 2006116728 | Nov 2006 | WO |
| WO-2007096206 | Aug 2007 | WO |
| WO-2007140584 | Dec 2007 | WO |
| WO-2008012827 | Jan 2008 | WO |
| WO-2008049775 | May 2008 | WO |
| WO-2008060494 | May 2008 | WO |
| WO-2008109058 | Sep 2008 | WO |
| WO-2008127011 | Oct 2008 | WO |
| WO-2008145260 | Dec 2008 | WO |
| WO-2009011708 | Jan 2009 | WO |
| WO-2009013729 | Jan 2009 | WO |
| WO-2009036040 | Mar 2009 | WO |
| WO-2009042863 | Apr 2009 | WO |
| WO-2009044400 | Apr 2009 | WO |
| WO-2009047628 | Apr 2009 | WO |
| WO-2009083915 | Jul 2009 | WO |
| WO 2009127840 | Oct 2009 | WO |
| WO-2010007614 | Jan 2010 | WO |
| WO-2010022278 | Feb 2010 | WO |
| WO-2010007614 | May 2010 | WO |
| WO-2010135425 | Nov 2010 | WO |
| WO 2010151619 | Dec 2010 | WO |
| WO-2010139376 | Dec 2010 | WO |
| WO 2010151619 | Dec 2010 | WO |
| WO-2011011749 | Jan 2011 | WO |
| WO-2011016019 | Feb 2011 | WO |
| WO-2011021184 | Feb 2011 | WO |
| WO-2011045002 | Apr 2011 | WO |
| WO-2011053607 | May 2011 | WO |
| WO-2011058556 | May 2011 | WO |
| WO-2011058565 | May 2011 | WO |
| WO 2011085020 | Jul 2011 | WO |
| WO-2011156495 | Dec 2011 | WO |
| WO-2012005766 | Jan 2012 | WO |
| WO-2012029065 | Mar 2012 | WO |
| WO-2012040243 | Mar 2012 | WO |
| WO-2012073232 | Jun 2012 | WO |
| WO-2012103632 | Aug 2012 | WO |
| WO-2012119293 | Sep 2012 | WO |
| WO-2012138169 | Oct 2012 | WO |
| WO-2013021380 | Feb 2013 | WO |
| WO-2013026393 | Feb 2013 | WO |
| WO-2013035088 | Mar 2013 | WO |
| WO-2013074576 | May 2013 | WO |
| WO-2013098815 | Jul 2013 | WO |
| WO 2013131639 | Sep 2013 | WO |
| WO-2013191699 | Dec 2013 | WO |
| WO-2014009875 | Jan 2014 | WO |
| WO-2014016820 | Jan 2014 | WO |
| WO-2014109653 | Jul 2014 | WO |
| WO-2014137344 | Sep 2014 | WO |
| WO-2014141229 | Sep 2014 | WO |
| WO-2014149021 | Sep 2014 | WO |
| WO-2014151431 | Sep 2014 | WO |
| WO-2014163020 | Oct 2014 | WO |
| WO-2014164926 | Oct 2014 | WO |
| WO-2015004540 | Jan 2015 | WO |
| WO-2015012639 | Jan 2015 | WO |
| WO-2015012672 | Jan 2015 | WO |
| WO-2015052705 | Apr 2015 | WO |
| WO-2015083305 | Jun 2015 | WO |
| WO-2015137733 | Sep 2015 | WO |
| WO-2015157725 | Oct 2015 | WO |
| WO-2015179571 | Nov 2015 | WO |
| WO 2016005719 | Jan 2016 | WO |
| WO-2016116747 | Jul 2016 | WO |
| WO-2016140871 | Sep 2016 | WO |
| WO-2017002065 | Jan 2017 | WO |
| WO-2017103923 | Jun 2017 | WO |
| WO-2017106878 | Jun 2017 | WO |
| WO-2017159959 | Sep 2017 | WO |
| WO-2017160097 | Sep 2017 | WO |
| WO-2017176621 | Oct 2017 | WO |
| WO 2017191624 | Nov 2017 | WO |
| WO-2017196548 | Nov 2017 | WO |
| WO-2017212253 | Dec 2017 | WO |
| WO 2017212258 | Dec 2017 | WO |
| WO-2018006086 | Jan 2018 | WO |
| WO-2018008023 | Jan 2018 | WO |
| WO-2018044825 | Mar 2018 | WO |
| WO 2018098417 | May 2018 | WO |
| WO-2018121998 | Jul 2018 | WO |
| WO-2018122535 | Jul 2018 | WO |
| WO-2017160097 | Sep 2018 | WO |
| WO-2018208992 | Nov 2018 | WO |
| WO-2019120420 | Jun 2019 | WO |
| WO 2019145762 | Aug 2019 | WO |
| WO-2019150378 | Aug 2019 | WO |
| WO 2019164471 | Aug 2019 | WO |
| WO-2019166965 | Sep 2019 | WO |
| WO-2019173866 | Sep 2019 | WO |
| WO-2019183622 | Sep 2019 | WO |
| WO-2020002801 | Jan 2020 | WO |
| WO-2020035852 | Feb 2020 | WO |
| WO-2020041502 | Feb 2020 | WO |
| WO-2020142470 | Jul 2020 | WO |
| WO-2020144486 | Jul 2020 | WO |
| WO-2020174444 | Sep 2020 | WO |
| WO-2020183508 | Sep 2020 | WO |
| WO-2020190514 | Sep 2020 | WO |
| WO-2020208590 | Oct 2020 | WO |
| WO-2020264263 | Dec 2020 | WO |
| WO-2021013654 | Jan 2021 | WO |
| WO 2012052986 | Apr 2021 | WO |
| WO-2021102365 | May 2021 | WO |
| WO 2022041657 | Mar 2022 | WO |
| WO 2022118028 | Jun 2022 | WO |
| WO 2022122923 | Jun 2022 | WO |
| WO 2022128991 | Jun 2022 | WO |
| WO 2022171218 | Aug 2022 | WO |
| WO 2022182756 | Sep 2022 | WO |
| WO 2022197674 | Sep 2022 | WO |
| WO 2022246320 | Nov 2022 | WO |
| WO 2022256388 | Dec 2022 | WO |
| WO 2023003501 | Jan 2023 | WO |
| WO 2023281448 | Jan 2023 | WO |
| WO 2023010656 | Feb 2023 | WO |
| WO 2023011503 | Feb 2023 | WO |
| WO 2023066020 | Apr 2023 | WO |
| Entry |
|---|
| US 10,398,895 B2, 09/2019, Tomá (withdrawn) |
| 2018 Cutera University, Clinical Forum, Cutera 20, 26 pages. |
| 501(k) K030708 Slendertone Flex Letter from Department of Health and Humane Serivces, Public Health Service, Jun. 25, 2003, 6 pages. |
| 501(k) K163165 AM-100 Letter from Department of Health and Human Services, Public Health Service, Feb. 16, 2017, 9 pages. |
| Abulhasan, J.F., et al., “Peripheral Electrical and Magnetic Stimulation to Augment Resistance Training,” Journal of Functional Morphology and Kinesiology, 1(3):328-342, (Sep. 2016). |
| Accent Radiofrequency System, Operator's Manual, Alma Lasers, Wellbeing Through Technology, 2008, 82 Pages. |
| Agilent Technologies, Inc., “Agilent 33500 Series 30 MHz Function / Arbitrary Waveform Generator User's Guide,” Publication No. 33520-90001 (Dec. 2010), 278 pages. |
| Agilent Technologies, Inc., “Agilent Announces 30 MHz Function/Arbitrary Waveform Generators,” Microwave J., URL: (Aug. 3, 2010), 8 pages. |
| Allergan, Inc. et al v. BTL Healthcare Technologies A.S., PTAB-PGR2021-00015, Paper 16 (Decision Denying Institution of Post-Grant Review), Jun. 17, 2021, 20 pages. |
| Allergan, Inc. et al v. BTL Healthcare Technologies A.S., PTAB-PGR2021-00016, Paper 16 (Decision Denying Institution of Post-Grant Review), Jun. 17, 2021, 20 pages. |
| Allergan, Inc. et al v. BTL Healthcare Technologies A.S., PTAB-PGR2021-00017, Paper 16 (Decision Denying Institution of Post-Grant Review), Jun. 16, 2021, 33 pages. |
| Allergan, Inc. et al v. BTL Healthcare Technologies A.S., PTAB-PGR2021-00018, Paper 16 (Decision Denying Institution of Post-Grant Review), Jun. 16, 2021, 42 pages. |
| Allergan, Inc. et al v. BTL Healthcare Technologies A.S., PTAB-PGR2021-00020, Paper 16 (Decision Denying Institution of Post-Grant Review), Jun. 16, 2021, 35 pages. |
| Allergan, Inc. et al v. BTL Healthcare Technologies A.S., PTAB-PGR2021-00021, Paper 17 (Decision Denying Institution of Post-Grant Review), Jun. 16, 2021, 33 pages. |
| Allergan, Inc. et al v. BTL Healthcare Technologies A.S., PTAB-PGR2021-00022; PTAB-PGR2021-00023; PTAB-PGR2021-00024; PTAB-PGR2021-00025; PTAB-IPR2021-00296; PTab-IPR2021-00312, Paper 11 (Decision Settlement Prior to Institution of Trial), Jul. 6, 2021, 4 pages. |
| Alma Lasers., “Accent Radiofrequency System, Operator's Manual,” Wellbeing Through Technology, 2008, Chapters 1-8, Appendix A. |
| Arjunan, P.A., et al., “Computation and Evaluation of Features of Surface Electromyogram to Identify the Force of Muscle Contraction and Muscle Fatigue,” BioMed research international 2014:197960, Hindawi Pub. Co, United States (2014). |
| Avram, M.M and Harry, R.S.,“Cryolipolysis for Subcutaneous Fat Layer Reduction,” Lasers in Surgery and Medicine, 41(10):703-708, Wiley-Liss, United States (Dec. 2009). |
| Bachasson, D., et al., “Quadriceps Function Assessment Using an Incremental Test and Magnetic Neurostimulation: a Reliability Study,” Journal of Electromyography and Kinesiology, 23(3):649-658, Elsevier, England, (Jun. 2013). |
| Barker, A.T, “An Introduction to the Basic Principles of Magnetic Nerve Stimulation,” Journal of Clinical Neurophysiology, 8(1):26-37, Lippincott Williams & Wilkins, United States, (Jan. 1991). |
| Barker, A.T., et al., “Non-Invasive Magnetic Stimulation of Human Motor Cortex,” Lancet 1(8437):1106-1107, Elsevier, England (May 1985). |
| Barker, A.T., “The History and Basic Principles of Magnetic Nerve Stimulation,” Electroencephalography and Clinical Neurophysiology 51:3-21, Elsevier, Netherlands (1999). |
| Barrett, J., et al., “Mechanisms of Action Underlying the Effect of Repetitive Transcranial Magnetic Stimulation on Mood: Behavioral and Brain Imaging Studies,” Neuropsychopharmacology 29(6):1172-1189, Nature Publishing Group, England (Jan. 14, 2004). |
| Behrens, M., et al., “Repetitive Peripheral Magnetic Stimulation (15 Hz RPMS) of the Human Soleus Muscle did not Affect Spinal Excitability,” Journal of Sports Science and Medicine, 10(1):39-44, Dept. of Sports Medicine, Medical Faculty of Uludag University, Turkey (Mar. 2011). |
| Beilin, G., et al., “Electromagnetic Fields Applied to the Reduction of Abdominal Obesity,” Journal of Cosmetic & Laser Therapy, 14(1):24-42, Informa Healthcare, England, (Feb. 2012). |
| Belanger, A-Y., “Chapter 13: Neuromuscular Electrical Stimulation,” in Therapeutic Electrophysical Agents: Evidence Behind Practice, 3rd Edition, Lupash, E., ed., pp. 220-255, Lippincott Williams & Wilkins, United States (2015). |
| Benton, et al., “Functional Electrical Stimulation—A Practical Clinical Guide,” Second Edition, The Professional Staff Association of the Rancho Los Amigos Hospital, Inc., 42 pages (1981). |
| Benton, L.A., et al., “Chapter 2: Physiological Basis of Nerve and Muscle Excitation” and “Chapter 4: General Uses of Electrical Stimulation,” in Functional Electrical Stimulation: A Practical Guide, 2nd Edition, pp. 11-30 and 53-71, Rancho Los Amigos Rehabilitation Engineering Center, Downey, CA (1981), 42 pages. |
| Bergh, U., and Ekblom, B., “Influence of Muscle Temperature on Maximal Muscle Strength and Power Output in Human Skeletal Muscles,” Acta Physiologica Scandinavica 107(1):33-37, Blackwell Scientific Publications, England (Aug. 1979). |
| Binder-Macleod, S.A., et al., “Force Output of Cat Motor Units Stimulated with Trains of Linearly Varying Frequency,” Journal of Neurophysiology 61(1):208-217, American Physiological Society, United States (Jan. 1989). |
| Binder-Macleod, S.A., et al., “Use of a Catchlike Property of Human Skeletal Muscle to Reduce Fatigue,” Muscle & Nerve 14(9):850-857, John Wiley & Sons, United States (Sep. 1991). |
| Bio Medical Research Limited., “Slendertone Flex Abdominal Training System, Instructions for Use,” All pages (Aug. 2006). |
| Bio Medical Research Limited., “Slendertone Flex Max Instruction Manual,” All pages (Apr. 2006). |
| Bio-Medical Research Ltd., K010335, 510(k) Summary, Slendertone Flex, All pages (Sep. 2001). |
| Bio-Medical Research Ltd., K022855 510(k) Summary, Slendertone, 1-6 (Mar. 2003). |
| Bischoff, C., et al., “Repetitive Magnetic Nerve Stimulation: Technical Considerations and Clinical Use in the Assessment of Neuromuscular Transmission,” Electroencephalography and Clinical Neurophysiology 93(1):15-20, Elsevier, Ireland (Feb. 1994). |
| Bourland, J.D., et al., “Transchest Magnetic (Eddy-Current) Stimulation of the Dog Heart,” Medical & Biological Engineering & Computing 28(2):196-198, Springer, United States (Mar. 1990). |
| BTL Industries, Inc., K163165 510(k) Summary, AM-100, All pages (Feb. 2017). |
| BTL Industries, Inc., K180813 510(k) Summary, Emsculpt, All pages (Mar. 2018). |
| BTL Industries, Inc. v. Allergan Ltd. et al DDE-1-20-cv-01046, Complaint for Patent Infringement and Exhibits 1-38, 821 pages (Aug. 2020). |
| BTL Industries, Inc. v. Allergan Ltd. et al., DDE-1-20-cv-01046, Order Administratively Closing Case, Jul. 26, 2021, 1 page. |
| BTL Industries, Inc. v. Allergan Ltd. et al DDE-1-20-cv-01046, Order Granting Motion to Stay Pending Resolution of Proceedings at the International Trade Commission (Unopposed), 2 pages (Oct. 2020). |
| BTL Industries, Inc. v. Allergan PLC et al DDE-1-19-cv-02356, Complaint for Patent Infringement and Exhibits 1-34, 375 pages. (Dec. 2019). |
| BTL Industries, Inc. v. Allergan PLC et al DDE-1-19-cv-02356, Order Granting Stipulation to Stay, Oct. 1, 2020, 1 page. |
| BTL Industries, Inc. v. Allergan USA, Inc. et al., DDE-1-19-cv-02356, Order Administratively Closing Case, Jul. 26, 2021, 1 page. |
| Buenos Aires, Oct. 14, 2014, Venus Concept, Provision No. 7246, 56 pages (With Machine Translation). |
| Burge, S.M and Dawber, R.P.,“Hair Follicle Destruction and Regeneration in Guinea Pig Skin After Cutaneous Freeze Injury,” Cryobiology, 27(2):153-163, Elsevier, Netherlands (Apr. 1990). |
| Busso, M. and Denkova, R., “Efficacy of High Intensity Focused Electro-Magnetic (HIFEM) Field Therapy When Used for Non-Invasive Buttocks Augmentation and Lifting: A Clinical Study” American Society for Laser Medicine and Surgery Abstracts, 382 (2018). |
| Bustamante, V., et al., “Muscle Training With Repetitive Magnetic Stimulation of the Quadriceps in Severe COPD Patients,” Respiratory Medicine, 104(2):237-245, Elsevier, England, (Feb. 2010). |
| Bustamante, V., et al., “Redox Balance Following Magnetic Stimulation Training in the Quadriceps of Patients With Severe Copd,” Free Radical Research, 42(11-12):939-948, Informa Healthcare, England, (Nov. 2008). |
| Callaghan, M.J., et al., “Electric Muscle Stimulation of the Quadriceps in the Treatment of Patellofemoral Pain,” Archives of Physical Medicine and Rehabilitation 85(6):956-962, W.B. Saunders, United Staes (Jun. 2004). |
| Carbonaro, M., et al., “Architectural Changes in Superficial and Deep Compartments of the Tibialis Anterior during Electrical Stimulation over Different Sites,” IEEE transactions on Neural Systems and Rehabilitation Engineering 28(11):2557-2565, IEEE, United States (Nov. 2020). |
| Caress, J.B., et al., “A Novel Method of Inducing Muscle Cramps Using Repetitive Magnetic Stimulation,” Muscle Nerve, 23(1):126-128, John Wiley & Sons, United States, (Jan. 2000). |
| Certain Non-Invasive Aesthetic Body Contouring Devices, Components Thereof, and Methods of Using the Same, Inv. No. 337-TA-1219, BTL's Statement of Suggested Claim Terms to Be Construed Pursuant to Ground Rule 6b, Nov. 4, 2020, 2 pages. |
| Certain Non-Invasive Aesthetic Body Contouring Devices, Components Thereof, and Methods of Using the Same, Inv. No. 337-TA-1219, Complainant BTL's Proposed Construction of Disputed Claim Terms, Dec. 8, 2020, 19 pages. |
| Certain Non-Invasive Aesthetic Body Contouring Devices, Components Thereof, and Methods of Using the Same, Inv. No. 337-TA-1219, Complaint, Aug. 5, 2020, 93 pages. |
| Certain Non-Invasive Aesthetic Body Contouring Devices, Components Thereof, and Methods of Using the Same, Inv. No. 337-TA-1219, Joint Claim Construction Chart, Dec. 14, 2020, 15 pages. |
| Certain Non-Invasive Aesthetic Body Contouring Devices, Components Thereof, and Methods of Using the Same; Inv. No. 337-TA-1219, Joint Claim Construction Chart, Dec. 18, 2020, 15 pages. |
| Certain Non-Invasive Aesthetic Body Contouring Devices, Components Thereof, and Methods of Using the Same, Inv. No. 337-TA-1219, Respondents' Allergan Limited, Allergan USA, Inc., Allergan, Inc., Zeltiq Aesthetics, Inc., Zeltiq Ireland Unlimited Company, and Zimmer MedizinSysteme GmbH's Notice of Prior Art, Nov. 20, 2020, 5 pages. |
| Certain Non-Invasive Aesthetic Body Contouring Devices, Components Thereof, and Methods of Using the Same, Inv. No. 337-TA-1219, Respondents' List of Claim Terms for Construction, Nov. 4, 2020, 8 pages. |
| Certain Non-Invasive Aesthetic Body Contouring Devices, Components Thereof, and Methods of Using the Same; Inv. No. 337-TA-1219, Respondents' List of Proposed Claim Constructions and Their Intrinsic and Extrinsic Support, filed Dec. 15, 2020, 23 pages. |
| Certain Non-Invasive Aesthetic Body Contouring Devices, Components Thereof, and Methods of Using the Same, Inv. No. 337-TA-1219, Response of Respondent Zimmer MedizinSysteme GmbH to the Complaint and Notice of Investigation, Oct. 22, 2020, 68 pages. |
| Certain Non-Invasive Aesthetic Body Contouring Devices, Components Thereof, and Methods of Using the Same, Inv. No. 337-TA-1219, Response of Respondents Allergan Limited, Allergan USA, Inc., Allergan, Inc., Zeltiq Aesthetics, Inc., and Zeltiq IrelandUnlimited Company to the Complaint and Notice of Investigation, Oct. 22, 2020, 69 pages. |
| Certain Non-Invasive Aesthetic Body-Contouring Devices, Components Thereof, and Methods of Using Same, Notice of Institution of Investigation, Inv. No. 337-TA-1219, Notice of Institution of Investigation, Sep. 2, 2020, 21 pages. |
| Certain Non-Invasive Aesthetic Body-Contouring Devices, Components Thereof, and Methods of Using the Same, Inv. No. 337-TA-1219, Order No. 17: Amending Procedural Schedule, Apr. 9, 2021, 4 pages. |
| Certain Non-Invasive Aesthetic Body-Contouring Devices, Components Thereof, and Methods of Using the Same, Inv. No. 337-TA-1219, Order No. 21 (Initial Determination), Apr. 28, 2021, 5 pages. |
| Certain Non-Invasive Aesthetic Body-Contouring Devices, Components Thereof, and Methods of Using the Same, Inv. No. 337-TA-1219, Order No. 30 (Order Concerning the Procedural Schedule), Aug. 4, 2021, 3 pages. |
| Certified English Translation of Belyaev, A.G., “Effect of Magnetic Stimulation on the Strength Capacity of Skeletal Muscles,” Ph.D. Thesis Abstract, Smolensk State Academy of Physical Culture, Sport, and Tourism, Dec. 11, 2020, 23 pages. |
| Certified English Translation of Belyaev, A.G., “Effect of Magnetic Stimulation on the Strength Capacity of Skeletal Muscles,” Ph.D. Thesis, Smolensk State Academy of Physical Culture, Sport, and Tourism, Dec. 11, 2020, 117 pages. |
| Chattanooga Group of Encore Medical, L.P., “Intelect SWD 100 User Manual, Operation & Installation Instructions for Intelect SWD 00—Model 1600,” All pages (2009). |
| Chesterton, L.S., et al.,“Skin Temperature Response to Cryotherapy,” Archives of Physical Medicine and Rehabilitation, 83(4):543-549, W.B. Saunders, United States (Apr. 2002). |
| Collins, D.F., et al., “Large Involuntary Forces Consistent With Plateau-Like Behavior of Human Motoneurons,” Journal of Neuroscience 21(11):4059-4065, Society for Neuroscience, United States (Jun. 2001). |
| Colson, S., et al., “Re-Examination of Training Effects by Electrostimulation in the Human Elbow Musculoskeletal System,” International Journal of Sports Medicine 21(4):281-288, Stuttgart, Thieme (May 2000). |
| Course in Physical Therapy, Presentation, Jan. 4, 2013, 156 pages. |
| CR Technologies, “Salus Talent Pop Manual KFDA First Approval Document” (English Translation), Nov. 25, 2011, 47 pages. |
| CR Technologies, “Notification of medical device manufacturing item permission, Salus Talent Pop KFDA Approval Document” (English Translation), 3 pages (Sep. 2011). |
| CR Technology Co, Ltd., “Salus-Talent Double Sales Brochure” 2 pages, (Oct. 2020). |
| CR Technology Co. Ltd., “Medical Laser Irradiator Salus-Talent-Pop User Manual Version 1.00” (Nov. 2020). |
| CR Technology Co. Ltd., Salus Talent Pop User Manual, Ver. 1.00, All pages, Approx. 2012. |
| CR Technology, Salus-Talent, Technical File of Electro-magnetic Stimulator, Document Number: TF-005, 2008, 241 pages. |
| CR Technology, Technology for Health and Business for Human Being, investor relations, 2008, 21 pages. |
| Currier, D. P., “Effects of Electrical and Electromagnetic Stimulation after Anterior Cruciate Ligament Reconstruction,” The Journal of Orthopaedic and Sports Physical Therapy 17(4):177-84, Williams and Wilkins, United States (1993). |
| Cutera, truSculptflex, Brochure, dated 2019, 2 pages. |
| CynoSure, SculpSure TM, The New Shape of Energy-Based bodyContouring, 2015, Cynosure Inc, 2 pages. |
| Cynosure,Smooth Shapes XV, Now with Smoothshape petite, Transforming non-invasive Body Shaping, Retrieved from the Internet: (www.cynosure.com), 2011, Cynosure Inc, 8 pages. |
| Davies, C.T., et al., “Contractile Properties of the Human Triceps Surae With Some Observations on the Effects of Temperature and Exercise,” European Journal of Applied Physiology and Occupational Physiology 49(2):255-269, Springer Verlag, Germany (Aug. 1982). |
| Deng, Z.D., et al., “Electric Field Depth-Focality Tradeoff in Transcranial Magnetic Stimulation: Simulation Comparison of 50 Coil Designs,” Brain stimulation 6(1):1-13, Elsevier, New York (Jan. 2013). |
| Depatment of Health and Human Services, 501(k) Letter and Summary for K092476 Body Control System 4M Powered Muscle Stimulator, dated May 7, 2010, 5 pages. |
| Depatment of Health and Human Services, 501(k) Letter and Summary for K160992 HPM-6000 Powered Muscle Stimulator, dated Oct. 21, 2016, 9 pages. |
| Depatment of Health and Human Services, 501(k) Letter and Summary for K163415 SlimShape System Powered Muscle Stimulator, dated Apr. 20, 2017, 8 pages. |
| Depatment of Health and Human Services, 501(k) Letter and Summary for K182106 BTL 799-2T Powered Muscle Stimulator, dated Oct. 23, 2018, 9 pages. |
| Depatment of Health and Human Services, 501(k) Letter and Summary for K190456 BTL 799-2L Powered Muscle Stimulator, dated Jul. 5, 2019, 9 pages. |
| Depatment of Health and Human Services, 501(k) Letter and Summary for K192224 BTL 899 Powered Muscle Stimulator, dated Dec. 5, 2019, 11 pages. |
| Doucet, B., et al., “Neuromuscular Electrical Stimulation for Skeletal Muscle Function,” Yale Journal of Biology & Medicine 85:201-215, Yale Journal of Biology and Medicine, United States (Jun. 2012). |
| Dudley, G. and Stevenson, S., “Use of Electrical Stimulation in Strength and Power Training,” Special Problems in Strength and Power Training :426-435 (2003). |
| Duncan, D., et al., “Noninvasive Induction of Muscle Fiber Hypertrophy and Hyperplasia: Effects of High-Intensity Focused Electromagnetic Field Evaluated in an In-Vivo Porcine Model: A Pilot Study,” Aesthetic Surgery Journal 40(5):568-574, Oxford University Press, United States (Apr. 2020). |
| DuoMAG Magnetic Stimulator, Alien Technik User Manuel, Jun. 26, 2012,48 pages, Version 2.1. |
| Dybek, T., et al.,“Impact of 10 Sessions of Whole Body Cryostimulation on Aerobic and Anaerobic Capacity and on Selected Blood Count Parameters,” Biology of Sport, 29(1):39-43 (Jan. 2012). |
| Dynatronics., “Better Rehab Solutions for Better Outcomes,” Rehabilitation Products Guide 2.3, 2017, 52 pages. |
| Effective PEMF Magnetic Fat Reduction Slimming Body Beauty Salon Machine (PEMF Star), Wolfbeauty 1980, PEMF Star, China, Retrieved from the Internet: (URL: https://www.ec21.com/product-details/Effective-PEMF-Magnetic-Fat-Reduction--8928746.html), 2019, 5 pages. |
| Elamed, Magnetic Therapeutic Apparatus for Running Pulse Mag-field small-sized ALMAG-01 Manual, allegedly accessed on Nov. 18, 2020, All pages. |
| Eliminate Stubborn Fat without Surgery or Downtime and Feel Great From Every Angle, Fear No Mirror®, Consultation Guide, Coolsculpting, 2014, 20 pages. |
| Energist Ltd—Acquired Chromogenez—Old Account, iLipo—Laser Liposuction (i-Lipo), Video Screenshots, Aug. 10, 2009, 5 pages. |
| Enoka, R.M., “Muscle Strength and Its Development,” Sports Medicine 6:146-168, Springer (Oct. 1988). |
| Epstein, C., et al., “The Oxford Handbook of Transcranial Stimulation,” 773 pages (2008). |
| European Commission, Neuodegenerative Disorders, 10 pages printed Dec. 27, 2016. |
| European Commission, “Neurogenerative Disorders,” 10 pages printed Dec. 27, 2016. |
| European Patent Office, International Search Report and Written Opinion for International Application No. PCT/IB2016/053930, dated Dec. 12, 2016, 19 pages. |
| Exilis, Operator's Manual, BTL, 2012, 44 Pages. |
| Faghri, P.D., et al., “The Effects of Functional Electrical Stimulation on Shoulder Subluxation, Arm Function Recovery, and Shoulder Pain in Hemiplegic Stroke Patients,” Archives of Physical Medicine and Rehabilitation 75(1):73-79, W.B. Saunders, United States (Jan. 1994). |
| FDA letter to Venus Legacy, Dec. 19, 2014, 7 pages. |
| Fischer, J., et al., “Precise Subpixel Position Measurement with Linear Interpolation of Cmos Sensor Image Data,” The 6th IEEE International Conference on Intelligent Data Acquisition and Advanced Computing Systems, 500-504 (Sep. 2011). |
| Fisher, R., et al., “ILAE Official Report: a Practical Clinical Definition of Epilepsy,” Epilepsia, 55(4):475-482, Blackwell Science, United States (Apr. 2014). |
| Fujimura, K., et al., “Effects of Repetitive Peripheral Magnetic Stimulation on Shoulder Subluxations Caused by Stroke: A Preliminary Study,” Neuromodulation : Journal of the International Neuromodulation Society 23(6):847-851, Wiley-Blackwell, United States (Nov. 2020). |
| Gaines, M., “Slendertone Abdominal Training System, the First FDA-Cleared Abdominal Belt, Introduced in United States by Compex Technologies on Time for Holiday Gift-Giving,” Business Wire 44199 (Oct. 2003). |
| Geddes, L.A., “History of Magnetic Stimulation of the Nervous System,” Journal of Clinical Neurophysiology 8(1):3-9, Lippincott Williams & Wilkins, United States (Jan. 1991). |
| Goetz, S.M., et al., “Coil Design for Neuromuscular Magnetic Stimulation Based on a Detailed 3-D Thigh Model,” IEEE Transactions on Magnetics, 50(6):10, IEEE, (Jun. 2014). |
| Goodman, B.E., “Channels Active in the Excitability of Nerves and Skeletal Muscles Across the Neuromuscular Junction: Basic Function and Pathophysiology,” Advances in Physiology Education 32(2):127-135, American Physiological Society, United States (Jun. 2008). |
| Gorgey, A., et al., “Effects of Electrical Stimulation Parameters on Fatigue in Skeletal Muscle,” The Journal of Orthopaedic and Sports Physical Therapy 39(9):684-692, Williams and Wilkins, United States (Sep. 2009). |
| Gorodnichev, R.M., et al., “The Effect of Electromagnetic Stimulation on the Parameters of Muscular Strength,” Human Physiology 40:65-69 (2014). |
| Gorodnichev, R.M., “Magnetic Stimulation of Muscles as New Method to Enhance Their Strength,” Velikie Luki State Academy of Physical Culture and Sport, Velikie Luki, 2016, 5 pages. |
| Guangzhou HEMS Tech, PEMF Star, May 31, 2019, 5 pages. |
| Halaas, Y. and Bernardy, J., “Biochemical Perspective of Fat Physiology after Application of HIFEM Field Technology: Additional Investigation of Fat Disruption Effects in a Porcine Study,” American Society for Laser Medicine and Surgery Abstracts, S4 (2019). |
| Hamnegard, C.H., et al., “Quadriceps Strength Assessed by Magnetic Stimulation of the Femoral Nerve in Normal Subjects,” Clinical Physiology and Functional Imaging, 24(5):276-280, Blackwell, England, (Sep. 2004). |
| Han, B.H., et al., “Development of four-channel magnetic nerve stimulator,” 2001 Proceedings of the 23rd Annual EMBS International Conference, pp. 1325-1327, Turkey (2001). |
| Han, T.R., et al., “Magnetic Stimulation of the Quadriceps Femoris Muscle: Comparison of Pain With Electrical Stimulation,” American Journal of Physical Medicine & Rehabilitation, 85(7):593-599, Lippincott Williams & Wilkins, United States, (Jul. 2006). |
| Harkey, M.S., “Disinhibitory Interventions and Voluntary Quadriceps Activation: A Systematic Review,” Journal of Athletic Training 49(3):411-421, National Athletic Trainers' Association, United States (2014). |
| Heidland, A., et al., “Neuromuscular Electrostimulation Techniques: Historical Aspects and Current Possibilities in Treatment of Pain and Muscle Waisting,” Clinical Nephrology 79 Suppl 1:S12-S23, Dustri-Verlag Dr. Karl Feistle, Germany (Jan. 2012). |
| Heisel, Jurgen, Physikalische Medizin, Stuttgart: Georg Thieme Verlag KG, 2005. ISBN 3-13-139881-7. p. 159. |
| Hera Estetik Medikal, “Lipostar” dated Jul. 7, 2014, accessed at https://www.youtube.com/watch?v=-R7OnFIK9go, accessed on Dec. 15, 2021. |
| Hera Estetik Medikal, “Lipostar Manyetik Incelme”, accessed at https://www.heraestetik.com/en/urundetay/liposter-manyetik-incelme, accessed on Dec. 15, 2021. |
| Hill, A., “The Influence of Temperature on the Tension Developed in an Isometric Twitch,” Proceeding of the Royal Society B 138:349-354, (Sep. 1951). |
| Hirvonen, H.E., et al.,“Effectiveness of Different Cryotherapies on Pain and Disease Activity in Active Rheumatoid Arthritis. A Randomised Single Blinded Controlled Trial,”Clinical and Experimental Rheumatology, 24(3):295-301, Clinical and Experimental Rheumatology S.A.S, Italy (May-Jun. 2006). |
| Hovey, C. and Jalinous, R., “The Guide to Magnetic Stimulation” Magstim, Pioneers in Nerve Stimulation and Monitoring, pp. 1-44 (2016). |
| Hovey, C., et al., “The Guide to Magnetic Stimulation,” The Magstim Company Limited, 48 pages (Jul. 2006). |
| Huang, Y.Z., et al., “Theta Burst Stimulation of the Human Motor Cortex,” Neuron 45(2):201-206, Cell Press, United States (Jan. 2005). |
| I-Lipo by Chromo genex, i-Lipo Ultra is the Intelligent, Non-Surgical Alternative to Liposuction, 2011, 2 pages. |
| Increasing Physiotherapy Presence in Cosmetology, Spa Inspirations, Jan. 2012, pp. 34-35. |
| Irazoqui P., Post Grant Review of U.S. Pat. No. 10,695,576, PTAB-PGR2021-00024, filed as EX1085, Dec. 14, 2020, 25 pages. |
| Iskra Medical, Magneto System, 2012, 2 pages. |
| Iskra Medical, “TESLA Stym—Functional Magnetic Stimulation FMS,” Nov. 2013, http://ww.iskramedical.eu/magneto-therapy-medical/tesla-stym, 5 pages. |
| Iskra Medical, “TESLA Stym Website,” URL: https://web.archive.org/web/20131106123126/ http:/www.iskramedical.eu:80/magneto-therapy-medical/tesla-stym (Nov. 6, 2013). |
| Izumiya, Y., et al., “Fast/Glycolytic Muscle Fiber Growth Reduces Fat Mass and Improves Metabolic Parameters in Obese Mice”, Cell Metabolism 7(2):159-172, Cell Press, United States (Feb. 2008). |
| Jacob, C., et al., “High Intensity Focused Electro-Magnetic Technology (HIFEM) for Non-Invasive Buttock Lifting and Toning of Gluteal Muscles: A Multi-Center Efficacy and Safety Study,” Journal of Drugs in Dermatology 17(11):1229-1232, Physicians Continuing Education Corporation, United States (Nov. 2018). |
| Jacob, C.I., et al., “Safety and Efficacy of a Novel High-Intensity Focused Electromagnetic Technology Device for Noninvasive Abdominal Body Shaping,” Journal of Cosmetic Dermatology, 17(5):783-787, Blackwell Science, United States (Oct. 2018). |
| Jacobm C., and Paskova, “A Novel Non-Invasive Technology Based on Simultaneous Induction of Changes in Adipose and Muscle Tissues: Safety and Efficacy of a High Intensity Focused Electro-Magnetic (HIFEM) Field Device Used for Abdominal Body Shaping,” American Society for Laser Medicine and Surgery, 2018 Electronic Posters (ePosters) Town Hall and ePosters, 369, p. 1, Wiley Periodicals, Inc. (2018). |
| Jalinous, R., “Technical and Practical Aspects of Magnetic Nerve Stimulation,” Journal of Clinical Neurophysiology 8(1):10-25, Lippincott Williams & Wilkins, United States (Jan. 1991). |
| Johari Digital Healthcare Ltd., 510(k)—K062439 Powertone Letter from Department of Health and Humane Services Summary, Public Health Service, Jan. 8, 2007, 6 pages. |
| Johari Digital Healthcare Ltd., “510(k)—K131291 Torc Body Letter from Department of Health and Humane Services”, Public Health Service, Jun. 14, 2013, 10 pages. |
| Johari Digital Healthcare Ltd., K131291 510(k) Summary, TorcBody, All pages (Jun. 2013). |
| Jutte, L.S., et al.,“The Relationship Between Intramuscular Temperature, Skin Temperature, and Adipose Thickness During Cryotherapy and Rewarming,” Archives of Physical Medicine and Rehabilitation, 82(6):845-850, W.B. Saunders, United States (Jun. 2001). |
| Katuscakova, Z.L., et al., High Induction Magnet Therapy in Rehabilitation, Department of Physiactric Rehabilitation, 2012, 72 pages. |
| Katz, B., et al., “Changes in Subcutaneous Abdominal Fat Thickness Following High-Intensity Focused Electro-Magnetic (HIFEM) Field Treatments: A Multi Center Ultrasound Study,” American Society for Laser Medicine and Surgery Abstracts, 360-361 (2018). |
| Katz, B., et al., “Ultrasound Assessment of Subcutaneous Abdominal Fat Thickness after Treatments with a High-Intensity Focused Electromagnetic Field Device: A Multicenter Study,” Dermatologic Surgery 45(12):1542-1548, Williams & Wilkins, United States (Dec. 2019). |
| Kavanagh, S., et al., “Use of a Neuromuscular Electrical Stimulation Device for Facial Muscle Toning: A Randomized, Controlled Trial,” Journal of Cosmetic Dermatology 11(4):261-266, Blackwell Science, United States (Dec. 2012). |
| Kent, D., and Jacob C., “Computed Tomography (CT) Based Evidence of Simultaneous Changes in Human Adipose and Muscle Tissues Following a High Intensity Focused Electro-Magnetic Field (HIFEM) Application: A New Method for Non-Invasive Body Sculpting,” American Society for Laser Medicine and Surgery Abstracts, p. 370 (2018). |
| Kent, D,E. and Jacob, C.I., Simultaneous Changes in Abdominal Adipose and Muscle Tissues Following Treatments by High-Intensity Focused Electromagnetic HIFEM Technology-Based Device: Computed Tomography Evaluation, Journal of Drugs in Dermatology 18(11):1098-1102, Physicians Continuing Education Corporation, United States (Nov. 2019). |
| Kim, Y.H., et al.,“The Effect of Cold Air Application on Intra-Articular and Skin Temperatures in the Knee,” Yonsei Medical Journal, 43(5):621-626, Yonsei University, Korea (South) (Oct. 2002). |
| Kinney, B.M. and Lozanova P., “High Intensity Focused Electromagnetic Therapy Evaluated by Magnetic Resonance Imaging: Safety and Efficacy Study of a Dual Tissue Effect Based Non-Invasive Abdominal Body Shaping,” Lasers in Surgery and Medicine 51(1):40-46, Wiley-Liss, United States (Jan. 2019). |
| Kocbach et al., “A Simulation Approach to Optimizing Perfermance of Equipment for Thermostimulation of Muscle Tissue using COMSOL Multiphysics” Article in Biophysics & Bioeng. dated 2011, 26 pages. |
| Kolin, A., et al., “Stimulation of Irritable Tissues by means of an Alternating Magnetic Field,” Proceedings of the Society for Experimental Biology and Medicine 102:251-253, Blackwell Science, United States (Oct. 1959). |
| Korman, P., et al.,“Temperature Changes in Rheumatoid Hand Treated With Nitrogen Vapors and Cold Air,” Rheumatology International, 32(10):2987-2992, Springer International, Germany (Oct. 2012). |
| Kotz, Y., “Theory and Practice of Physical Culture,” Training of Skeletal Muscle With Method of Electrostimulation, 64-67 (Mar. 1971). |
| Kotz, Y., “Theory and Practice of Physical Culture,” Training of Skeletal Muscle With Method of Electrostimulation, 66-72 (Apr. 1971). |
| Krueger, N. et al., “Safety and Efficacy of a New Device Combining Radiofrequency and Low-Frequency Pulsed Electromagnetic Fields for the Treatment of Facial Rhytides,” Journal of Drugs in Dermatology 11(11):1306-1309, Physicians Continuing Education Corporation, United States (Nov. 2012). |
| Kumar, N. and Agnihotri, R.C., “Effect of Frequency and Amplitude of Fes Pulses on Muscle Fatigue During Toning of Muscles,” Journal of Scientific and Industrial Research 67(4):288-290, (Apr. 2008). |
| Lampropoulou, S.I., et al., “Magnetic Versus Electrical Stimulation in the Interpolation Twitch Technique of Elbow Flexors,” Journal of Sports Science and Medicine, 11(4):709-718, Dept. of Sports Medicine, Medical Faculty of Uludag University, Turkey (Dec. 2012). |
| Langford, J. and Mccarthy, P.W., “Randomised controlled clinical trial of magnet use in chronic low back pain; a pilot study,” Clinical Chiropractic 8(1):13-19, Elsevier (Mar. 2005). |
| Lee, P.B., et al., “Efficacy of Pulsed Electromagnetic Therapy for Chronic Lower Back Pain: a Randomized, Double-blind, Placeb-controlled Study,” The Journal of International Medical Research 34(2):160-167, Cambridge Medical Publications, England (Mar.-Apr. 2006). |
| Leitch, M., et al., “Intramuscular Stimulation of Tibialis Anterior in Human Subjects: The Effects of Discharge Variability on Force Production and Fatigue,” Physiological Reports 5(15):e13326, Wiley Periodicals, Inc., United States (Aug. 2017). |
| Leon-Salas, W.D., et al., “A Dual Mode Pulsed Electro-Magnetic Cell Stimulator Produces Acceleration of Myogenic Differentiation,” Recent Patents on Biotechnology 7(1):71-81, Bentham Science Publishers, United Arab Emirates (Apr. 2013). |
| Letter from Department of Health and Human Services, Public Health Service, Dec. 19, 2014, 7 pages. |
| Lin, V.W., et al., “Functional Magnetic Stimulation: A New Modality for Enhancing Systemic Fibrinolysis,” Archives of Physical Medicine and Rehabilitation 80(5):545-550, W.B. Saunders, United States (May 1999). |
| Lin, V.W., et al., “Functional Magnetic Stimulation for Conditioning of Expiratory Muscles in Patients with Spinal Cord Injury.,” Archives of Physical medicine and Rehabilitation 82(2):162-166, W.B. Saunders, United States (Feb. 2001). |
| Lin, V.W., et al., “Functional Magnetic Stimulation for Restoring Cough in Patients With Tetraplegia,” Archives of Physical Medicine and Rehabilitation, 79(5):517-522, W.B. Saunders, United States, (May 1998). |
| Lin, V.W., et al., “Functional Magnetic Stimulation of Expiratory Muscles: a Noninvasive and New Method for Restoring Cough,” Journal of Applied Physiology (1985), 84(4):1144-1150, American Physiological Society, United States, (Apr. 1998). |
| Lin, V.W., et al., “Functional Magnetic Stimulation of the Respiratory Muscles in Dogs,” Muscle & Nerve 21(8):1048-1057, John Wiley & Sons, United States (Aug. 1998). |
| Linehan, C., et al., Brainwave the Irish EpilepsyAssoication, “The Prevalence of Epilepsy in Ireland” Summary Report,pp. 1-8 (May 2009). |
| Lotz, B.P., et al., “Preferential Activation of Muscle Fibers with Peripheral Magnetic Stimulation of the Limb,” Muscle & Nerve, 12(8):636-639, John Wiley & Sons, United States (Aug. 1989). |
| Lumenis Be Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2021-01402, Declaration of Dr. Marom Bikson (EX1002), Sep. 13, 2021, 244 pages. |
| Lumenis Be Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2021-01402, U.S. Pat. No. 10,821,295 Petition for Inter Partes Review, Sep. 13, 2021, 81 pages. |
| Lumenis Be Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2021-01403, Declaration of Dr. Marom Bikson (EX1002), Sep. 13, 2021, 243 pages. |
| Lumenis Be Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2021-01403, U.S. Pat. No. 10,821,295 Petition for Inter Partes Review, Sep. 13, 2021, 84 pages. |
| Lumenis Be Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2021-01404, Declaration of Dr. Marom Bikson (EX1002), Sep. 13, 2021, 245 pages. |
| Lumenis Be Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2021-01404, U.S. Pat. No. 10,124,187 Petition for Inter Partes Review, Sep. 13, 2021, 82 pages. |
| Lumenis Be Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2021-01405, Declaration of Dr. Marom Bikson (EX1002), Sep. 13, 2021, 247 pages. |
| Lumenis Be Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2021-01405, U.S. Pat. No. 10,124,187 Petition for Inter Partes Review, Sep. 13, 2021, 86 pages. |
| Lumenis Be Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2022-00126, Declaration of Dr. Marom Bikson (EX1002), Nov. 10, 2021, 263 pages. |
| Lumenis Be Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2022-00126, U.S. Pat. No. 10,695,576 Petition for Inter Partes Review, Nov. 10, 2021, 83 pages. |
| Lumenis Be Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2022-00127, Declaration of Dr. Marom Bikson (EX1002), Nov. 10, 2021, 269 pages. |
| Lumenis Be Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2022-00127, U.S. Pat. No. 10,695,576 Petition for Inter Partes Review, Nov. 10, 2021, 84 pages. |
| Lumenis Be Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2022-00451, Declaration of Dr. Marom Bikson (EX1002), Jan. 24, 2022, 236 pages. |
| Lumenis Be Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2022-00451, U.S. Pat. No. 10,806,943 Petition for Inter Partes Review, Jan. 24, 2022, 87 pages. |
| Lumenis Be Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2022-00452, Declaration of Dr. Marom Bikson (EX1002), Jan. 24, 2022, 229 pages. |
| Lumenis Be Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2022-00452, U.S. Pat. No. 10,806,943 Petition for Inter Partes Review, Jan. 24, 2022, 81 pages. |
| Lumenis Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2021-01273, Declaration of Dr. Marom Bikson (EX1002), Aug. 13, 2021, 225 pages. |
| Lumenis Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2021-01273, U.S. Pat. No. 10,478,634, Petition for Inter Partes Review, Aug. 13, 2021, 70 pages. |
| Lumenis Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2021-01275, Declaration of Dr. Marom Bikson (EX1002), Aug. 5, 2021, 282 pages. |
| Lumenis Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2021-01275, U.S. Pat. No. 10,632,321, Petition for Inter Partes Review, Aug. 5, 2021, 92 pages. |
| Lumenis Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2021-01276, Declaration of Dr. Marom Bikson (EX1002), Aug. 5, 2021, 241 pages. |
| Lumenis Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2021-01276, U.S. Pat. No. 10,965,575, Petition for Inter Partes Review, Aug. 5, 2021, 79 pages. |
| Lumenis Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2021-01278, Declaration of Dr. Marom Bikson (EX1002), Aug. 13, 2021, 255 pages. |
| Lumenis Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2021-01278, U.S. Pat. No. 10,709,894, Petition for Inter Partes Review, Aug. 13, 2021, 85 pages. |
| Lumenis Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2021-01279, Declaration of Dr. Marom Bikson (EX1002), Aug. 5, 2021, 258 pages. |
| Lumenis Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2021-01279, U.S. Pat. No. 10,709,895, Petition for Inter Partes Review, Aug. 5, 2021, 88 pages. |
| Lumenis Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2021-01280, Declaration of Dr. Marom Bikson (EX1002), Aug. 13, 2021, 235 pages. |
| Lumenis Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2021-01280, U.S. Pat. No. 10,478,634, Petition for Inter Partes Review, Aug. 13, 2021, 69 pages. |
| Lumenis Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2021-01282, Declaration of Dr. Marom Bikson (EX1002), Aug. 5, 2021, 267 pages. |
| Lumenis Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2021-01282, U.S. Pat. No. 10,632,321, Petition for Inter Partes Review, Aug. 5, 2021, 89 pages. |
| Lumenis Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2021-01283, Declaration of Dr. Marom Bikson (EX1002), Aug. 5, 2021, 241 pages. |
| Lumenis Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2021-01283, U.S. Pat. No. 10,695,575, Petition for Inter Partes Review, Aug. 5, 2021, 84 pages. |
| Lumenis Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2021-01284, Declaration of Dr. Marom Bikson (EX1002), Aug. 5, 2021, 279 pages. |
| Lumenis Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2021-01284, U.S. Pat. No. 10,709,895, Petition for Inter Partes Review, Aug. 5, 2021, 93 pages. |
| Lumenis Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2021-01285, Declaration of Dr. Marom Bikson (EX1002), Aug. 13, 2021, 249 pages. |
| Lumenis Ltd. v. BTL Healthcare Technologies A.S., PTAB-IPR2021-01285, U.S. Pat. No. 10,709,894, Petition for Inter Partes Review, Aug. 13, 2021, 79 pages. |
| Madariaga, V.B., et al., “[Magnetic Stimulation of the Quadriceps: Analysis of 2 Stimulators Used for Diagnostic and Therapeutic Applications],” Archivos De Bronconeumologia, 43(7):411-417, Elsevier Espana, Spain, (Jul. 2007). |
| Maffiuletti, N. A., et al., “Activation of Human Plantar Flexor Muscles Increases After Electromyostimulation Training,” Journal of Applied Physiology 92(4):1383-1392, American Physiological Society, United States (Nov. 2001). |
| Maffiuletti, N. A., et al., “The Effects of Electromyostimulation Training and Basketball Practice on Muscle Strength and Jumping Ability,” International journal of sports medicine 21(6):437-443, Thieme, Germany (Aug. 2000). |
| Mag Venture, Magnetic Stimulation, Accessories Catalogue, Accessories Catalogue, 2011, 54 pages. |
| Magstim Company Limited, K051864 510(k) Summary, Magstim Rapid and Magstim Super Rapid, All pages (Dec. 2005). |
| Magstim Company US, LLC, K060847 510(k) Summary, Magstim Model 200-2 with Double 70mm Remote Coil, All pages (Sep. 2006). |
| Magstim Corporation US, K992911 510(k) Summary, Magstim Rapid, All pages (Jan. 2000). |
| MagVenture, MagPro® by MagVenture®, Versatility in Magnetic Stimulation, World Leading Transcranial Magnetic Stimulation Systems, 2011, 6 Pages. |
| Man, W.D-C., et al., “Magnetic Stimulation for the Measurement of Respiratory and Skeletal Muscle Function,” The European Respiratory Journal 24(5):846-60, European Respiratory Society, England (2004). |
| Manstein, D., et al.,“Selective Cryolysis: A Novel Method of Non-Invasive Fat Removal,” Lasers in Surgery and Medicine, 40(9):595-604, Wiley-Liss, United States (Nov. 2008). |
| Mantis, The non-invasive solution that restores natural beauty, improves health, and offers a renewed psychophysical sense of balance, MR991 theramagnetic, 2020, 8 pages. |
| Mantis Theramagnetic Compact: the compact that guarantees utmost efficiency and maximum performance, theramagnetic, 2020, 8 pages. |
| Mantovani, A., et al., “Applications of Transcranial Magnetic Stimulation to Therapy in Pyschiatry,” Psychiatric Times 21(9), Intellisphere, 29 pages (Aug. 2004). |
| Marek Heinfarth, “Lipostar” dated Jan. 9, 2013, accessed at https://www.youtube.com/watch?v=hZurkn8iU_U , accessed on Dec. 15, 2021. |
| Markov, M.S., “Pulsed Electromagnetic Field Therapy History, State of the Art and Future,” Environment Systems and Decisions 27(4):465-475, Springer (Dec. 2007). |
| MecoTec Freezing Technology, Presentation Cryoair Whole Body Cryotherapy Chambers, Germany, Jul. 2017, 52 Pages. |
| Medline, Body Temperature Norms, 2 pages (Year: 2019). |
| Mekawy et al., “Influence of Electro-lipolysis on Lipid Profile and Central Obesity in Obese Premenopausal Women” Bull. Fac. Ph. Th. Cairo Univ., vol. 17, No. (1), dated Jan. 2012, pp. 59-68. |
| Mettler J.A., et al., “Low-Frequency Electrical Stimulation With Variable Intensity Preserves Torque,” Journal of Electromyography and Kinesiology : Official Journal of the International Society of Electrophysiological Kinesiology 42:49-56, Oxford:Elsevier, England (Oct. 2018). |
| Mogyoros, I., et al., “Strength-Duration Properties of Human Peripheral Nerve,” Brain 119(Pt 2):439-447, Oxford University Press, England (Apr. 1996). |
| Moon, Chi-Woong“Study on the Pulsed Electromagnetic Fields Effect of Adipocyte Decomposition” Final Report of a Middle-grade Researcher Support Project, Inje University, 2017. |
| Morrissey. M., “Electromyostimulation from a Clinical Perspective,” Sports Medicine 6(1):29-41, Springer International, New Zealand (Aug. 1988). |
| Mustafa, B., “Design and Construction of a Low Cost dsPIC Controller Based Repetitive Transcranial Magnetic Stimulator TMS,” Journal of medical systems 34(1):15-24, Kluwer Academic/Plenum Publishers, United States (2010). |
| Nadler, S.F., et al.,“The Physiologic Basis and Clinical Applications of Cryotherapy and Thermotherapy for the Pain Practitioner,” Pain Physician, 7(3):395-399, American Society of Interventional Pain Physicians, United States (Jul. 2004). |
| Nassab, R., “The Evidence Behind Noninvasive Body Contouring Devices,” Aesthetic Surgery Journal, 35(3):279-293, Oxford University Press, England (Mar. 2015). |
| National Institute of Neurological Disorders and Stroke, Epilepsy Information Page, www.ninds.nih.gov/disorders/epilepsy/epilepsy.htm, pp. 1-6 (Feb. 1, 2016). |
| Neotonus, Inc., K973096 510(k) Summary, Neotonus Model 1000 Muscle Stimulator System, All pages (Jun. 1998). |
| Neotonus, Inc., K973929 510(k) Summary and FDA Correspondence, Neotonus, All pages (May 1998). |
| Neuro Star , TMS Therapy, Bringing Hope to Patients with Depression, 2013, 6 Pages. |
| Neurosoft, Ivanovo, Since 1992, Magnetic Stimulator, NEURO-MS, Technical Manual, Neurosoft Ltd, Ivanovo, Russia, 2006, 67 Pages. |
| Nexstim NBS System, Navigated Brain Stimulation, Noninvasive, direct cortical mapping, 2012, 5 Pages. |
| Neyroud, D., et al., “Comparison of Electrical Nerve Stimulation, Electrical Muscle Stimulation and Magnetic Nerve Stimulation to Assess the Neuromuscular Function of the Plantar Flexor Muscles,” European journal of applied physiology 115(7):1429-1439, Springer-Verlag, Germany (2015). |
| Nielsen, J.F., et al., “A New High-frequency Magnetic Stimulator With an Oil-cooled Coil,” Journal of Clinical Neurophysiology 12(5):460-467, Lippincott Williams & Wilkins, United States (Sep. 1995). |
| Non Final Office Action dated Jun. 23, 2017, in U.S. Appl. No. 15/473,390, Schwarz, T., et al., filed Mar. 29, 2017. |
| Notice of Allowance dated Jul. 21, 2021 for U.S. Appl. No. 17/087,850 (pp. 1-8). |
| Notice of Allowance dated May 6, 2020 for U.S. Appl. No. 16/194,800 (pp. 1-8). |
| Notice of Allowance dated Oct. 8, 2019 for U.S. Appl. No. 15/603,162 (pp. 1-8). |
| Notice of Allowance dated Mar. 24, 2021 for U.S. Appl. No. 17/087,850 (pp. 1-8). |
| Novickij, V., et al., “Compact Microsecond Pulsed Magnetic Field Generator for Application in Bioelectronics,” Elektronika ir Elektrotechnika 19(8):25-28 (Oct. 2013). |
| Novickij, V., et al., “Design and Optimization of Pulsed Magnetic Field Generator for Cell Magneto-Permeabilization,” Elektronika ir Elektrotechnika(Electronics and Electrical Engineering) 23(2):21-25 (Apr. 2017). |
| Novickij, V., et al., “Magneto-Permeabilization of Viable Cell Membrane Using High Pulsed Magnetic Field,” IEEE Transactions on Magnetics 51(9), All pages (Sep. 2015). |
| Novickij, V., et al., “Programmable Pulsed Magnetic Field System for Biological Applications,” IEEE Transactions on Magnetics 50(11):5 (Nov. 2014). |
| NPF Electroapparat, Amplipulse-5Br Manual, allegedly accessed on Nov. 18, 2020, All pages. |
| Nuerosoft Ltd., “Neurosoft—Neuro-MS Transcranial Magnetic Simulator Technical Manual,” All pages (Nov. 2014). |
| Obsluze, “Apparatus for High Induction Magnetic Stimulation,” 2016, 42 pages. |
| Obsluze, N.K.,Usage Instructions, User's Manual, Device for high-induction magnetic stimulation of type designation:Saluter Moti, 2016,88 Pages. |
| Office Action dated Aug. 15, 2019 for U.S. Appl. No. 16/194,800 (pp. 1-12). |
| Office Action dated Jul. 10, 2020 for U.S. Appl. No. 15/678,915 (pp. 1-9). |
| Office Action dated Jun. 14, 2021 for U.S. Appl. No. 15/786,303 (pp. 1-13). |
| Office Action dated Jun. 28, 2021 for U.S. Appl. No. 16/727,458 (pp. 1-11). |
| Office Action dated Oct. 7, 2019 for U.S. Appl. No. 15/678,915 (pp. 1-8). |
| Oliveira, P.DE., et al., “Neuromuscular Fatigue After Low-and Medium-frequency Electrical Stimulation in Healthy Adults,” Muscle & Nerve 58(2):293-299, John Wiley & Sons, United States (Aug. 2018). |
| Operating Manual: Magstim ® 2002, P/N 3001-23-04, The Magstim Company Limited, Mar. 18, 2005, 34 pages. |
| Operating Manual: Magstim D702 Coil, MOP06-EN, Revision 01, The Magstim Company Limited, Feb. 2012, 14 Pages. |
| Operating Manual: Magstim Magstim 2002, MOP01-EN, Revision 01, The Magstim Company Limited, Sep. 2011, 25 Pages. |
| Operating Manual: Magstim, Magstim Alpha Coil Range, MOP11-EN, Revision 01, Oct. 2012, 18 Pages. |
| Operating Manual: Magstim, Magstim Bistim2, MOP02-EN, Revision, The Magstim Company Limited, 01, Sep. 2011, 27 Pages. |
| Operating Manual, Magstim, Model 200, P/N 3001-01, Double 70mm, Remote Coil, P/N 3190-00, The Magstim Company Limited, 2006, 32 pages. |
| Operating Manual: Magstim R, 2nd, Generation Coil Family, 3100-23-02, Magstim Coils, The Magstim Company Limited, Nov. 2002, 14 Pages. |
| Operating Manual, Magstim R Air-Cooled Double 70mm Coil System, 1600-23-04, The Magstim Company Limited, 1999, 18 Pages. |
| Operating Manual: Magstim R, Bistim System, P/N 3234-23-01, The Magstim Company Limited, Nov. 2004, 30 Pages. |
| Operating Manual: Magstim R, Coils & Accessories, 1623-23-07, Magstim Coils & Accessories, May 2010, 24 Pages. |
| Operating Manual: Magstim, RAPID2, P/N 3576-23-09, The Magstim Company Ltd, Nov. 2009, 61 Pages. |
| Operator's Manual: BTL Emsculpt, Btl Industries Ltd, United Kingdom, 2018, 35 pages. |
| Operator's Manual: BTL, HPM-6000U, BTL Industries Ltd, United Kingdom, Dec. 2016, 36 pages. |
| Otte, J.S., et al.,“Subcutaneous Adipose Tissue Thickness Alters Cooling Time During Cryotherapy,”Archives of Physical Medicine and Rehabilitation, 83(11):1501-1505, W.B. Saunders, United States (Nov. 2002). |
| Pain Management Technologies, “Pain Management Technologies Product Catalog,” (2012). |
| Papimi, for Scientific Research, Pap Ion Magnetic Inductor, Presentation, Magnetotherapeutic Device, Nov. 2009, 61 Pages. |
| Pascual-Leone, A., et al., “Handbook of Transcranial Magnetic Stimulation,” Chapters 1-4, 58 pages, Arnold Publishers, England (2002). |
| Periso SA, CTU mega Diamagnetic Pump 20: Device for Diamagnetic Therapy, CTU Mega 20 Manual, dated Aug. 28, 2019, 44 pages, Pazzallo Switzerland. |
| Photograph, Alleged Photograph of Components of a Salus Talent Pop Double Device with an Alleged Manufacture date of Nov. 14, 2012, 1 page. |
| Physiomed, MAG-Expert, Physiomed Manual, Dec. 19, 2012. |
| Platil, A., “Magnetopneumography Using Optical Position Reference,” Sensor Letters 11(1):69-73, ResearchGate (2013). |
| Podebradsky.K., et al., Clinical study of high-inductive electromagnetic stimulator SALUS talent, 2010, 8 pages. |
| Pohanka, J., et al., “An Embedded Stereovision System: Aspects of Measurement Precision,” 12th Biennial Baltic Electronics Conference, pp. 157-160 (Oct. 2010). |
| Polk, C., “Therapeutic Applications of Low-Frequency Sinusoidal and Pulsed Electric and Magnetic Fields,” The Biomedical Engineering Handbook, vol. 1, 2000, Second edition, CRC Press LLC, pp. 1625-1636. |
| Polkey M.I., et al., “Functional Magnetic Stimulation of the Abdominal Muscles in Humans,” American Journal of Respiratory and Critical Care Medicine 160(2):513-522, American Thoracic Society, United States (Aug. 1999). |
| Polkey, M.I., et al., “Quadriceps Strength and Fatigue Assessed by Magnetic Stimulation of the Femoral Nerve in Man,” Muscle Nerve 19(5):549-555, John Wiley & Sons, United States, (May 1996). |
| Pollegen, K200545, Legend Pro DMA, Indications for use, dated Oct. 20, 2021,11 pages. |
| Pollogen, Trilipo MED Procedure, Brochure, dated Apr. 7, 2021, 76 pages. |
| Pollogen, Maximus Non-invasive body shaping System, User Manual, dated May 1, 2012, 44 pages, http://download.lifvation.com/Maximus_UserManual.pdf. |
| Porcari, J.P., et al., “Effects of Electrical Muscle Stimulation on Body Composition, Muscle Strength, and Physical Appearance,” Journal of Strength and Conditioning Reasearch 16(2):165-172, Human Kinetics Pub., United States (May 2002). |
| Porcari, J.P., et al., “The Effects of Neuromuscular Electrical Stimulation Training on Abdominal Strength, Endurance, and Selected Anthropometric Measures,” Journal of Sports Science and Medicine 4(1):66-75, Dept. of Sports Medicine, Turkey (Mar. 2005). |
| Pribula, O. and Fischer, J., “Real Time Precise Position Measurement Based on Low-Cost CMOS Image Sensor,” IEEE, 5 pages (2011). |
| Pribula, O., et al., “cost-effective Image Acquisition System for Precise Pc-based Measurements,” Przeglad Elektrotechniczny (Electrical Review), 259-263, 2011. |
| Pribula, O., et al., “Optical Position Sensor Based on Digital Image Processing: Magnetic Field Mapping Improvement,” Radioengineering 20 (1):55-60, (Apr. 2011). |
| Pribula, O., et al., “Real-Time Video Sequences Matching Spatio-Temporal Fingerprint,” IEEE, 911-916 (Jun. 2010). |
| Prouza, O., et al., “High-Intensity Electromagnetic Stimulation Can Reduce Spasticity in Post-Stroke Patients,” International Journal of Physiotherapy 5(3):87-91 (2018). |
| Prouza, O., “Ex-Post Analyza Spot Rebnich Dani,” All pages, (2008). |
| Prouza, O., “Targeted Radiofrequency Therapy for Training Induced Muscle Fatigue—Effective or Not?,” International Journal of Physiotherapy 3(6):707-710 (Dec. 2016). |
| PTAB-IPR2021-00296, U.S. Pat. No. 10,493,293, Petition for Inter Partes Review, Dec. 14, 2020, 117 pages. |
| PTAB-IPR2021-00312, U.S. Pat. No. 10,478,634, Petition for Inter Partes Review, Dec. 14, 2020, 108 pages. |
| PTAB-PGR2021-00015, U.S. Pat. No. 10,709,895, Petition for Post-Grant Review, Dec. 14, 2020, 140 pages. |
| PTAB-PGR2021-00016, U.S. Pat. No. 10,709,895, Petition for Post-Grant Review, Dec. 14, 2020, 144 pages. |
| PTAB-PGR2021-00017, U.S. Pat. No. 10,632,321, Petition for Post-Grant Review, Dec. 14, 2020, 121 pages. |
| PTAB-PGR2021-00018, U.S. Pat. No. 10,632,321, Petition for Post-Grant Review, Dec. 14, 2020, 140 pages. |
| PTAB-PGR2021-00020, U.S. Pat. No. 10,695,575, Petition for Post-Grant Review, Dec. 14, 2020, 112 pages. |
| PTAB-PGR2021-00021, U.S. Pat. No. 10,695,575, Petition for Post-Grant Review, Dec. 14, 2020, 117 pages. |
| PTAB-PGR2021-00022, U.S. Pat. No. 10,709,894, Petition for Post-Grant Review, Dec. 14, 2020, 119 pages. |
| PTAB-PGR2021-00023, U.S. Pat. No. 10,709,894, Petition for Post-Grant Review, Dec. 14, 2020, 136 pages. |
| PTAB-PGR2021-00024, U.S. Pat. No. 10,695,576, Petition for Post-Grant Review, Dec. 14, 2020, 136 pages. |
| PTAB-PGR2021-00025, U.S. Pat. No. 10,695,576, Petition for Post-Grant Review, Dec. 14, 2020, 135 pages. |
| Publication of Medical Device Manufacturing Approval of Salus-Talent-Pro, approval date Mar. 11, 2014, 39 pages. |
| Quick Start Manuals, Magstim Super Rapid Plus Quick Start, Aalto TMS Laboratory, Aalto School of Science, 2013, 7 pages. |
| Radakovic T. and Radakovic N., “The Effectiveness of the Functional Magnetic Stimulation Therapy in Treating Sciatica Syndrome,” Open Journal of Therapy and Rehabilitation 3(3):63-69 (2015). |
| Reaction User Manual, Viora, Doc No. MK-004 A, 2008, 53 Pages |
| Reshaping the Future of Your Practice, Cool sculpting, A Revolution in Aesthetic Fat Reduction, 2011, 10 Pages. |
| Riehl., M., “Chapter 3: TMS Stimulator Design” The Oxford Handbook of Transcranial Stimulation, Wasserman, E.M., ed., pp. 13-23, Oxford University Press, 26 pages, United Kingdom (2008). |
| Roots, H., and Ranatunga, K.W., “An Analysis of the Temperature Dependence of Force, During Steady Shortening at Different Velocities, in (Mammalian) Fast Muscle Fibres,” Journal of Muscle Research and Cell Motility 29(1):9-24, Springer, Netherlands (Jun. 2008). |
| Ruiz-Esparza, J. and J. Barba Gomez., “The Medical Face Lift: A Noninvasive, Nonsurgical Approach to Tissue Tightening in Facial Skin Using Nonablative Radiofrequency,” Dermatologic Surgery 29(4):325-332, Williams & Wilkins, United States (Apr. 2003). |
| Russian excerpt of Werner, R., Magnetotherapy, Pulsating energy resonance therapy, 41-67 (Jun. 2007). |
| Rutkove, S., “Effects of Temperature on Neuromuscular Electrophysiology,” Muscle & Nerve 24(7):867-882, John Wiley & Sons, United States (Jul. 2001). |
| Salus Talent Pop, The first sales bill, Authorization No. 20120221-41000096-66667961, 2 pages, (Feb. 2012). |
| Salus Talent-A, Remed, User Guide, High Intensity Electro Magnetic Field Therapy, 2017, 37 pages. |
| Sargeant, A.J., “Effect of Muscle Temperature on Leg Extension Force and Short-term Power Output in Humans,” European Journal of Applied Physiology and Occupational Physiology 56(6):693-698, Springer Verlag, Germany (Sep. 1987). |
| Schaefer, D.J., et al., “Review of Patient Safety in Time-Varying Gradient Fields,” Journal of Magnetic Resonance Imaging 12:20-29, Wiley-Liss, United States (Jul. 2000). |
| Shimada, Y., et al., “Effects of therapeutic magnetic stimulation on acute muscle atrophy in rats after hindlimb suspension,” Biomedical Research 27(1):23-27, Biomedical Research Foundation, Japan (Feb. 2006). |
| Silinskas, V., et al., “Effect of Electrical Myostimulation on the Function of Lower Leg Muscles,” Journal of strength and Conditioning Research 31(6):1577-1584, Human Kinetics Pub, United States (2017). |
| Sport-Elec S.A., K061914 510(k) Summary, Sport-Elec, All pages (Jul. 2007). |
| Sport-Elec S.A., K081026 510(k) Summary, Sport-Elec, All pages (Nov. 2008). |
| Stallknecht, B., et al., “Are Blood Flow and Lipolysis in Subcutaneous Adipose Tissue Influenced by Contractions in Adject Muscles in Humans?,” American Journal of Physiology. Endocrinology and Metabolism 292(2):E394-E399, American Physiological Society, United States (Feb. 2007). |
| Starbelle, PEMF Shape, Webpage, dated Feb. 10, 2020, 3 pages, available at http://www.starbelle.cn/info/PEMFShape.html. |
| Stedman, T.L., “Aponeurosis—Apparatus,” in Stedman's Medical Dictionary, 27th Edition, Pugh, M.B., ed., pp. 113-114, Lippincott Williams & Wilkins, Baltimore, MD (2000). |
| Stevens, J.E., et al., “Neuromuscular Electrical Stimulation for Quadriceps Muscle Strengthening After Bilateral Total Knee Arthroplasty: A Case Series,” Journal of Orthopaedic and Sports Physical Therapy 34(1):21-29, Williams and Wilkins, United States (Jan. 2004). |
| Struppler, A., et al., “Facilitation of Skilled Finger Movements by Repetitive Peripheral Magnetic Stimulation (RPMS)—A New Approach in Central Paresis.,” NeuroRehabilitation 18(1):69-82, IOS Press, Amsterdam (2003). |
| Struppler, A., et al., “Modulatory Effect of Repetitive Peripheral Magnetic Stimulation on Skeletal Muscle Tone in Healthy Subjects: Stabilization of the Elbow Joint,” Experimental Brain Research 157(1):59-66, Springer Verlag, Germany (Feb. 2004). |
| Suarez-Bagnasco, D., et al., “The Excitation Functional for Magnetic Stimulation of Fibers.,” Annual International Conference of the IEEE Engineering in Medicine and Biology Society, IEEE Engineering in Medicine and Biology Society, Annual International Conference, 2010:4829-4833, IEEE, United States (2010). |
| Swallow, E.B., et al., “A Novel Technique for Nonvolitional Assessment of Quadriceps Muscle Endurance in Humans,” Journal of Applied Physiology 103(3):739-746, American Physiological Society, United States (Sep. 2007). |
| Szecsi, J., et al., “A Comparison of Functional Electrical and Magnetic Stimulation for Propelled Cycling of Paretic Patients,” Archives of Physical Medicine and Rehabilitation 90(4):564-570, W.B. Saunders, United States, (Apr. 2009). |
| Szecsi, J., et al., “Force-pain Relationship in Functional Magnetic and Electrical Stimulation of Subjects With Paresis and Preserved Sensation,” Clinical Neurophysiology 121(9):1589-1597, Elsevier, Netherlands, (Sep. 2010). |
| Taylor, J.L, “Magnetic Muscle Stimulation Produces Fatigue Without Effort,” Journal of Applied Physiology (1985) 103(3):733-734, American Physiological Society, United States, (Sep. 2007). |
| Tesla Stym, Iskra Medical, Tone the inner muscle with FMS Functional Magnetic Stimulation, 2013, 4 pages. |
| The Burn Centre Care, Education, 3 pages, printed from internet Nov. 13, 2017. |
| The Magstim Company Ltd, K080499 510(k) Summary, Magstim Double 70mm Air Film Coil, All pages (Dec. 2008). |
| The Magstim Company Ltd., K130403 510(k) Summary, Magstim D702 coil, All pages (Aug. 2013). |
| Thermi Launches Arvati, powered by Thermi, with newest advances in True Temperature Controlled Radiofrequency Technology, 5 pages (2018). |
| Thompson, M.T., “Inductance Calculation Techniques—Part II: Approxmiations and Handbook Methods,” Power Control and Intelligent Motion, 11 pages (Dec. 1999) http://www.pcim.com/. |
| Thompson, M.T., “Inductance Calculation Techniques—Part II: Classical Methods,” Power Control and Intelligent Motion, 25(12):40-45, (Dec. 1999) http://www.pcim.com/. |
| Tomek, J., et al., “Magnetopneumography—Incorporation of optical position reference,” Journal of Electrical Engineering, All pages (2012). |
| Torbergsen, T., “Abstracts of the International Course and Symposium in Single Fibre EMG and Quantitative EMG Analysis. Tromsø, Norway, Jun. 4-8, 1984,” Muscle & Nerve 9(6):562-574, John Wiley & Sons, United States (Jul.-Aug. 1986). |
| Trifractional FAQs, http://pollogen.lifvation.com/Faq/TriFractional%20FAQs.pdf, Aug. 2011 (4pages). |
| TriLipo Med Procedure, http://download.lifvation.com/Maximus_TriLipoMED_Intro.pdf, Apr. 2013, 76 pages. |
| TSEM Med Swiss SA, Diamagnetic Therapy: a Revolutionary Therapy, CTU Mega 20 Catalogue, dated 2016, 24 pages, Lugano Switzerland. |
| Turley, J., “Agilent Technologies Announces 30 MHz Function/Arbitrary Waveform Generators with Unparalleled Signal Accuracy,” Elec. Eng'g J., URL: (Aug. 4, 2010), 8 pages. |
| Ultra Slim Professional, The very best body Contouring, Wardphotonics LLC, 2018, 16 pages. |
| U.S. Appl. No. 60/848,720, inventor Burnett, D., filed Sep. 30, 2006 (Not Published). |
| U.S. Appl. No. 62/331,060, inventor Schwarz, T., filed May 3, 2016 (Not Published). |
| U.S. Appl. No. 62/331,072, inventor Schwarz, T., filed May 3, 2016 (Not Published). |
| U.S. Appl. No. 62/331,088, inventor Schwarz, T., filed May 3, 2016 (Not Published). |
| U.S. Appl. No. 62/333,666, inventor Schwarz, T., filed May 9, 2016 (Not Published). |
| U.S. Appl. No. 62/351,156, inventor Schwarz, T., filed Jun. 16, 2016 (Not Published). |
| U.S. Appl. No. 62/357,679, inventor Schwarz, T., filed Jul. 1, 2016 (Not Published). |
| U.S. Appl. No. 62/440,905, inventors Schwarz, T. et al., filed Dec. 30, 2016 (Not Published). |
| U.S. Appl. No. 62/440,912, inventors Schwarz, T. et al., filed Dec. 30, 2016 (Not Published). |
| U.S. Appl. No. 62/440,922, inventor Schwarz, T., filed Dec. 30, 2016 (Not Published). |
| U.S. Appl. No. 62/440,936, inventor Schwarz, T., filed Dec. 30, 2016 (Not Published). |
| U.S. Appl. No. 62/440,940, inventor Schwarz, T., filed Dec. 30, 2016 (Not Published). |
| U.S. Appl. No. 62/441,805, inventor Prouza, O., filed Jan. 3, 2017 (Not Published). |
| U.S. Appl. No. 62/786,731, inventor Schwarz, T., filed Dec. 31, 2018 (Not Published). |
| User Guide: Mag Venture, Magpro family, MagPro R30, MagPro R30 with MagOption, MagPro X100, MagPro X100 with MagOption, MagPro software v.5.0, US-edition, MagPro family User Guide, 2010, 52 Pages. |
| User Guide, Salus Talent Pro, REMED, High Intensity Electro magnetic Field Therapy—2 Channel, 2017, Version M-1.0.0, 45 pages. |
| User Guide, Salus Talent, REMED, High Intensity Electro magnetic Field Therapy, Version. M-1.0.0, 2017, 40 pages. |
| User'S Manual: BTL-6000, Super Inductive System Elite, BBTL Industries Ltd, United Kingdom, Sep. 2016, 36 pages. |
| User Manual: Electro-magnetic Stimulator, Salus-Talent, Version 1.00, Rehabilitation Medical Company,2013, 34 Pages. |
| User Manual: Regenetron PRO, System Information, Regenetron PRO User Manual, Nov. 2014, 7 Pages. |
| Vance, C., et al., “Effects of Transcutaneous Electrical Nerve Stimulation on Pain, Pain Sensitivity, and Function in People with Knee Osteoarthritis,” Physical Therapy 92:898-910 (2012). |
| Vanquish Operator's Manual, BTL, 2012, 48 Pages. |
| Venus Concept Ltd., VenusFreeze MP2, User Manual, dated Jun. 2012, 46 Pages. |
| Venus Concept Ltd., VenusViva, User Manual, dated Aug. 2013, 51 pages. |
| Venus Legacy, User Manual International, 2009, Venus Concept, 49 pages. |
| Venus Swan, Experience the Difference, Venus Concept, Delivering the Promise, http://www.medicom.cz/UserFiles/File/LekarskeNenue/020Swan%20EN.pdf , 2 pages (Apr. 2016). |
| Venus, Venus legacy marca argentina, Oct. 14, 2014, 20 pages. |
| Verges S., et al., “Comparison of Electrical and Magnetic Stimulations to Assess Quadriceps Muscle Function,” Journal of Applied Physiology (1985) 106(2):701-710, American Physiological Society, United States, (Feb. 2009). |
| Wada, K., et al., “Design and Implementation of Multi-Frequency Magnetic Field Generator Producing Sinusoidal Current Waveform for Biological Researches,” IEEE, 9 pages (2016). |
| Wanitphakdeedecha, R., et al., “Treatment of Abdominal Cellulite and Circumference Reduction With Radiofrequency and Dynamic Muscle Activation” Journal of Cosmetic and Laser Therapy 17(5):246-251, Informa Healthcare, England (2015). |
| Ward, A.R. and Shkuratova, N., “Russian Electrical Stimulation: The Early Experiments,” Physical therapy 82(10):1019-1030, Oxford University Press, United States (2002). |
| Wasilewski, M.L., Academy of Aesthetic and Anti-Aging Medicine, Application of magnetic fields with deep stimulation in the fight against local obesity of lower limbs, BTL, 2012, 4 pages. |
| Web MD, what is normal body temperature? 3 pages, printed Mar. 4, 2019. |
| Weight to volume aluminum, 2 pages. printed from internet Sep. 25, 2018. |
| Weight to volume copper, 2 pages printed from internet Sep. 25, 2018. |
| Weiss, R.A., et al., “Induction of Fat Apoptosis by a Non-Thermal Device: Mechanism of Action of Non-Invasive High-Intensity Electromagnetic Technology in a Porcine Model,” Lasers in surgery and medicine 51(1):47-53, Wiley-Liss, United States (Jan. 2019). |
| Weng, O., “Electromagnetic Activation of the Calf Muscle Pump,” UMI Dissertation Publishing (2014). |
| Weyh, T., et al., “Marked Differences in the Thermal Characteristics of Figure-of-eight Shaped Coils Used for Repetitive Transcranial Magnetic Stimulation,” Clinical Neurophysiology 116(6):1477-1486, Elsevier, Netherlands (Mar. 2005). |
| Woehrle, J., et al., “Dry Needling and its Use in Health Care—A Treatment Modality and Adjunct for Pain Management,” Journal of Pain & Relief 4(5):1-3, (Aug. 2015). |
| Yacyshy, A.F., et al., “The Inclusion of Interstimulus Interval Variability Does Not Mitigate Electrically-evoked Fatigue of the Knee Extensors,” European Journal of Applied Physiology 120(12):2649-2656, Springer-Verlag, Germany (Sep. 2020). |
| ZAO OKB RITM, Electroneurostimulants, Transdermal Scenar-NT Instructions, All pages (Nov. 2013). |
| ZAO OKB RITM, Percutaneous Electrical Stimulators With Individual Biofeedback Dosing Impact on Reflex Zones, All pages (2017). |
| Zelickson, B., et al.,“Cryolipolysis for Noninvasive Fat Cell Destruction: Initial Results From a Pig Model,” Dermatologic Surgery 35(10):1462-1470, Hagerstown, MD Lippincott, Williams & Wilkins, United States (Oct. 2009). |
| Zeltiq System User Manual—Print and Binding Specifications, Zeltiq Aesthetics, Inc, Mar. 2011, 88 pages. |
| Zerona R-Z6 by Erchonia, Specifications,Retrieved from the Internet: (www.myzerona.com), 2015, 1 page. |
| Zhang, G., et al., “A Method of Nerve Electrical Stimulation by Magnetic Induction,” Annual International Conference of the IEEE Engineering in Medicine and Biology Society 2009:622-625, IEEE, United States (2009). |
| Zhi-De, D., “Electromagnetic Field Modeling of Transcranial Electric and Magnetic Stimulation: Targeting, Individualization, and Safety of Convulsive and Subconvulsive Applications,” Academic Commons (2013). |
| Zhu, Y., et al., “Magnetic Stimulation of Muscle Evokes Cerebral Potentials by Direct Activation of Nerve Afferents: A Study During Muscle Paralysis,” Muscle & Nerve 19(12):1570-1575, John Wiley & Sons, United Sates (Dec. 1996). |
| Letter from U.S. Food & Drug Administration to Johari Digital Healthcare Ltd. regarding K212866, attaching 510(K) summary; Dec. 3, 2022; 17 pages. |
| Lanzamiento de BTL Vanquish ME en Argentina, BTL Aesthetics Int., 2018 at 0:33, 0:34; available at: https://www.youtube.com/watch?v=5yb5IMmN76Q&ab_channe1=BTLAestheticsInt, downloaded Jul. 12, 2023; 2 pages. |
| Magneris—ASTAR—magnetotherapy unit, 2010 at 1:16, 1:35, 1:40 and 1:50 available at: https://www.youtube.com/watch?v =1oO1LYnaq4g&ab_channe1=Astar-aparatydlafizjotera, downloaded Jul. 12, 2023; 2 pages. |
| File History for U.S. Appl. No. 62/812,123, to Caselino et al., filed Feb. 28, 2019. |
| File History for U.S. Appl. No. 62/884,099, to Caselino et al., filed Aug. 7, 2019. |
| File History for U.S. Appl. No. 62/908,741, to Caselino et al., filed Oct. 1, 2019. |
| Number | Date | Country | |
|---|---|---|---|
| 20230201589 A1 | Jun 2023 | US |
| Number | Date | Country | |
|---|---|---|---|
| 63019619 | May 2020 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 17941777 | Sep 2022 | US |
| Child | 18177269 | US | |
| Parent | 17664161 | May 2022 | US |
| Child | 17941777 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 17518243 | Nov 2021 | US |
| Child | 17664161 | US | |
| Parent | PCT/IB2021/000300 | May 2021 | US |
| Child | 17518243 | US |
